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ABSTRACT 
HEATHER BETHEA:  Structural and Functional Analysis of Heparan Sulfate 
Sulfotransferases 
(Under the direction of Jian Liu, Ph.D.) 
 
Heparan sulfate (HS), a major polysaccharide component of the vascular system, is 
involved in regulating a number of functions of the blood vessel wall including blood 
coagulation, cell differentiation, and the inflammatory response.  The wide range of 
biological functions makes HS an attractive therapeutic target.  The long term goal of our 
research involves utilizing an enzyme-based approach to develop HS-based therapeutics for 
treating thrombotic diseases, cancer and excessive inflammatory responses.  The biosynthesis 
of HS involves multiple specialized sulfotransferases such as 2-O-sulfotransferase (2OST) 
and 6-O-sulfotransferase (6OST), which are essential for preparing HS with activities in 
regulating vascular development and blood coagulation.  The substrate specificity of the HS 
sulfotransferases controls the sulfation patterns of HS, permitting HS to exhibit a specific 
function, however, limited knowledge regarding the mechanism of these enzymes has 
hindered our ability to prepare functionally-specific HS.  We aim to understand the 
mechanism of action of these two enzymes in hopes of developing heparin/HS with 
improved anticoagulant efficacy.   
In this dissertation, we present successful crystallization of 2OST in complex with 3’-
phosphoadenosine 5’-phosphate (PAP).  The substrate recognition mechanism of 2OST was 
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examined by way of extensive structurally guided mutational analysis.  Several residues were 
identified, including Arg-189, Tyr-94, and His-106, that are responsible for dictating the 
substrate specificity of 2OST.  Despite success with the crystallization of 2OST, the 
crystallization of 6OST has been an ongoing process.  A promising expression construct for 
crystallization purposes has been identified for 6OST-1.  Using a homology model of 6OST-
3 with structurally known 3OST-3, several residues involved in PAPS and substrate binding 
were proposed.   
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Chapter I 
Introduction 
 
Heparan Sulfate Proteoglycans 
 Heparan sulfate (HS), a highly sulfated and ubiquitous polysaccharide, is a member 
of the glycosaminoglycan (GAG) family.  Other members of the GAG family include 
chondroitin sulfate (CS), keratan sulfate, and hyaluronic acid (1).  The GAG macromolecules 
differ in the structure of repeating disaccharide units as well as the level of sulfation on the 
polysaccharide.  Hyaluronic acid is in sharp contrast with the other GAG members in that it 
possesses no sulfo groups.  With the exception of hyaluronic acid, GAGs are covalently 
attached to a core protein and termed proteoglycans (2).  The core proteins of HS 
proteoglycans consist of syndecans, serglycin, glypicans, agrin, perlecans and collagen 
XVIII, ranging in size from 32 to 500 kDa (Figure 1) (3).  The core proteins can be 
categorized into two groups, membrane-bound and non-membrane bound.  The syndecans 
and glypicans are associated with the membrane-bound group, containing different types of 
anchors.  Syndecans are anchored to the cell membrane via the transmembrane domain 
whereas glypicans rely on the glycosylphosphatidylinositol (GPI) anchor (2,4).  The non-
membrane bound members include perlecan, agrin, and collagen XVIII (2,3).  The heparin 
proteoglycan, serglycin, is a specialized proteoglycan that is an exclusive product of mast 
cells (5).  HS proteoglycans are involved in many biological processes including blood 
coagulation, wound healing, viral infections, embryonic development, and cancer (4).  The 
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heparan sulfate side chain controls the biological functions through interaction with other 
biologically relevant proteins whereas the core protein determines the location of the HS 
within tissues (2).   
 
Figure 1.  Schematic Representation of the heparan sulfate proteoglycans.  Syndecans are integrated into 
the cell membrane via a transmembrane anchor and carry more than one HS side chain.  Glypicans are attached 
to the membrane via a GPI anchor.  Collagen XVIII, perlecan, and agrin are not attached to the cell membrane 
but instead exist in the ECM. 
 
 
Chemical Structure of Heparan Sulfate and Heparin  
Heparan sulfate is initially synthesized in the Golgi apparatus as a repeating structure 
of D-glucuronic acid (GlcUA) and D-N-acetyl glucosamine (GlcNAc) attached through 
alternating β-1,4 and α-1,4 glycosidic linkages (Figure 2).  The disaccharide repeat is 
synthesized a total of 50-100 times to produce the polysaccharide backbone (6).  Heparin, a 
commonly used anticoagulant, is a structural analog of heparan sulfate.  The nascent 
backbone of both heparin and HS is susceptible to modifications by several biosynthetic 
enzymes.  The glucuronic acid can be converted to L-iduronic acid (IdoUA) by altering the 
C5-position, and the uronic acid (GlcUA or IdoUA) can be sulfated at the 2-OH position.  For 
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the glucosamine residue, it can be sulfated at the 3-OH and 6-OH positions and the N-
position can exist in unsubstituted, acetylated, or sulfated forms.  The reactions catalyzed by 
these biosynthetic enzymes do not proceed to completion thus resulting in heparin/HS with 
heterogeneous structures.  Most of the residues within HS are N-sulfated and N-acetylated 
with approximately 1-7% being unsubstituted glucosamine (4,7).  Since most of the 
modification enzymes rely on adjacent N-sulfo glucosamine residues, there are several highly 
sulfated regions within the HS polysaccharide chain known as NS-domains that resemble 
heparin.   The NS domains alternate with larger unmodified regions consisting of mostly 
GlcNAc residues known as the NA domain.  The area between the NS and NA domains 
contains mixed sequences of alternating N-acetylated and N-sulfated glucosamine 
disaccharides termed the NA/NS domain (8,9).  The structural diversity of HS has been 
implicated in several biological functions.   
 
Figure 2.  Chemical structure of the disaccharide repeating units of heparan sulfate and heparin.  
Sulfation (R= -SO3
-
) at C6 of glucosamine is common.  Sulfation at C2 of iduronic acid is common.  Sulfation 
at C3 of glucosamine is rare.  Both N-acetyl (R’=acetyl, GlcNAc) and N-sulfo glucosamine (R’= -SO3
-
, GlcNS) 
are common.  N-unsubstituted glucosamine (R’ = -H, GlcNH2) is a low abundant component.                                                                            
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The completion of NMR and molecular modeling studies has indicated that heparin 
and HS adopt an overall helical structure with the sulfate and carboxylate groups projected 
outward (10).  The glycosidic linkages appear to be stiff.  The presence of an IdoUA within 
the chain possesses high flexibility with a conformational equilibrium between chair and 
skew boat conformations.  The presence of sulfate groups affects the conformational 
equilibrium of IdoUA more so than the overall shape of heparin or HS (11).  The overall 
presentation of negative charge on the exterior of heparin and heparan sulfate allows for 
extensive ionic interactions with proteins carrying positive charges such as fibroblast growth 
factors and antithrombin (12-15). 
Heparan Sulfate versus Heparin  
Both heparin and HS are expressed as proteoglycans, however, they differ in their 
cellular localization.  Heparan sulfate proteoglycans are ubiquitously expressed on the 
surface and within the extracellular matrix of animal cells, but heparin proteoglycans are 
exclusive to mast cells (16).  Although heparin and HS possess similar structures, they are 
strikingly different in the level of sulfation and epimerization (15).  On average, the heparin 
disaccharide contains 2.6 sulfo groups per disaccharide whereas HS contains approximately 
0.6.  In terms of epimerization level, approximately 20% of uronic acid residues within HS 
are IdoUA whereas heparin contains approximately 90% IdoUA (15,16).  With a higher level 
of sulfation and IdoUA content, heparin can be considered a specialized form of heparan 
sulfate.  The most prevalent disaccharide structure in heparin, constituting 75-90% of 
disaccharide sequences, is IdoUA2S-GlcNS6S whereas 10-50% of HS disaccharide 
sequences consist of GlcUA-GlcNAc (16).  Therefore, HS has a higher level of structural 
variability than heparin, possibly explaining its roles in a wide range of biological functions.   
  
5 
Biosynthesis of Heparin and Heparan Sulfate 
 The biosynthesis of heparin and heparan sulfate takes place in the Golgi apparatus, 
involving a series of specialized glycosyltransferases, sulfotransferases and an epimerase.  
The HS biosynthetic pathway involves a non-template, enzyme driven process that can be 
separated into three steps: (1) chain initiation, (2) chain elongation, and (3) chain 
modification.  Essentially all of the biosynthetic enzymes have been successfully cloned and 
purified to date, enhancing our ability to understand their role in the synthesis of functionally 
specific heparan sulfate (17).   
Chain Initiation 
 The biosynthesis of the heparan sulfate chain is initiated by the addition of a 
tetrasaccharide linkage region, -GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-[Ser], to specific serine 
residues on the translated core protein (Figure 3).  This tetrasaccharide linkage region, 
common to heparin, heparan sulfate, dermatan sulfate, and chondroitin sulfate, serves as a 
precursor to heparan sulfate biosynthesis (18).  The addition of each sugar within the linkage 
region from the activated UDP sugars is performed sequentially by four glycosyltransferases 
that include xylosyltransferase (XylT), galactosyltransferase I (GalTI), galactosyltransferase 
II (GalT-II), and glucuronyltransferase I (GlcUAT-I) (Figure 4). 
 
Figure 3.  Biosynthesis of the tetrasaccharide linkage region.  The tetrasaccharide linkage region (GlcUA-
Gal-Gal-Xyl) is attached to specific serine residues on the core protein.  The glycosyltransferase responsible for 
the addition of each sugar is labeled in parentheses under the corresponding sugar unit.  R = proton or sulfate; 
R
’ = 
proton or phosphate. 
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Figure 4.  Initiation and elongation of the heparan sulfate nascent chain.  Chain initiation begins with the 
synthesis of the tetrasaccharide linkage region, which is covalently attached to specific serine residues of the 
core protein.  Upon completion of the linkage region, the elongation step begins to complete synthesis of the 
nascent HS chain.    
 
 
Xylosyltransferase (XylT) 
 XylT is responsible for the transfer of xylose from UDP-xylose to specific serine 
residues of a translated core protein (19-21).  This is the first and rate-limiting step in 
tetrasaccharide linkage biosynthesis (22). Two isoforms of XylT (XylT-I and XylT-II) have 
been identified in vertebrates with approximately 55% sequence identity among human 
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XylTs (22,23).  The full-length human XylT-I was successfully expressed in mammalian 
cells in its active form, demonstrating localization in the early Golgi cisternae (22).  The N-
terminal 214 amino acid residues of XylT-I were determined to be important for localization 
to the Golgi but not for enzymatic activity (22).  Studies have shown that CHO cells deficient 
in XylT-I expression were unable to synthesize heparan sulfate or chondroitin sulfate, 
suggesting the importance for XylT-I in initiating synthesis of the linkage region (24), 
Until recently, the enzymatic activity of XylT-II had not been elucidated.  Using 
Pichia pastoris as a host, an enzymatically active, soluble form of XylT-II was successfully 
expressed.  Studies using various xylosidases to cleave different substrates modified by 
XylT-II determined that XylT-II is indeed a β-xylosyltransferase (25).  As with XylT-I, the 
postulated concensus sequence for xylosylation is a-a-a-a-G-S-G-a-a/G-a (a represents Asp 
or Glu), which is consistent with the short minimal motifs G-S-G and G-S-x-G (x represents 
any amino acid) (26-30).  In vitro studies with various peptides demonstrated no significant 
difference in specificity between the two isoforms, suggesting that more specific acceptor 
molecules are necessary for distinguishing the two enzymes (30).   
Galactosyltransferases I and II (GalT-I & GalT-II) 
 Once the xylose residue has been covalently attached to the serine residue of a core 
protein, two galactose residues are added by way of two galactosyltransferases, relying on 
UDP-galactose as the sugar donor.  The first galactose residue is added by 
galactosyltransferase I (GalT-I) while the second galactose is added by galactosyltransferase 
II (GalT-II).  Localized in the medial Golgi cisternae, Gal-TI belongs to the β1,4-
galactosyltransferase gene family (31) while GalT-II is the sixth member of the β1,3-
galactosyltransferase family (32).  Transfection of GalTI-deficient CHO cells with GalTI 
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cloned DNA completely restored both heparan sulfate and chondroitin sulfate biosynthesis 
(33).  The importance of GalT-II in vivo was confirmed by the noticeable blocking of GAG 
biosynthesis upon silencing of GalT-II in HeLa S3 cells (32). These results demonstrate the 
functional importance of both GalT-I and GalT-II to heparan sulfate biosynthesis.  Mutations 
of GalT-I have been implicated in the onset of a progeroid variant of Ehlers-Danlos 
syndrome, a connective tissue disorder due to little proteoglycan biosynthesis in humans 
(34,35).  However, more studies must be completed in order to determine if other 
glycosyltransferases such as XylT, GalT-II, or GlcUAT-I play a role in this disorder.   
Glucuronyltransferase I (GlcUAT-I) 
 The tetrasaccharide linkage region synthesis is completed by the addition of the final 
residue, a glucuronic acid.  The transfer of glucuronic acid from the sugar donor UDP-
glucuronic acid to the second galactose residue via a β1,3-linkage is catalyzed by 
glucuronyltransferase I (GlcUAT-I) .  After several attempts, the GlcUAT-I was successfully 
purified to homogeneity from human placenta (36-38).  Enzymatic assays determined that 
modifications on the xylose and galactose residues of the tetrasaccharide linkage region, 
specifically a 2-O-phosphate group on xylose and 6-O-sulfo group on the first galactose, 
enhanced the activity of GlcUAT-I (39).  It is important to note that these modifications have 
not been identified simultaneously on the chain (29) however there is a possibility that 
modifications to the tetrasaccharide region may play an important role in completing GAG 
biosynthesis. 
 The crystal structure of GlcUAT-I has been solved in the presence of donor and 
acceptor substrates (40,41).  A ternary complex of GlcUAT-I with the sugar donor UDP and 
the acceptor substrate Galβ1,3Galβ1,4Xyl revealed that the enzyme mainly recognizes 
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Galβ1,3Gal with xylose residing outside the substrate binding cavity, potentially serving as a 
spacer between the Galβ1,3Gal and the core protein (40).  The binary complex of GlcUAT-I 
with the complete UDP-GlcUA sugar donor provides support for an in-line displacement 
mechanism for this glycosyltransferase with a glutamic acid implicated as the potential 
catalytic base (41).   
With approximately 43% sequence identity, an additional β1,3-glucuronyltransferase 
GlcUAT-P, known to add GlcUA to glycoproteins, was determined to possess similar 
substrate specificity to GlcUAT-I (42).  Interestingly, an in vivo study utilizing GlcUAT-I 
deficient CHO cells demonstrated restoration of GAG synthesis upon transfection with either 
GlcUAT-I or GlcUAT-P (42).  Despite their similar substrate specificities, GlcUAT-I and 
GlcUAT-P have different tissue expression, with GlcUAT-I being expressed in all examined 
tissues and GlcUAT-P exclusively expressed in the brain (42).  The exclusive expression of 
GlcUAT-P suggests a potential role for GAG production in neural tissues.   
Chain Polymerization 
 Following preparation of the tetrasaccharide linkage region (GlcUA-Gal-Gal-Xyl), 
the heparan sulfate nascent chain is biosynthesized by the addition of the first N-acetyl 
glucosamine residue to the non-reducing end GlcUA by CHO derived GlcNAc transferase I 
(GlcNAcT-I).  The addition of the initial GlcNAc residue to the tetrasaccharide linkage 
region is a commitment step for heparan sulfation polymerization.  The GlcNAcT-I enzyme 
is not to be confused with the GlcNAc transferase II (GlcNAcT-II) that is responsible for the 
addition of GlcNAc residues during chain polymerization/elongation (43).  The GlcNAcT-I 
activity was identified in two mammalian enzymes encoded by the exostosin-like (EXTL) 
family, EXTL-2 and EXTL-3 (44,45).  EXTL-2 possesses solely GlcNAcT-I activity whereas 
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EXTL-3 harbors both GlcNAcT-I and GlcNAcT-II activities (45).  In vitro studies using N-
acetyl heparosan oligosaccharides and a known synthetic substrate for GlcNAcT-I activity, 
GlcUAβ1–3Galβ1-O-C2H4NH-benzyloxycarbonyl, showed EXTL-3 activity with both 
substrates (45).  This result suggests that EXTL-3 could be involved in both initiation and 
elongation.  In vivo studies are essential for understanding the role of EXTL-2 and EXTL-3 
in initiating HS polymerization.  Mutations in the zebrafish EXT-like boxer gene, 
homologous to human EXTL-3, resulted in defective fin and branchial arch development, 
possibly due to defective FGF10 signaling (46).  The zebrafish mutant presented significantly 
reduced HS levels, further supporting the role of EXTL-3 in HS initiation (47).  A GlcNAc 
transferase known as rib-2 was identified in C. elegans and determined to be involved in both 
heparan sulfate chain initiation and elongation with similar substrate specificity to EXTL-3, 
suggesting a distinct mechanism from mammals (48).   
 Once committed to HS biosynthesis with the addition of the first GlcNAc residue by 
GlcNAcT-I, chain elongation begins by the alternating addition of GlcUAβ4 and GlcNAcα4 
residues, from UDP-GlcUA and UDP-GlcNAc respectively, by a set of mammalian 
glycosyltransferases belonging to the exostosin (EXT) gene family known as EXT-1 and 
EXT-2.  The EXT family was initially recognized as causative genes of a genetic bone 
disorder as well as tumor suppressor genes (49,50).  Mutations in EXT-1 or EXT-2 are also 
responsible for multiple hereditary exostoses, hallmarked by tumors within the cartilage 
(51,52).  When expressed, EXT-1 and EXT-2 were determined to exhibit both GlcUA and 
GlcNAc transferase activities, indicating their functional role as a co-polymerase (53,54).  
Studies have demonstrated that EXT-1 and EXT-2 form a stable complex accumulating in 
the Golgi apparatus with significantly higher glycosyltransferase activities when co-
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expressed than when expressed individually (52,54).  A cell line defective in EXT-1 
expression demonstrated no compensation by EXT-2 in the absence of EXT-1, suggesting 
that the EXT-1/EXT-2 complex represents the active form within cells (52).  Mice deficient 
in EXT-1 exhibited early embryonic lethality as well as poor gastrulation and defective bone 
growth (55).  Like with EXT-1 disruption, the EXT-2 knockout mice show embryonic 
lethality and poor gastrulation (56).  Targeted disruption of either the EXT-1 or EXT-2 genes 
in mice resulted in abolition of HS synthesis (55,56).  Kim et al. reported in vitro 
polymerization of the synthetic linkage region of GlcUA-Gal-O-C2H4NH-benzyloxycarbonyl 
upon co-transfection with EXT-1 and EXT-2 (50).  Interestingly, no polymerization occurred 
when a mixture of individually expressed EXT-1 and EXT-2 were incubated with the natural 
tetrasaccharide linkage region of GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser (50), suggesting 
the importance of hydrophobic residues near the linkage region that can be achieved by the 
artificial aglycon, C2H4NH-benzyloxycarbonyl (45). 
In addition to EXT-1 and EXT-2, there are two other mammalian enzymes, EXTL1 
and EXTL3, which are known to possess GlcNAcT-II activity (45).  Neither EXTL1 nor 
EXTL3 demonstrated GlcUAT-II activity as determined by in vitro studies using N-acetyl 
heparosan oligosaccharides with the non-reducing terminal GlcNAc (45).  As for EXT-1 and 
EXT-2, there was no GlcNAc transfer to the natural tetrasaccharide linkage for EXTL1 or 
EXTL2 further supporting the potential necessity for hydrophobic residues near the linkage 
region like with the artificial aglycon on the synthetic substrate (45).  The role of EXTL1 and 
EXTL2, both possessing GlcNAcT-II activity, in HS chain polymerization remains to be 
determined.  Further studies are necessary to determine whether EXTL1 and/or EXTL3 
interact with EXT-1 and/or EXT-2 to complete polymerization.   
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Chain Modification 
Once the native heparan sulfate polysaccharide backbone has been synthesized, it is 
then susceptible to numerous modifications involving a series of specialized enzymes 
including an epimerase and various sulfotransferases as illustrated in Figure 5 (57-59).  The 
HS backbone is first modified by N-Deacetylase/N-Sulfotransferase (NDST) which serves to 
convert N-acetylated glucosamine (GlcNAc) residues to N-sulfo glucosamine (GlcNS).  
Following N-sulfation, C5-epimerase converts D-glucuronic acid (GlcUA) to L-iduronic acid 
(IdoUA).  The backbone is then modified by several O-sulfotransferases including 2-O-
sulfotransferase (2OST) that introduces 2-O-sulfo groups to GlcUA or IdoUA units as well 
as  6-O-sulfotransferase (6OST) and 3-O-sulfotransferase (3OST) which add 6-O-sulfo and 
3-O-sulfo groups to the glucosamine unit respectively.  The sulfotransferases rely on a 
biologically active sulfo donor, 3’-phosphoadenosine 5’-phosphosulfate (PAPS) that is 
synthesized by PAPS synthase in the cytoplasm and nucleus of animals (Figure 6A) (60).  
Once synthesized, PAPS must be transported to the Golgi apparatus by the action of the 
PAPS transporter for heparan sulfate biosynthesis (61,62). 
Combined structural and mutational analyses have provided some insight into the 
catalytic mechanism of the HS sulfotransferases especially that of 3OST-3 whose crystal 
structure includes a ternary complex of human 3OST-3 with PAP and a tetrasaccharide HS 
substrate (63).  The ternary complex of 3OST-3 suggests that sulfo group transfer occurs by a 
SN2-like in-line displacement mechanism with the potential catalytic base, such as glutamic 
acid, deprotonating the 3-OH position of glucosamine for nucleophilic attack on the sulfo 
group of PAPS as illustrated in Figure 6B.  These chain modification reactions do not 
proceed to completion, resulting in high structural variability of the HS products (64).   
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Figure 5.  Modification of the heparan sulfate polysaccharide backbone.  Once the HS nascent polymer is 
synthesized by specialized glycosyltransferases, the chain is susceptible to several enzymatic modifications 
including N-sulfation and epimerization of GlcUA to IdoUA followed by O-sulfation by different HS O-
sulfotransferases.  The sulfotransferase reactions utilize the universal sulfo donor PAPS to transfer the sulfo 
groups to the chain.  Several of the modification enzymes exist in more than one isoform as indicated by the 
number in parentheses.  N-sulfation is a prerequisite for subsequent modifications but does not proceed to 
completion, resulting in three domains differing in the level of N-sulfation. 
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Figure 6.  Mechanism of the heparan sulfate sulfotransferases.  (A) General mechanism of HS 
sulfotransferases.  The sulfotransferase catalyzes the transfer of the 5’-sulfo group from the donor PAPS to the 
heparan sulfate substrate resulting in the sulfated product and PAP.  (B)  Proposed catalytic mechanism of HS 
sulfotransferases.   
 
 
Factors Controlling Substrate Specificity  
The biosynthesis of HS is not a template-driven process therefore the final HS 
products are dictated by the substrate specificity of the biosynthetic enzymes.  The substrate 
recognition of these enzymes is controlled at the monosaccharide level.  This control is 
dependent upon the regioselectivity of the residue at the site of modification (2).  For 
example, 2OST recognizes either GlcUA or IdoUA and specifically transfers a sulfo group to 
the 2-OH position to generate GlcUA2S or IdoUA2S respectively.  The specificity of the 
enzymes is also controlled at the oligosaccharide level through recognition of the sulfation 
pattern surrounding the modification site.  With 2OST, a non-reducing end GlcNS residue is 
required for sulfation (65).  The lack of homogeneous polysaccharide substrates has hindered 
our ability to complete elaborate substrate specificity studies for the biosynthetic enzymes.      
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With the exception of C5-epi and 2OST that exist in a single isoform, the presence of 
multiple isoforms of the modification enzymes including NDST, 6OST, and 3OST serves to 
regulate the sulfation pattern of the final heparan sulfate structures (2,66-69).  Studies have 
indicated that the different isoforms recognize different sulfation patterns around the 
modification site, implicating their role in preparing specific sequences within the HS chain 
(2,18).  The presence of multiple isoforms of the modification enzymes suggests that the 
biosynthesis of heparan sulfate is strictly regulated in vertebrates.   
The substrate specificity of HS sulfotransferases controls the sulfation patterns of HS, 
permitting HS to exhibit a specific function, however, limited knowledge regarding the 
mechanism of these enzymes has hindered our ability to prepare functionally-specific HS.  
Therefore, understanding the substrate recognition mechanism used by the sulfotransferases 
is necessary for advancing the enzymatic synthesis of HS as well as delineating the 
biosynthetic mechanism of HS.  Coupling a structural biology approach with site-directed 
mutagenesis offers an effective methodology for understanding the substrate recognition 
mechanism of the HS sulfotransferases.  The crystal structures of several HS 
sulfotransferases, including N-sulfotransferase domain of NDST and three isoforms of 3OST, 
have already been elucidated.  However, more extensive studies must be completed of the 
structurally unknown 2OST and 6OST to gain more insight into their molecular mechanism.      
Glucosaminyl N-Deacetylase/N-Sulfotransferase (NDST) 
 The bi-functional enzyme, N-Deacetylase/N-Sulfotransferase, is the initial step in the 
modification of both heparan sulfate and heparin, which is absolutely mandatory for 
subsequent epimerization and O-sulfations to occur (67).  The NDST enzyme catalyzes 
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deacetylation of the GlcNAc residue to produce free amine at the C-2 position, immediately 
followed by N-sulfation to produce GlcNS (70) (Figure 7).   
 
Figure 7.  Reactions catalyzed by heparan sulfate NDST.  NDST catalyzes deacetylation of glucosamine 
(GlcNAc) followed by N-sulfation in the presence of the sulfo donor PAPS to produce N-sulfo glucosamine 
(GlcNS). 
 
 
 
 Four isoforms of NDST have been identified in vertebrates including both human and 
mouse.  These four isoforms have been successfully cloned and possess distinct tissue 
expression patterns (71-76).  NDST-1 and NDST-2 being uniformly expressed across all 
examined tissues whereas NDST-3 and NDST-4 were predominately expressed in the brain 
(71).  There are two subtypes of NDSTs, consisting of NDST-1/2 and NDST-3/4 (71).  
NDST-1 and NDST-2 share 70% sequence identity whereas NDST-3 and NDST-4 share 
80% identity.  NDST-2 is highly expressed in mast cells and has been speculated to be 
involved in biosynthesis of heparin but not heparan sulfate (74).   The isoforms possess 
strikingly different enzymatic properties.  NDST-1 and -2 demonstrated similar levels in 
deacetylase and sulfotransferase activities but with NDST-1 having a slightly higher level of 
sulfotransferase activity (71).  On the other hand, NDST-3 possesses high deacetylase 
activity but weak sulfotransferase activity whereas NDST-4 presented weak deacetylase 
activity and high sulfotransferase activity (71).   The distinct activity and expression patterns 
of the four isoforms suggest a potential for varying substrate recognition among each 
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isoform.  Unfortunately, substrate specificity studies have yet to be completed for the NDSTs 
therefore the specific structure recognized by this enzyme is currently unknown (2).   
The NDST protein, comprised of 883 amino acid residues with an approximate 
molecular weight of 100 kDa (74), is divided into two domains: the N-terminal deacetylase 
domain and the C-terminal sulfotransferase domain.  The deacetylase domain of NDST 
comprises the first 600 amino acid residues whereas the sulfotransferase domain comprises 
the final 283 residues (77).  Both domains have been expressed individually and determined 
to exhibit their anticipated activities (78,79).  A crystal structure of the C-terminal NST 
domain of human NDST-1 in complex with the inactive sulfo donor, PAP, was determined at 
a resolution of 2.3 Å (79) (Figure 8).  The overall fold of NST-1 is consistent with that of a 
type II membrane-bound sulfotransferase with a α/β fold containing a central five-stranded 
parallel β-sheet and a large open cleft with a hydrophilic surface for HS binding (79).  The 
substrate binding site of NST-1 is very distinct from the structurally known cytosolic 
sulfotransferases such as estrogen sulfotransferase (EST), which possesses a hydrophobic 
binding pocket for estradiol (80).  The catalytic mechanism of NST was proposed based on a 
molecular model of NST-1 with a docked hexasaccharide in the active site (81).  Analysis of 
residues within the active site revealed a potential role for Glu-642 as the catalytic base due 
to its hydrogen bonding distance with the NH3
+
 
 
group of glucosamine and complete abolition 
of sulfotransferase activity when mutated (81).  Although the crystal structure of the N-
sulfotransferase domain of NDST-1 has provided insight into its catalytic mechanism, the 
crystal structure of the N-deacetylase domain has yet to be determined, limiting our 
knowledge of the deacetylation mechanism.  A better understanding of the deacetylase 
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mechanism of NDST could help explain the difference in deacetylase activities as well as 
decipher the substrate requirements among the isoforms.   
.  
Figure 8.  Ribbon representation of the structure of the N-sulfotransferase domain of human NDST-1 in 
complex with PAP.  Helices are colored yellow, β-strands in green, random coil in blue, and PAP in red.  
Structure taken from (79).  
  
 The role of N-sulfation in mammalian development has been established through 
several NDST knockout mouse models.  Mice deficient in NDST-1 exhibited incomplete 
lung development and respiratory distress, resulting in neonatal death (82).  In addition to 
lung formation, NDST-1 expression is essential for forebrain, eye and face development (83).  
Recently, a prominent role for N-sulfation in inflammation was established through a 
knockout study of NDST-1 within endothelial cells and leukocytes of mice.  The absence of 
NDST-1 expression within these specific tissues resulted in a decreased inflammatory 
response, including a reduction in the recruitment of inflammatory cells as well as a 
decreased allergen response (84).  
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  As mentioned previously, it has been speculated that NDST-2 is exclusive for 
synthesis of heparin and not heparan sulfate in mast cells (74).  It was previously determined 
that mast cells have high levels of expression of NDST-2 but little to none of NDST-1 (76).  
Indeed, mice deficient in NDST-2 were incapable of producing sulfated heparin, possessing 
fewer connective-tissue mast cells as well as significantly reduced histamine and mast-cell 
proteases (85).  Recently, it was determined that NDST-2 plays a key role in the granule 
storage capacity of mast cells which is promoted by serglycin, a glycoprotein with several 
attached HS/CS chains.  NDST-2 expression increased during mast cell maturation, 
suggesting a role in formation of highly sulfated heparin attached to the serglycin core 
protein (86).  NDST-2 is essential for heparin biosynthesis however the role in synthesizing 
heparan sulfate  is less clear since there was no apparent difference in the level of N-sulfation 
among wild-type and NDST-2
-/- 
 mice (85).   
 A targeted disruption of NDST-3 in mice presented no significant alteration in 
development or homeostasis, only demonstrating slight abnormalities in hematological 
parameters and behavior (87).  A series of double knockout mice studies were completed to 
determine a potential compensatory effect by the other NDSTs when NDST-3 expression 
was eliminated.  A NDST-2/NDST-3 deficient mouse appeared normal whereas mice 
deficient in both NDST-1 and NDST-3 did not survive birth and exhibited developmental 
defects caused by severe HS undersulfation, suggesting a potential role for NDST-3 in HS 
biosynthesis in the absence of NDST-1 (87).  Any potential roles for NDST-4 have yet to be 
established. 
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Glucuronosyl C5-Epimerase (C5-epi)  
Heparan sulfate C5-epimerase (C5-epi) is the first modification known to occur on the 
uronic acid residue, catalyzing the conversion from D-glucuronic acid to L-iduronic acid 
through abstraction and readdition of a proton at the C5 position of the uronic acid residue by 
way of a carbanion intermediate  (88,89) (Figure 9).  Because of the reversibility of the 
reaction catalyzed by C5-epi, the resultant polysaccharide contains both GlcUA and IdoUA 
units.  The conversion of GlcUA to IdoUA increases the flexibility within HS since the 
IdoUA unit can adopt several conformations including the low energy chair (
4
C1 and 
1
C4) and 
skew boat (
2
S0) conformations (11,90).  The GlcUA, on the other hand, only exits in a single 
4
C1 conformation (11).  Studies have indicated that the flexibility of the HS caused by the 
presence of IdoUA contributes to the various biological functions (14).   
 
 
Figure 9.  Proposed reaction mechanism of C5-epi.  The C5-epi catalyzes the abstraction of a proton from the 
C-5 position of the uronic acid residue to form a carbanion intermediate.  The readdition of a proton results in 
conversion from the D-glucuronic acid to L-iduronic acid.  The epimerase reaction recognizes an N-sulfo 
glucosamine residue at the non-reducing end.   
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C5-epi consists of 618 amino acids with a molecular weight of approximately 70 kDa 
(91).  The C5-epi was successfully purified from mouse mastocytoma (91,92) and bovine 
liver (93) and cloned from bovine lung (89).  The enzyme exists in a single isoform among 
all vertebrate and invertebrate species with human C5-epi possessing greater than 95% 
sequence identity to mice (91).  Previous substrate specificity studies have indicated that a 
non-reducing end N-sulfo glucosamine (GlcNS) residue is required for the epimerization 
reaction to occur (94).  Therefore, -GlcNS-GlcUA-GlcNAc- is an appropriate substrate for 
C5-epi while -GlcNAc-GlcUA-GlcNS- is not (94).  The presence of O-sulfo groups have 
been determined to inhibit the reactivity of the uronic acid residue with C5-epi, suggesting 
that epimerization precedes O-sulfation within heparan sulfate biosynthesis (94).   
In vivo functions of C5-epi were uncovered through gene knockout experiments. 
Targeted disruption of C5-epi in mice resulted in abnormal heparan sulfate structure, lacking 
iduronic acid residues and possessing a severely distorted sulfation pattern (68). C5-epi 
knockout mice are lethal, manifesting immature lung phenotype, abundant skeletal 
abnormalities and kidney agenesis (95).  It should be noted that C5-epi and 2OST reportedly 
form a complex in vivo, suggesting the intimate relationship between those two enzymes 
(96).  As expected, the phenotypes displayed by C5-epi-knockout mice are similar to those 
observed in 2OST-null mice (239).   
With the knowledge gained from understanding the catalytic mechanism of C5-
epimerase, Campbell et al. reported a method to measure the epimerase activity by 
determining the released tritium, using a site-specific 
3
H-labeled polysaccharide substrate. In 
this method, the 
3
H-label was introduced at the C5 position of GlcUA/IdoUA unit of CDSNS 
heparin (93). The C5-epi de[
3
H]protonates at the C5-position of a GlcUA or IdoUA unit, 
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dissociating the 
3
H-label from the polysaccharide.  The activity of C5-epi can be determined 
by measuring the amount of 
3
H-label released from the polysaccharide (93).  Although this 
method was successfully employed to purify the C5-epi (89), the preparation of the site-
specifically 
3
H-labeled polysaccharide involves the use of a large amount of [
3
H]H2O, which 
cannot be readily prepared in a standard academic lab.  The development of an efficient 
method for assaying C5-epi activity could enhance our understanding of the mechanism of 
C5-epi. 
Uronosyl 2-O-Sulfotransferase (2OST) 
 Heparan sulfate 2OST is the only sulfotransferase known to modify the uronic acid 
residue, catalyzing the transfer of a sulfo group from PAPS to the 2-OH position of uronic 
acid.  Like epimerase, 2-O-sulfation only occurs within the N-sulfated rich regions of 
heparan sulfate, with a non-reducing end GlcNS residue being an absolutely requirement 
(65).   Substrate specificity studies have indicated that 2OST can modify both GlcUA and 
IdoUA but possesses a selective preference for iduronic acid when both residues are present 
within the HS chain (97,98) (Figure 10).    
 
Figure 10.  Reactions catalyzed by heparan sulfate 2OST.  2OST sulfates both GlcUA and IdoUA with a 
selective preference for IdoUA.   
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 The 2OST enzyme, significantly smaller than C5-epi, consists of 356 amino acid 
residues with a molecular weight of 43 kDa, originally purified to homogeneity from Chinese 
hamster ovary cells with gel filtration analysis revealing the protein may exist as a dimer or 
trimer (99).  2OST is present in a single isoform in most vertebrate and invertebrate 
genomes, possessing high sequence conservation among species.  Human 2OST shares 97% 
sequence identity with mouse and 92% identity with chicken.  The high degree of sequence 
identity suggests a central physiological role in these organisms.  The role of 2-O-sulfation in 
fine structure formation has been examined in several species.  The 2OST knockout mice 
demonstrate renal agenesis and die in the neonatal period, demonstrating retarded eye 
development and skeletal over-mineralization (100).  In C. elegans, 2OST has been 
determined to be essential for axon migration or guidance and nervous system development 
(101).  It was also determined that 2OST is important for proper limb bud formation in 
chicken (102,103).  Dependence on 2-O-sulfation is notably less critical in Drosophila 
fibroblast growth factor signaling.  It was suggested that 2OST -/- mutant synthesizes HS 
with a higher level of 6-O-sulfation, which may compensate for the reduced 2-O-sulfation in 
Drosophila. 
 The lack of an X-ray crystal structure for 2OST had hindered our understanding of its 
substrate recognition mechanism.  Extensive mutagenesis studies based on homology to other 
structurally known sulfotransferases (EST and 3OST-1) identified key amino acid residues 
involved in the binding of 2OST to PAPS and the HS substrate (104).  Isothermal titration 
calorimetry (ITC) was utilized to determine the binding of the 2OST mutants to PAP; PAPS 
is chemically unstable and therefore cannot be used with ITC.  Residues Lys-83, Thr-84, Ser-
86, and Thr-87 were speculated to interact through hydrogen bonding with the 5’-
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phosphosulfate group of PAPS (104) while Arg-164 and Ser-172 contributed to binding the 
3’-phosphate group.  Mutation of these residues significantly reduced and often eliminated 
PAP binding, suggesting their importance in the binding of 2OST to PAPS.   
A structural neighbor search using GenTHREADER revealed that 2OST is 
structurally similar to estrogen sulfotransferase (EST) and 3-O-sulfotransferase (3OST) 
(104), especially within the β7 region of EST known to possess the catalytic base, His-108.  
The EST catalytic base aligns with His-142 of 2OST, suggesting that His-142 may serve as 
the base for 2OST.  Another histidine residue, His-140, for 2OST may be within a similar 
distance to the catalytic site, therefore both histidine residues were mutated and presented a 
similar reduction in sulfotransferase activity compared to the wild-type enzyme.  A double 
mutation of H140A/H142A completely abolished sulfotransferase activity while maintaining 
PAP binding, suggesting an important role for these two histidine residues to the activity of 
2OST (104).  Using the ternary complex of 3OST-3 with PAP and a HS tetrasaccharide 
substrate, several residues of Arg-80, Arg-178, Asp-181, Arg-189, and Arg-288 were 
identified to potentially influence substrate binding (104).  The revelation of a crystal 
structure for 2OST provided validation to the preliminary mutational analysis as well as 
heightening our understanding of the mechanism of action of the enzyme.   
Glucosaminyl 6-O-Sulfotransferase (6OST) 
 Heparan sulfate 6OST catalyzes the transfer of a sulfo group to the 6-OH position of 
the glucosamine residue within the heparan sulfate chain (Figure 11).  6-O-sulfation occurs 
mostly within the NS domain of HS however it can occur within the NA domain to generate 
GlcNAc6S (66).  This is the only sulfation known to occur within the NA domain of heparan 
sulfate since both 2OST and 3OST modifications rely on N-sulfation for the reactions to 
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occur (18).  6-O-sulfation is an essential modification for generating HS structures with 
specific biological functions, including antithrombin binding for blood anticoagulation as 
well as fibroblast growth factor (FGF) binding for triggering FGF-mediated signaling 
pathways (105,106). 
 
Figure 11.  Reactions catalyzed by heparan sulfate 6OST.  6OST can transfer a sulfo group to either a 
GlcNS or GlcNAc residue to generate GlcNS6S and GlcNAc6S respectively. The enzyme recognizes either 
GlcUA or IdoUA at the non-reducing end of the glucosamine residue.      
 
 
 The full-length 6OST enzyme contains 401 amino acids with a molecular weight of 
approximately 47 kDa (107), demonstrating type II transmembrane protein properties.  The 
enzyme was originally isolated to homogeneity from Chinese hamster ovary cells with gel 
filtration analysis revealing that 6OST exists as a monomer (108).  Invertebrates including 
Drosophila and C. elegans possess only a single ortholog of 6OST however vertebrates have 
a more diverse distribution with mouse and human having three isoforms (66, 107, 109-111).  
With a deletion of 40 amino acids, a shorter form of human 6OST-2, 6OST-2S, due to 
alternative splicing was identified in humans that maintained similar substrate preference to 
the longer form 6OST-2 (112).  The shorter form of 6OST-2 has been identified in chicken, 
which is known to possess two isoforms (111,113).   
 Preliminary substrate specificity studies have been completed for the 6OST isoforms 
however the results are inconsistent.  In 2000, Habuchi et al. determined that all of the 6OST 
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isoforms were capable of sulfating N-sulfo glucosamine residues within completely de-O-
sulfated N-sulfated (CDSNS) heparin and N-sulfo heparosan but not N-acetylated 
glucosamine (114).  This study suggests that none of the isoforms are capable of recognizing 
GlcNAc residues.  Comparison of the susceptibilities of the 6OSTs to either a GlcUA-
containing polysaccharide (N-sulfo heparosan) or an IdoUA-containing polysaccharide 
(CDSNS heparin) demonstrated a slight preference among the isoforms.  The 6OST-1 
appears to prefer IdoUA-GlcNS sequences whereas 6OST-3 has equal recognition for 
IdoUA-GlcNS and GlcUA-GlcNS.  Interestingly, 6OST-2 appears to depend on substrate 
concentration with an increase in activity as the amount of GlcUA-GlcNS increased but a 
decrease in activity as IdoUA-GlcNS increased (114).  In 2003, Smeds et al. further 
investigated the effect of the uronic acid residue adjacent to glucosamine as well as the 
presence of 2-O-sulfo groups on the specificity of the 6OST isoforms (115).  The results of 
this study were highly contradictory to the previous report in that all the isoforms were 
capable of sulfating both GlcNS and GlcNAc residues, suggesting similar specificity among 
the isoforms.  All of the isoforms targeted glucosamine residues to the reducing end of either 
a GlcUA or IdoUA although IdoUA-containing disaccharides were preferred whenever 
present.  The presence of 2-O-sulfo groups did not affect the recognition by the 6OST 
isoforms (115,116).  One major contradiction is that 6OST-1, originally found to prefer 
IdoUA-GlcNS, demonstrated a preference for GlcUA-GlcNS in this study, which can only be 
explained by the use of heterogeneous polysaccharide substrates (115).  The ambiguity of the 
specificity for the 6OST isoforms can only be resolved by the use of homogeneous heparan 
sulfate substrates with defined structures.   
  
27 
 The biological and physiological relevance of 6OST has been established through 
systematic deletion of the 6OST isoforms in different organisms.  Targeted disruption of 
6OST-1 in mice demonstrated late embryonic lethality, abnormal placentation, and decreased 
growth, which is strikingly similar to phenotypes seen in Wnt-2 knockout mice (117,118).  
Wnt-2 is known to initiate expression of vascular endothelial growth factor-A (VEGF-A), an 
inducer of angiogenesis, and has an affinity for heparan sulfate (119).  The 6OST-1 knockout 
mice exhibit reduced Wnt-2 binding and reduced levels of VEGF-A, suggesting 6OST is 
important for Wnt-2 recognition to assist with placental vasculogenesis (117).  Analysis of 
the HS structures from different tissues from the 6OST-1 null mice showed a marked 
decrease in the levels of GlcNAc6S and GlcNS6S in the liver, kidney and lungs, which were 
previously identified to express high levels of 6OST-1 (114).  This marked decrease implies 
that 6OST-1 may be important for the development of these specific tissues.  A morpholino 
knockdown of 6OST in zebrafish, possessing greater than 50% identity with human 6OSTs, 
demonstrated a role for 6-O-sulfation in muscle development  that appears to regulate the 
Wnt-signaling pathway (120).   Taken together, these knockout studies support the 
importance of 6OST for developmental processes in vertebrates.     
 The role of 6-O-sulfation has also been analyzed in simpler organisms, including 
Drosophila and C. elegans.  Disruption of 6OST expression in Drosophila resulted in 
embryonic lethality and defective tracheal development (109).  The Drosophila tracheal 
system shares several features in common with the vertebrate vascular system, further 
implicating a role of 6OST in vascular development as is indicated by the mouse model 
(121).   This study provides strong in vivo evidence that 6-O-sulfated HS is crucial for FGF 
signaling during tracheal development in Drosophila (122,123).   Within C. elegans, 
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mutations of the hst-6 gene resulted in viable and fertile offspring with neuron-specific 
defects in axon and cellular guidance (124,125).   The effects seen with the 6OST-defective 
C. elegans have been linked to two important signaling systems, Slit/Robo and KAL-1 
pathways, for nervous system development (124,125).    
To date, there is no known crystal structure for 6OST however a structural neighbor 
search using mGenThreader has predicted that 6OST is most likely more structurally similar 
to NST and the 3OSTs instead of 2OST.  The overall fold of the protein is most likely similar 
to NST and 3OST, however, there are some striking differences.  The 6OST enzyme has ten 
evolutionary conserved cysteine residues while the NST and 3OSTs only possess two 
conserved cysteine residues whereas 2OST possesses four.  Six of the cysteine residues 
within 6OST are located near the 5’-phosphate and 3’-phosphate groups of the proposed 
PAPS binding site where the other sulfotransferases have none in that site.  The additional 
four cysteine residues are located after the 3’-phosphate of the PAPS binding site as is the 
case with 2OST.  These four cysteine residues could potentially be important for the stability 
of 6OST as mutation of these same cysteine residues in 2OST destabilizes the protein (126).   
A combination of structural and extensive mutational analysis will guide our understanding 
of the substrate recognition mechanism of 6OST as well as contribute to our enzymatic 
approach to synthesizing structurally defined HS.      
Glucosaminyl 3-O-Sulfotransferase (3OST) 
 The rarest modification to heparan sulfate is 3-O-sulfation of the glucosamine residue 
catalyzed by 3-O-sulfotransferase (Figure 12).  The 3OST catalyzes transfer of the sulfo 
group from PAPS to the 3-O-position of either an unsubstituted or N-sulfated glucosamine 
residue within heparan sulfate (127).  Studies have indicated that 3-O-sulfation accounts for 
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only 0.5% of the total sulfate within a heparan sulfate chain (128,129).  Due to its 
infrequency, 3-O-sulfation of HS is of special interest since it has been identified to play a 
critical role in several biological processes including anticoagulation, herpes simplex virus 
(HSV) infection, circadian rhythms and various cancers of the breast, colon, lung and 
pancreas (127,130-132). 
 
 
 
Figure 12.   Reaction catalyzed by heparan sulfate 3OST.  3OST can transfer a sulfo group to either a 
GlcNH2 or GlcNS residue to generate GlcNH23S and GlcNS3S respectively.  The different 3OST isoforms are 
highly dependent on the non-reducing end residue adjacent to glucosamine. 
 
 
 Seven isoforms of 3OST have been identified in humans and mice and successfully 
cloned to date, consisting of 3OST-1, -2, -3A, -3B, -4, -5, and -6 (133-136).  Based on 
sequence homology within the sulfotransferase domain, the isoforms can be divided into two 
subgroups, the 3OST-1-like and 3OST-3-like subgroups (137).  The 3OST-1-like subgroup 
consists of 3OST-1 and 3OST-5, with approximately 75% sequence identity within the 
sulfotransferase domain (137,138).  The 3OST-3-like subgroup consists of the other 3OST 
isoforms of 3OST-2, 3OST-3A, 3OST-3B, 3OST-4, and 3OST-6, possessing greater than 80% 
sequence identity within the sulfotransferase domain (137,138).  Eight 3OST isoforms have 
been identified in zebrafish with members of the zebrafish family showing 63% identity with 
the corresponding isoform with the exception of the 3OST-5 isoform with 53%.  The novel 
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zebrafish 3OST-7 gene was determined to be a member of the 3OST-1 like subgroup with 
66% sequence identity to human 3OST-1 (137).  A single 3OST gene, hst-3, has been 
identified in C. elegans (110) and two within Drosophila, 3OST-A and 3OST-B (138).   The 
Drosophila 3OST-A is more homologous the 3OST-1 like subgroup whereas 3OST-B 
demonstrates higher identity with the 3OST-3 like group, suggesting that 3OST diverged into 
two branches with different specific functions during early evolution (138).   
Despite the extensive characterization of the significance of 3-O-sulfation in the 
interaction of HS and antithrombin within anticoagulation, the role of 3OST in animal 
development has not been thoroughly investigated.  The only available knockout model is 
that of 3OST-1 within mice, demonstrating normal hemostasis with abnormal phenotypes 
including genetic background-dependent lethality and intrauterine growth retardation 
(139,140).  The interaction among HS and AT was unaffected in the knockout mice 
(139,140).  The level of anticoagulantly active HS and factor Xa activity were reduced but 
not completely eliminated in the 3OST
-/-
 mice, suggesting that the other 3OST isoforms may 
compensate for the loss of 3OST-1 (139,140).  These phenotypes are significantly distinct 
from AT knockout mice, which resulted in embryonic lethality due to thrombosis in both the 
liver and myocardium (141,142).  The differences in the 3OST-1 and AT knockout mouse 
studies indicate that 3-O-sulfation may play a role in other biological processes and therefore 
more work must be carried out to explore this idea.  A disruption of 3OST-B in Drosophila 
via RNA interference revealed a role for 3-O-sulfation in Notch signaling by markedly 
reducing the level of the Notch protein (138).   
In contrast to the 6OSTs, the 3OST isoforms have very distinct substrate specificities, 
recognizing unique disaccharide structures within HS and generating HS with diverse 
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biological functions (Figure 13).  The substrate requirements of 3OST-1, -3, and -5 have 
been extensively studied.  The 3OST-1 enzyme transfers a sulfate to an N-sulfated 
glucosamine residue linked to a glucuronic acid or iduronic acid at the non-reducing end to 
generate GlcUA-GlcNS3S±6S and IdoUA-GlcNS3S±6S respectively.  On the other hand, the 
3OST-3 enzyme can sulfate two substrates, IdoUA2S-GlcNH2 and IdoUA2S-GlcNH26S, 
which were found within the highly sulfated NS domains of heparan sulfate (135).  Studies 
have determined that substrates modified by members of the 3OST-3-like family, including 
3OST-2, 3OST-3, 3OST-4, and 3OST-6 do not possess anticoagulant activity as the HS 
modified by 3OST-1 but instead act as entry receptors for herpes simplex virus (HSV) 1 
entry (134-136,144,145).  The 3OST-3 enzyme can also recognize disaccharides carrying N-
sulfated glucosamine linked to an IdoUA2S residue at the non-reducing end (143).  The other 
members of the 3OST-3-like subgroup, 3OST-2, 3OST-4, and 3OST-6, were determined to 
recognize only disaccharides containing N-sulfated glucosamine linked to a 2-O-sulfated 
IdoUA at the non-reducing end (IdoUA2S-GlcNS±6S) (136,143,144,146) .   
Interestingly, the 3OST-5 is very promiscuous in that it can recognize and sulfate the 
substrates for both 3OST-1 and 3OST-3, which includes recognition of glucosamine residues 
attached to a glucuronic acid, iduronic acid, or even a 2-O-sulfated iduronic acid at the non-
reducing end (147).  As a result of its broad specificity, HS modified by 3OST-5 can possess 
either anticoagulant activity or serve as an entry receptor for HSV-1 infection (145,147).  
Disaccharide analysis of both 3OST-1 and 3OST-5 modified HS isolated from CHO cells 
revealed the presence of a rare disaccharide of IdoUA-GlcNS3S±6S whose function is 
currently unknown (147-149).   
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Figure 13.  Substrate specificity of the 3OST isoforms.  3OST-1 sulfates the 3-OH position of a GlcNS 
residue linked to either GlcUA or IdoUA at the non-reducing end.  3OST-3 sulfates the 3-OH position of a 
GlcNS or GlcNH2 linked to an IdoUA2S residue at the non-reducing end.  3OST-2, -4, and -6 can modify a 
GlcNS residue with an IdoUA2S residue at the non-reducing end that serves as an entry receptor for herpes 
simplex virus 1. 3OST-5 is promiscuous and can sulfate the substrates of both 3OST-1 and 3OST-3.  The 
substrate modified by 3OST-1 possesses anticoagulant activity while the substrate modified by 3OST-3 is an 
entry receptor for herpes simplex virus 1.  The 3OST-5 modified HS can demonstrate either anticoagulant 
activity or serve as an HSV entry receptor.  The 3-O-sulfo group is colored red. 
 
 
 
 
  The crystal structures of the sulfotransferase domains of 3OST-1, 3OST-3, and 
3OST-5 have been elucidated (63,150,151), providing a plethora of information regarding the 
catalytic and substrate recognition mechanisms of 3OST.  The sulfotransferase domain of the 
3OST isoforms were determined to be structurally similar to NST-1 with the exception of 
distinguishing features within the HS binding cleft.  The 3OSTs have an overall folded 
structure with a large open HS binding cleft.  Like NST-1, the 3OSTs have a central α/β 
motif.  The PAPS binding site within the 3OSTs is nearly identical among the 3OSTs and 
NST-1, relying on a conserved glutamate as the catalytic base.  The striking difference 
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between NST-1 and 3OSTs is that the 3OSTs have an increased positive charge within the 
substrate binding cleft, suggesting recognition of a highly negatively charged HS substrate 
(150).   This finding may explain some of the differences in substrate specificity for these 
two biosynthetic enzymes.    
 The knowledge regarding the substrate recognition mechanisms for the 3OSTs was 
further advanced by the revelation of a ternary complex of 3OST-3 with PAP and a known 
3OST-3 HS substrate,  ΔUA2S-GlcNS6S-IdoUA2S-GlcNS6S (63,143) (Figure 14).  It 
should be noted that the Δ4,5 unsaturated 2-O-sulfo uronic acid (ΔUA2S) is not present in the 
HS polysaccharide however the skew boat conformations of IdoUA2S and ΔUA2S present 
similar positioning of functional groups.  Therefore, the ΔUA2S is a sufficient mimic of 
IdoUA2S for recognition by 3OST-3 (63).  The tetrasaccharide binding site of 3OST-3 
demonstrated extensive interactions with the non-reducing end UA2S unit as well as the 
identified the 3-OH position of non-reducing end glucosamine residue as the site of 3-O-
sulfation (63).  The amino acid residues (Lys-161, Arg-166, Lys-215, Gln-215, Lys-368, and 
Arg-370) within 3OST-3 involved in HS binding are conserved across the isoforms, 
suggesting an important role for these residues in dictating substrate binding (2,63).  
Mutation of these potential substrate binding residues within 3OST-3 resulted in a drastic 
loss of enzymatic activity, confirming their importance in substrate recognition (63).  
Interestingly, two 3OST-3 mutants, Q255A and K368A, nearly abolished sulfotransferase 
activity however mutation of the corresponding residues in 3OST-1 (Gln-166 and Lys-274) 
maintained 34% and 17% activity respectively (63).  These results suggest that Gln-255 and 
Lys-368 are important for the substrate specificity of 3OST-3 since these residues were 
found to interact with UA2S and IdoUA2S residues within the bound tetrasaccharide.  These 
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findings can also be supported by the fact that 3OST-1 recognizes a GlcUA instead of an 
IdoUA2S residue as a substrate.  The information gained from the crystal structure of 3OST-
3 with a bound tetrasaccharide provided insight into the substrate specificity of 3OST 
however crystal structures of the other isoforms with appropriate oligosaccharides are 
necessary for a clear picture of the substrate recognition mechanism of the 3OSTs. 
 
 
Figure 14.  Crystal structure of ternary complex 3-OST-3/PAP/tetrasaccharide. (A) Crystal structure of 
3OST-3A in complex with PAP (blue) and HS tetrasaccharide (green).  (B) Superposition of PAPS onto PAP in 
the active site of 3OST-3A.  The relative orientation of the acceptor 3’-OH position of the HS substrate is 
displayed.  The side chains that are involved in substrate binding are labeled.  A sodium ion involved in binding 
is labeled pink.  The arrow indicates a kink in the polysaccharide.  Structure taken from (152). 
 
 
 
 
 With an initial attempt to engineer the HS biosynthetic enzymes, the crystal structure 
of 3OST-5 was determined and successfully demonstrated the feasibility for tailoring the 
substrate specificity of the 3OST isoforms (Figure 15A) (151).  As mentioned previously, 
3OST-5 has been determined to possess both 3OST-1 (anticoagulant) and 3OST-3 (HSV-1 
viral entry) activities therefore a structurally-guided mutagenesis study was completed to 
selectively remove the 3OST-1-like and 3OST-3 like activities of 3OST-5.  As seen in Figure 
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15B&C, a gate was found to be formed by specific residues along the non-reducing end of 
the binding clefts of 3OST-1 (Glu-88 and His-271) and 3OST-3 (Gly-182 and Gly-365) and 
speculated to possibly confer the specificity of the enzymes.  The gate residues form a 
narrow cleft for 3OST-1 whereas a much wider cleft is present for 3OST-3.  3OST-5 was 
determined to be more structurally similar to 3OST-3 with the gate residues (Ser-120 and 
Ala-306) forming a wider cleft (Figure 15D).  Mutation of the corresponding gate residues in 
3OST-5 to the 3OST-1 gate residues altered the specificity of 3OST-5 and vice versa.  For 
example, mutation of the 3OST-1 gate residues to the corresponding 3OST-5 gate residues 
increased recognition for the IdoUA2S-GlcNS containing polysaccharide, a HS structure 
normally recognized by 3OST-3 and 3OST-5 instead of 3OST-1.  Additional support was 
provided when mutation of the 3OST-5 gate residues to the 3OST-1 gate residues reduced 
the recognition for the IdoUA2S-GlcNS containing substrate, a known 3OST-3 substrate, 
while increasing recognition of the known 3OST-1 substrate containing GlcUA-GlcNS.  The 
results suggested that the gate residues among the 3OST isoforms along with catalytic site 
are responsible for recognizing the appropriate polysaccharide substrate, specifically the 
presence of the IdoUA2S unit, a distance of three saccharide residues away from the site of 
sulfation (151).  The information gained from the 3OST-5 structural analysis demonstrated 
the potential for engineering the sulfotransferases to generate HS with desired biological 
functions.   
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Figure 15.  Structural analysis of the gate residues within the 3OST isoforms.  (A) Ribbon diagram of the 
crystal structure of human 3OST-5 with PAP bound (cyan).  (B-D) Identification of the substrate binding gate 
residue with the 3OST isoforms.  The position of the substrate binding cleft is shown as a dashed green arrow.  
The measured distances between the gate residues are labeled black.  The key amino acid residues forming a 
gate at the non-reducing end of the binding cleft of mouse 3OST-1 (B), human 3OST-3 (C), and human 3OST-5 
(D) are labeled and the surface colored in red.  The bound tetrasaccharide substrate, ΔUA2S-GlcNS6S-
IdoUA2S-GlcNS6S, is depicted in ball and stick and the glucosamine residue to be sulfated is circled yellow.  
Structure taken from (151). 
 
 
Current Methodologies for Structural Analysis of Heparan Sulfate 
There is accumulating evidence explaining the role of heparan sulfate polysaccharides 
in regulating biological functions in both normal and disease states.  Probing the structure-
function relationship of heparan sulfate polysaccharides is essential for understanding their 
biological roles however the structural heterogeneity, complexity and anionic nature within 
the chains make sequencing of the polysaccharides difficult.  Another barrier to sequencing is 
that the non-template based synthesis of the polysaccharides prevents amplification as is 
possible with DNA and proteins (4,153).   
The most common analytical technique for determining the structural characteristics, 
which include acetylation, sulfation, and epimerization state, of HS polymers includes 
cleavage of the polysaccharide to disaccharides followed by reverse phase ion-pairing high 
performance liquid chromatography (RPIP-HPLC) or capillary electrophoresis to 
characterize the disaccharide species present in a cleaved polysaccharide sample (4).  RPIP-
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HPLC is a very effective technique because simply altering the chromatography conditions 
allows for determination of disaccharides with different sulfation states ranging from non-
sulfated to tetrasulfated as well as epimerization states.  The major limitation to this 
analytical technique is that only information regarding disaccharide fragments is provided 
and no decipherable information is available to identify how these fragments are pieced 
together to form the polysaccharide.  Additional analytical techniques including mass 
spectrometry can be employed to determine the number of sulfo groups as well as the length 
of the oligosaccharide chain (146,153).   
There are currently two cleavage methods for completing disaccharide analysis for 
HS compounds in our laboratory:  (1) chemical degradation with nitrous acid and (2) 
enzymatic degradation with heparin lyases.  Both depolymerization techniques cleave the 
glycosidic linkage between a non-reducing glucosamine residue and a reducing end uronic 
acid residue via an elimination reaction (15).   
Chemical Degradation Using Nitrous Acid 
 Depolymerization of HS polysaccharides using nitrous acid offers an effective 
method for determining the sulfation types within a HS chain.  The use of nitrous acid serves 
to cleave HS between a non-reducing end glucosamine residue and reducing end uronic acid 
to produce a disaccharide containing a non-reducing end uronic acid and a reducing terminal 
2,5-anhydromannose, which can be reduced to anhydromannitol (AnMan) using sodium 
borohydride (Figure 16) (15).  The cleavage reaction with the glucosamine residue is highly 
dependent on pH.  The glycosidic bonds of N-sulfo glucosamine residues react with nitrous 
acid at pH 1.5 whereas the bonds of N-unsubstituted glucosamine residues are cleaved when 
treated with nitrous acid at pH 4.5-5.5 (4,15).  Unfortunately, the N-acetyl glucosamine 
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residues do not react with nitrous acid at either pH and must first be converted to N-
unsubstituted glucosamine (GlcNH2) using hydrazine, allowing for subsequent cleavage with 
nitrous acid at pH 4.5.  The advantage of this method is that the configuration of the uronic 
acid is unaltered, allowing one to distinguish between IdoUA and GlcUA.  The major 
disadvantage is the need for the use of a radioactive tag or fluorescent label must be 
incorporated prior to disaccharide analysis since the disaccharides do not possess intrinsic 
UV absorbance (4).  
  
 
 
Figure 16.  Nitrous acid cleavage of heparan sulfate.  At pH 1.5, nitrous acid cleaves between aGlcNS 
residue and uronic acid.  Nitrous acid cleaves between GlcNH2 residues and uronic acid at pH 4.5.  The GlcNAc 
residue must first be hydrolyzed to GlcNH2 using hydrazine followed by nitrous acid cleavage at pH 4.5.  
Adapted from (4). 
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Enzymatic Degradation Using Heparin Lyases  
Enzymatic degradation has been utilized extensively for the characterization of HS 
polysaccharides.  This degradation technique employs heparin lyases, originally purified 
from Flavobacterium heparinum.  There are three heparin lyases, I-III, which have been 
determined to possess slightly different substrate requirements for cleavage of the glycosidic 
bond between glucosamine and uronic acid via a β-elimination reaction (Figure 17).  Heparin 
lyase I cleaves the glycosidic bond between an N-sulfo glucosamine residue and 2-O-sulfated 
iduronic acid.  Heparin lyase III recognizes the linkage between either N-acetylated or N-
sulfated glucosamine and unsulfated glucuronic acid.  On the other hand, heparin lyase II is 
much more promiscuous in that it recognizes the substrates for both lyases I and II, cleaving 
between GlcNS/GlcNAc and GlcUA/IdoUA (15,153).  For each lyase, the catalyzed reaction 
generates a Δ4,5-unsaturated uronic acid at the non-reducing end of the product that possesses 
an intrinsic UV absorbance at 232 nm, allowing for easy monitoring with RPIP-HPLC 
techniques.  The major limitation to the enzymatic degradation is the loss of the 
configuration of the C5 position of uronic acid residue upon formation of the Δ
4,5
-double 
bond.  This prevents discrimination between the IdoUA and GlcUA residues within the 
product.  Noteworthy, exhaustive digestion of a mixture of the lyases does not completely 
cleave the polysaccharide or oligosaccharide to disaccharides.  Therefore, a significant 
amount of material remains as oligosaccharides which cannot be detected by the separation 
techniques, resulting in an underestimation of amount of sample present (4).   
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Figure 17.  Substrate specificity of the heparin lyases.  Heparin lyase I cleaves between GlcNS and IdoUA2S 
whereas heparin lyase III cleaves between GlcNAc/GlcNS and unsulfated glucuronic acid.  Lyase II can cleave 
the substrates of both I and III. Adapted from (4) 
 
 
 
Physiological and Pathophysiological Functions of Heparan Sulfate 
 The modifications implemented by the HS sulfotransferases and epimerase are 
directly involved in contributing to the structural diversity of heparan sulfate.  The structural 
diversity of HS allows for interaction with a variety of biologically relevant proteins, 
suggesting an important regulatory role for HS in different physiological and 
pathophysiological functions.  The structure-function relationship of HS with such proteins 
as antithrombin, fibroblast growth factors, and glycoprotein D has been extensively 
characterized.     
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Anticoagulation 
 The blood coagulation pathway is essential for both hemostasis and thrombosis, 
consisting of a proteolytic cascade resulting in formation of fibrin thrombi, or a blood clot 
(Figure 18) (152).  The cascade consists of several serine proteases existing as inactive 
zymogens that are cleaved and activated by an upstream protease, serving to catalyze the 
activation of the subsequent reaction in the cascade.  The blood coagulation cascade can be 
divided into two separate pathways, intrinsic and extrinsic.  The intrinsic pathway is 
triggered by contact activation of plasma factor XII when exposed to a damaged surface.  
The primary extrinsic pathway is initiated at a site of injury in response to the release of 
tissue factor.  Although distinctly initiated, the two pathways do converge to a single 
pathway known as the factor X activation pathway.  Once factor Xa serves to activate 
thrombin, its primary role is to convert fibrinogen to fibrin. Fibrin then forms cross-links to 
generate a blood clot (154).   
Antithrombin-III (AT) is a key regulatory protein in the coagulation cascade that 
serves to maintain proper blood flow and prevent thrombosis (155).  The role of AT in 
embryogenesis was established using an in vivo mice knockout model, which resulted in 
embryonic lethality and subcutaneous hemorrhage.  The AT deficient mice exhibited 
excessive fibrin deposition in the myocardium and liver, suggesting an important regulatory 
role for AT (142).   
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Figure 18.  Blood coagulation cascade.  The coagulation process includes a series of inactive proteases that 
are cleaved, activated, and then proceed to activate the subsequent zymogen.  The cascade is initiated by two 
pathways, intrinsic and extrinsic pathways.  The two pathways converge into one pathway for factor X 
activation ultimately leading to the formation of a blood clot.  The “a” denotes the activated from of each 
protease.  Coagulation can be counteracted by the inhibitory action of an AT/HS complex (indicated by the red 
lines) against both factor Xa and thrombin.   
 
 
 
The coagulant activity of the blood coagulation pathway can be counteracted by the 
binding of HS/HEPARIN to AT.  Although AT has an innate ability to inhibit thrombin and 
factor Xa, the inhibitory activity is significantly enhanced 9,000 fold for thrombin and 17,000 
fold for factor Xa by the binding of heparin (156).  Binding of HS/HEPARIN to AT results in 
a conformational change of AT to an active form that can inhibit blood coagulation factors 
Xa and IIa (thrombin) (12,15,152).  Heparin, the product of degranulated mast cells, has a 
much stronger anticoagulant activity than endothelial HS with HS possessing only 1-10% 
anticoagulant activity (152).  Heparin can inhibit both factor Xa and thrombin for complete 
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anticoagulant activity, possibly explaining the discrepancy among HS and heparin activity 
(152,157,158).   
Extensive structural and functional studies have identified a pentasaccharide domain 
within both HS and heparin that is crucial for AT binding (12,159) (Figure 19).  Studies have 
revealed that 3-O-sulfation of the internal N-sulfo glucosamine residue is essential for AT 
binding, demonstrating a 20,000 fold decrease in activity when removed (160).  6-O-
sulfation at the nonreducing end, which can be either GlcNAc or GlcNS) of the HS 
pentasaccharide has also been shown to be important with removal resulting in complete 
abolition of AT binding (161).  It was originally determined that the IdoUA2S at the reducing 
end of the 3-O-sulfated glucosamine residue was essential for the binding of heparin to AT 
however recent studies have indicated that neither the IdoUA residue nor 2-O-sulfation of the 
IdoUA is necessary (162).  It was also suggested that the IdoUA residue is necessary for AT 
binding when the oligosaccharide is smaller than a hexasaccharide but inessential once the 
oligosaccharide becomes larger in size (162).  Therefore, elimination of these unnecessary 
features could aid in the synthesis of an anticoagulant agent with reduced side effects.   
 
 
 
Figure 19.  Antithrombin binding heparan sulfate pentasaccharide.  The critical 3-O-sulfo group is colored 
red for emphasis.  The abbreviated name is listed under each monosaccharide unit.  The HS pentasaccharide 
binds antithrombin with a Kd of 15-20 nM. 
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The AT binding pentasaccharide was chemically synthesized and marketed as the 
antithrombotic drug Arixtra in 2001; this pentasaccharide only has the ability to inhibit factor 
Xa activity (163).  A longer polysaccharide (approximately 14-20 saccharides) is necessary 
to inhibit the activities of both factors Xa and thrombin for complete anticoagulant activity 
(164).  For thrombin inhibition, the longer polysaccharide must contain a negatively charged 
template to allow formation of a ternary complex with both AT and heparin (165).  Chemical 
synthesis of the pentasaccharide takes more than 60 steps however Kuberan et al. were able 
to rely on the HS biosynthetic enzymes to synthesize the pentasaccharide in solely 6 steps 
with a much higher yield.  The efficiency of enzymatic synthesis offers a promising approach 
to design structurally defined HS compounds with distinct biological functions.   
Cell Proliferation 
The fibroblast growth factor (FGF) family is involved in many important biological 
processing including cell proliferation, differentiation and migration during morphogenesis 
as well as regulating tissue repair, wound healing, and tumor angiogenesis among adult 
organisms (166).  Currently, 22 FGFs have been identified to date and they all have been 
established as having affinity for both heparin and HS (167).  These growth factors mediate 
their cellular responses through binding and activation of a family of receptor tyrosine 
kinases known as FGF-receptors (FGFR) (166).  Heparan sulfate functions to enhance the 
affinity between FGF and FGFR as well as promote the dimerization and activation of 
FGFRs (168).  Structural studies have focused on two members of the FGF family, namely 
FGF1 and FGF2.  Crystal and co-crystal structures have been solved for FGFs bound to 
different HS oligosaccharides and FGFRs (168-170).   
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Structural analysis using surface plasmon resonance, NMR, and mass spectrometry 
has implicated a disaccharide sequence possessing several sulfate groups that are important 
for linking FGF and FGFR.  The 2-O-sulfo group on IdoUA and N-sulfo group on 
glucosamine are necessary for both FGF1 and FGF2 binding and signaling.  The 6-O-sulfo 
group on glucosamine is essential for binding and activation of FGF1 but not for FGF2 
binding (122,171).  It was also shown that saccharide length plays a crucial role in promoting 
dimerization (122,171-173).  Maccarana et al. identified the minimal heparin structure 
responsible for binding to FGF-2 as a pentasaccharide with the sequence ΔUA-GlcNS-UA-
GlcNS-IdoUA2S (Figure 20) (2,174).  The FGF-1 binding site, on the other hand, requires at 
least a penta- to hexasaccharide and contains a critical IdoUA2S-GlcNS6S disaccharide unit 
(2,175).  Chen et al. explored the effects of FGF-2 mediated cell proliferation by 
enzymatically modifying completely de-O-sulfated N-sulfated heparin with a combination of 
different HS biosynthetic enzymes to generate different sulfation patterns.  The results of this 
study demonstrated that the compounds with both 2-O- and 6-O-sulfations were capable of 
binding FGF-2 and promote cell proliferation compared to heparin, suggesting that these 
modifications are essential for promoting FGF-2-mediated cell proliferation on a 
polysaccharide level (176).   
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Figure 20.  Heparan sulfate structures implicated in FGF-1 and FGF-2 binding.  Adapted from (2) 
 
 
Until recently, it was believed that a specific sulfation pattern on heparan sulfate was 
responsible for the interaction between HS and growth factors based on in vitro studies (177).  
However, recent in vivo studies using Drosophila Hs2st and Hs6st mutants revealed a 
compensatory increase in sulfation to maintain the overall negative charge of the HS.  This 
suggests that charge density is more important than HS structures with precisely positioned 
sulfate groups for mediating FGF signaling (178).  A detailed understanding of the 
mechanism of FGF binding and activation by HS will help target the suppression of tumor 
angiogenesis as an anti-cancer approach.   
Inflammation 
 Heparan sulfate is a key player in the regulation of leukocyte transmigration during 
inflammation through interaction with various chemokines and cytokines.  A hallmark of the 
inflammatory response includes leukocyte recruitment to the site of infection (179).  The 
recruitment is initiated by the binding of leukocytes to different lectins (L-selectin and P-
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selectin) expressed on the surface of the endothelium that allow for leukocytes to roll along 
the surface.  Studies have indicated that both heparin and HS interact with P- and L-selectins, 
interfering with selectin-mediated leukocyte rolling (180,181).  The removal of HS from the 
aortic endothelial cell surface resulted in inhibition of L-selectin mediated binding of 
monocytes in vitro (181).  Independent of anticoagulant activity (182), the use of heparin and 
heparin-like oligosaccharides demonstrated anti-inflammatory activity by blocking both P- 
and L-selectin binding (183,184).   
 Although HS has been shown to interact with both P- and L-selectins, it is not known 
whether it is the ligand under physiological conditions since these selectins can also interact 
with mucins.  Studies have indicated that heparin and HS have a lower affinity for P-selectin 
than L-selectin, suggesting that L-selectin is a natural substrate (183).  The L-selectin can 
interact with sulfated, sialylated, and fucosylated mucins on the cell surface, and these 
mucins are speculated to be the ligand during chronic inflammation (185,186).  However, 
during the acute inflammatory response, studies have indicated that HS is the dominant L-
selectin ligand (187).  The inactivation of the NDST enzyme in endothelial cells resulted in 
partially sulfated HS that presented a significant reduction in the recruitment of neutrophils 
to inflamed tissues (187).  That reduction was due in part to the lack of L-selectin binding to 
HS.  It was also demonstrated that partially sulfated HS on the surface of leukocytes did not 
affect recruitment to inflamed tissues (187).  Despite these contradictory results, it is still 
clear that HS plays an important role during the inflammatory response.   
 Endothelial HS also plays a role in the interaction of chemokines with their cognate 
receptors on the surface of neutrophils as well as chemokine transportation (i.e. transcytosis) 
across the endothelial cell barrier (188,189).  Heparan sulfate interaction with chemokines 
  
48 
provides protection from proteolysis and stimulates chemokine oligomerization 
(179,190,191).  This interaction allows for immobilization of chemokines on the endothelial 
surface, which must occur in order for leukocytes to interact with the endothelium and 
migrate.  This theory was supported by a recent study showing immobilized chemokines 
induced extension of the lymphocyte functional-associated antigen 1 (LFA-1), an integrin 
that promotes stable cell adhesion (192).  The role of heparan sulfate in promoting 
chemokine transcytosis has also been established.  Macrophages and mast cells release 
chemokines during an inflammatory response that must be transported to the endothelial cell 
barrier to be displayed on the endothelial cell surface.  These transported chemokines are 
normally bound to heparan sulfate, suggesting that HS may assist with this process.  An in 
vivo study using HS deficient mice demonstrated that the efficiency of mediating chemokine 
transcytosis is significantly reduced, suggesting that HS is indeed involved in transcytosis 
however the mechanism is still poorly understood (179,187).   
 Since heparan sulfate plays a role in many stages of the inflammatory process, it 
seems potentially favorable to generate inhibitors of heparan sulfate function as an anti-
inflammatory therapy (179).  It has long been established that heparin possesses anti-
inflammatory activity (193-196).  However, its structural diversity has been implicated in a 
variety of undesired side effects.  Therefore, it could be possible to develop heparin or HS 
mimetics that target leukocyte transmigration as anti-inflammatory therapeutics.   
Viral Infection  
 The initial step for propagation of viral infection includes binding of a viral particle to 
target cells.  Heparan sulfate has been shown to serve as a docking site for viruses through 
interaction of viral envelope proteins and facilitates viral internalization (4,130,197).  Since 
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heparan sulfate is present on the surface of virtually all mammalian cells, it is not surprising 
that a multitude of human pathogenic viruses rely on interactions with HS including human 
immunodeficiency virus (HIV) (198), hepatitis C (199), human papillomavirus (HPV) (200), 
and herpes simplex virus-1 (HSV-1) (4,197).   
The role of HS in mediating HSV-1 infection, hallmarked by facial mucocutaneous 
lesions and keratitis, has been extensively studied (201,202). HSV-1 infection occurs in two 
stages: attachment to cells and entry into cells (Figure 21) (202,203).  The initial binding of 
HSV-1 to target cells occurs through interaction of viral envelope glycoprotein C (gC) and 
sometimes glycoprotein B (gB) with cell surface HS, labeled as the binding receptor 
(204,205) (206).  The removal of cell surface HS prevented HSV-1 binding and rendered the 
cells partially resistant to HSV-1 infection, implicating its role in assisting HSV-1 attachment 
to target cells (202).  Structural studies of the HS involved in binding to gC have indicated 
that at least 10-12 saccharide units containing both IdoUA2S units and 6-O-sulfated 
glucosamine (GlcNAc6S/GlcNS6S) are essential for interaction (207).   
Once the HSV-1 is attached to the target cell, the viral envelope must fuse with the 
host membrane to allow for viral entry (4).  The fusion between the viral envelope and cell 
membrane is triggered by multiple receptor-ligand mediated interactions at the cell surface 
(201).  In vitro studies have indicated that HSV-1 utilizes three specific host cell surface 
receptors for viral entry: (1) herpesvirus entry mediator (HVEM), a membrane of the tumor 
necrosis factor family, (2) nectin 2, and (3) nectin 1 (4,208,209).  The nectin receptors are 
members of the immunoglobulin family.  Each of these three receptors relies on interaction 
with the viral envelope glycoprotein D (gD), possessing binding in the low micromolar 
  
50 
range, however this single interaction is not enough to trigger fusion (210-213).  There are 
other key viral glycoproteins, gB, gH, and gL, that are important for the fusion process (210).   
 
 
Figure 21.  Interactions between a HSV-1 viral particle and the cell surface HS binding and entry 
receptors.  Cell surface heparan sulfate, containing IdoUA2S and 6-O-sulfated glucosamine, are required for 
binding of the HSV-1 particle to the target cell through interaction with gC and sometimes gB.  A specific 3-O-
sulfated heparan sulfate serves as an entry receptor for HSV-1 through interaction with gD on the viral 
envelope.   
 
Interestingly, Shukla et al. discovered a specific 3-O-sulfated HS acts as an entry 
receptor for HSV-1 infection through interaction with viral gD, predominately containing 
disaccharides of IdoUA2S-GlcNH23S±6S (130).  This disaccharide is generated by 3OST-3 
modified heparan sulfate but not those modified by 3OST-1.  The implication of the 3-O-
sulfated HS in HSV-1 entry was confirmed by the ability of HSV-1 resistant CHO cells to 
confer susceptibility to infection when 3OST-3 was introduced (214).  In addition to 3OST-3, 
studies have indicated that several 3OST isoforms are responsible for generating the HS 
implicated in gD binding including 3OST-2, -4, -5, and -6 (63,134,136,143-145).  The HS 
involved in binding and entry were determined to be different as unmodified HS isolated 
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from CHO cells is completely functional for promoting HSV-1 binding but not entry, 
suggesting that modification by specific 3OSTs is specific for generating HS involved in gD 
binding for viral entry (197).   Characterization of a gD binding octasaccharide identified 
from a 3OST-3 modified oligosaccharide library was determined to possess the structure 
ΔUA-GlcNS-IdoUA2S-GlcNAc-UA2S-GlcNS-IdoUA2S-GlcNH26S3S ( 
Figure 22) (203).  This oligosaccharide contains the previously identified signature 
disaccharide IdoUA2S-GlcNH26S3S necessary for viral gD binding.  Identification of this 
gD binding octasaccharide enhanced our understanding of the role of HS in assisting HSV-1 
infection.  
  
 
 
Figure 22.  Structure of the gD binding heparan sulfate octasaccharide.  The octasaccharide was 
determined to bind gD with a Kd of 18µM.  The abbreviated name is labeled under each monosaccharide unit 
with the critical 3-O-sulfo group for gD binding colored red. 
 
 
Cell surface heparan sulfate plays a role in several stages of infection for multiple 
viruses and therefore is an attractive therapeutic target for treating these infections.  
Targeting HS as an anti-viral agent could prevent the attachment and entry of viruses, 
reducing the risk of infection.  After several attempts with sulfated polymers (215,216), 
Copeland et al. identified a HS mimetic of 3-O-sulfated heparin octasaccharide, ΔUA2S-
GlcNS-IdoUA2S-GlcNS6S-IdoUA2S-GlcNS6S3S-IdoUA2S-GlcNS6S, that was capable of 
inhibiting HSV-1 infection with an IC50 of 40µM (217).  This heparin octasaccharide actually 
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mimicked the gD binding site of 3-O-sulfated HS to completely block HSV-1 viral entry 
(217).  It was previously established that heparin prevents HSV-1 infection, which is further 
confirmed by this study (197).  Identification of the inhibitory heparin octasaccharide 
supports the potential for targeting 3-O-sulfated HS mimetics as an effective anti-viral 
therapy.   
Tumor Progression 
 Heparan sulfate proteoglycans are present on the surface of tumor cells as well as 
cells involved in tumor survival, playing a role in both angiogenesis and tumor metastasis. 
HSPGs have the ability to interact with a variety of pro-angiogenic growth factors including 
vascular endothelial growth factor (VEGF), FGF-1/FGF-2 as well as anti-angiogenic factors 
such as endostatin (218).  The binding site for endostatin was determined to be distinct from 
that of pro-angiogenic factors, and therefore endothelial cells may be modulating their HSPG 
profiles to become more or less sensitive to angiogenesis (218).  The tumor cell surface 
HSPGs have the ability to contribute to tumor metastasis by recognizing and binding P-
selectin, a ligand involved in cell adhesion to platelets or the endothelial lining.  This binding 
to P-selectin allows for tumor cells to enter the bloodstream and invade other tissues 
(218,219).   
Interestingly, heparin, a highly sulfated HS, has been shown to demonstrate anti-
tumor effects when administered to cancer patients (220,221).  Clinical studies have 
indicated that heparin may be beneficial for treatment of patients with small cell lung cancer 
(222).  An in vivo mouse study indicated that administration of pharmacological doses of 
heparin inhibited tumor cell adhesion through inhibition of P-selectin binding (219,223).  
Thrombosis has been tightly associated with cancer as tumor cells are known to release 
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procoagulants such as tissue factors and cysteine proteases that serve to activate the blood 
coagulation pathway and form a fibrin shell around the tumor (224).  The formation of this 
shell is speculated to protect the tumor from the immune response as well as cause resistance 
to chemotherapy, which can be interrupted by heparin administration (221).   
Heparanase, an endo-β-D-glucuronidase, is known to cleave cell surface HS into 
small fragments, resulting in remodeling of the extracellular matrix (2,225).   Heparanase 
cleavage has been attributed to tumor metastasis, and indeed heparanase is upregulated in 
numerous tumor cells including pancreatic tumors, esophageal carcinomas, and liver 
carcinomas (226).  Therefore, heparanase is an excellent molecular target for the treatment of 
cancer (226).  Studies have indicated that heparin and low molecular weight (LMW) heparin, 
a shorter version of heparin, is an inhibitor of heparanase (225,227,228).  Despite its high 
inhibitory activity against heparanase, heparin is unsuitable for cancer treatment because of 
its potent anticoagulant activity.  If the anti-cancer and anticoagulant activities could be 
separated, then heparin would offer a suitable treatment.  The only issue is that patients may 
still require heparin for the treatment of thrombosis associated with cancer thus making 
heparin somewhat of a double-edged sword.  The development of a structurally similar 
heparin mimetic possessing no anticoagulant activity could be a very effective therapeutic for 
cancer patients.   In vitro studies analyzing different sulfated oligosaccharides against 
heparanase activity identified a promising heparin mimetic, phosphomannopentose sulfate 
(PI-88).  PI-88 has an inhibitory activity against heparanase similar to heparin and clearly 
demonstrated promise in treating solid tumors during phase I clinical trials.  The potential 
drug entered phase II clinical trials and demonstrated promise for treating post-resection liver 
patients.  Despite the successful phase II clinical trials, the lack of a global partner caused 
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termination of multinational phase III clinical trials (229).  Therefore, the search continues 
for an effective heparanase inhibitor for targeting angiogenesis and metastasis.   
Based on the currently available research, heparin indeed plays a role in the 
prevention of tumor progression however it is unclear which mechanisms are responsible for 
this activity.  There is certainly potential for the development of a heparin mimetic that can 
be utilized as an anti-cancer therapeutic.   
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Statement of Problem 
 
 
 
 Heparan sulfate (HS), a highly sulfated linear polysaccharide, is present on the 
surface and within the extracellular matrix of most animal cells.  This polysaccharide 
regulates several functions of the blood vessel wall including blood coagulation, cell 
differentiation, and the inflammatory response.  The wide range of biological functions 
makes HS an attractive target for the development of anti-cancer and anti-inflammatory 
agents.  The functional diversity of HS is mediated by its structural heterogeneity.  The 
backbone HS chain consists of repeating disaccharide units of glucuronic acid and N-acetyl 
glucosamine during biosynthesis.  The HS backbone is susceptible to several modifications 
carried out by HS biosynthetic enzymes, generating uniquely sulfated saccharide sequences 
that determine the specific functions as seen by the anticoagulant activity of HS and heparin.  
The major route to preparing HS oligosaccharide structures is chemical synthesis however 
synthesis of HS oligosaccharides larger than a hexasaccharide is tedious and time-consuming 
therefore our laboratory plans to employ the use of heparan sulfate biosynthetic enzymes to 
synthesize homogeneous polysaccharides. 
 The biosynthesis of HS is a non-template driven process therefore understanding the 
mechanism of action and substrate specificity of the HS biosynthetic enzymes is critical for 
our approach to synthesizing biologically active HS compounds.  The main goal of this 
dissertation was to characterize the structure-function relationship of two important HS O-
sulfotransferases, specifically 2OST and 6OST.  The combination of a crystal structure and 
elaborate mutational analysis should help provide some insight into the substrate recognition 
mechanism of these two enzymes.   
  
Chapter II 
Materials and Methods 
 
Preparation of Competent Cells 
 A two µL aliquot of the competent cell stock was inoculated into 1 mL sterile LB 
medium containing appropriate antibiotics if necessary.  For example, Origami B (DE3) 
competent cells have antibiotic resistance to both tetracycline and kanamycin.  The cells were 
incubated at 37°C with shaking at 220 rpm overnight.  A 1 mL aliquot of the saturated 
overnight culture was added to 100 mL sterile LB medium without any antibiotics.  The cells 
were incubated at 37°C with shaking at 220 rpm until O.D.600 reached 0.5 after 
approximately 3 to 4 hours.  The flask was then chilled on ice for 20 minutes and the cells 
were collected by centrifugation at 6000 rpm for 10 minutes at 4°C.  The cells were then 
resuspended in 10 mL ice-cold filtered TSS (Transformation and Storage Solution) solution.  
The TSS solution was prepared fresh each time and contained 85% LB medium, 10% 
polyethylene glycol (wt/vol, mol wt. 8000), 5% dimethyl sulfoxide (DMSO), 50 mM MgCl2, 
pH 6.5-6.6.  The solution was filtered using a sterile 0.45 µM syringe filter (Millipore).  Once 
resuspended, the cells were then aliquoted into microcentrifuge tubes, flash frozen, and 
stored at -80°C. 
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Chemical Transformation of Competent Cells 
 To transform competent cells, a 1-2 µL aliquot (100 ng) of plasmid DNA was added 
to 50 µL competent cells that were thawed on ice.  The cells were incubated on ice for 30 
minutes with occasional mixing.  The cells were then heat shocked at 42°C for 40 seconds 
followed by incubation on ice for an additional 2 minutes.  A 1 mL aliquot of sterile LB 
medium was added to the cells.  The cells were then incubated at 37°C for 2-3 hours at 220 
rpm.  Following incubation, 100 µL of the transformation reaction was plated on LB plates 
with the appropriate antibiotics.  The plate was incubated overnight at 37°C. 
Expression of Heparan Sulfate Sulfotransferases in Origami B/Origami B
chap
 cell lines 
 Origami B (DE3) or Origami B
chap
 (Origami B cells expressing chaperonin proteins 
GroEL/GroES) cells were transformed using the protocol above.  For Origami B (DE3) cells, 
a single colony was inoculated into 3 mL sterile LB medium 12.5 µg/mL tetracycline, 50 
µg/mL carbenicillin (only if plasmid has resistance), and 15 µg/mL kanamycin and incubated 
at 37°C with shaking at 220 rpm for 3-4 hours.  For Origami B
chap
 cells,  a single colony was 
inoculated into 3 mL sterile LB medium 12.5 µg/mL tetracycline, 50 µg/mL carbenicillin 
(only if plasmid has resistance), 15 µg/mL kanamycin, and 40 µg/mL chloramphenicol 
incubated at 37°C with shaking at 220 rpm for 3-4 hours.  Once the O.D.600 reached 0.6-0.8, 
the temperature was reduced to 22°C to cool down the culture.  For the Origami B (DE3) 
cells, isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final concentration of 0.2 
mM and the cells were allowed to shake overnight at 22°C.  For Origami B
chap
 cells, 1 
mg/mL L-arabinose was added first to induce expression of the chaperonin proteins followed 
by the addition of 0.2 mM IPTG after approximately 15 minutes of constant shaking.   
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Protein Purification Coupled to the FPLC system 
Nickel Sepharose Fast Flow Affinity Chromatography for His6-Tagged Proteins 
 The cells were harvested at 6000 rpm for 10 minutes.  For a 1 liter culture, the cell 
pellet was resuspended in 25 mL buffer A containing 25 mM Tris pH 7.5, 500 mM NaCl, 30 
mM imidazole.  Once resuspended, the cells were lysed by sonication in a 50 mL centrifuge 
tube for 3 x 1 minute (duty cycle 50%, output 7) followed by centrifugation at 11,000 rpm 
for 30 minutes.  Once pelleted, the cell lysate was filtered through a 1.5 micron filter 
(Whatman) prior to loading onto a pre-equilibrated 7 mL Nickel Sepharose 6 Fast Flow (GE 
Healthcare) column at a flow rate of 3 mL/min.  The column was washed with 7 column 
volumes (CV) of Ni buffer A to remove unbound sample.  The protein of interest was eluted 
in 3 mL fractions using Ni buffer B containing 300 mM imidazole during a 4 CV gradient 
length followed by 60 mL of elution with 100% buffer B.  The protein typically eluted in 35-
40 mL total volume. 
Amylose Affinity Chromatography for MBP Fusion Proteins 
 For a 1 liter culture, the cell pellet was resuspended in 25 mL buffer A containing 25 
mM Tris pH 7.5, 500 mM NaCl following centrifugation for 10 min at 6000 rpm.  Once 
resuspended, the cells were lysed by sonication in a 50 mL centrifuge tube for 3 x 1 minute 
(duty cycle 50%, output 7) followed by centrifugation at 11,000 rpm for 30 minutes.  Once 
pelleted, the cell lysate was filtered through a 1.5 micron filter (Whatman) prior to loading 
onto a pre-equilibrated 10 mL Amylose (New England BioLabs) column at a flow rate of 2 
mL/min.  The column was washed with 10 CV of amylose buffer A to remove unbound 
sample.  The protein of interest was eluted in 3 mL fractions using amylose buffer B 
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containing 30 mM maltose during a 3 CV gradient length and 40 mL gradient delay.  The 
protein typically eluted within 20-25 mL total volume.   
Glutathione Sepharose 4 Fast Flow Affinity Chromatography for GST fusion proteins 
 Glutathione Sepharose 4 fast flow affinity chromatography is used to purify 
glutathione S-transferase (GST) fusion proteins.  This resin contains glutathione-agarose 
beads that bind GST-tagged proteins which can be eluted from the resin using free 
glutathione.  The cell pellet harvested from a 1L culture was resuspended in 25 mL GST 
buffer A containing 20 mM NaH2PO4 pH 7.2, 500 mM NaCl.  The cells were then disrupted 
by sonication on ice for 2 x 30 seconds (duty cycle 50, output control 7) followed by 
centrifugation at 11,000 rpm for 30 min in a 50 mL centrifuge tube.  The supernatant was 
filtered through a 1.5 micron filter and then loaded onto a pre-equilibrated 10 mL 
Glutathione Sepharose 4 Fast Flow (GE Healthcare) column at a flow rate of 2 mL/min.  The 
column was washed with 10 CV buffer A to remove unbound sample.  The GST-tagged 
protein was eluted in 3 mL fractions using a gradient length of 3 CV and delay of 90 mL.  
The protein typically eluted in 40-45 mL total volume.   
Hi-Load Superdex 75/200 Gel Filtration Chromatography 
 Gel filtration chromatography can be used as a final purification for a protein of 
interest in order to remove impurities such as aggregated protein or free tag like thioredoxin 
or maltose binding protein which co-elute during affinity chromatography with the desired 
protein.  The fractions from the affinity column were combined and the protein was 
concentrated to approximately 5 mL (~ 10 mg/mL final concentration) using an Amicon 
centrifugal concentrator.  The concentrated protein was then injected into a 10 mL sample 
loop and loaded onto the 100 mL Superdex 75 (200 for larger proteins) filtration column pre-
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equilibrated overnight with 20 mM MOPS pH 7.0, 400 mM NaCl.  The column was washed 
with the MOPS buffer at 1 mL/min collecting 2 mL fractions.  To determine which peak is 
the protein of interest, a set of molecular mass standards including cytochrome c (12.4 kDa), 
carbonic anhydrase (29 kDa), BSA (66 kDa), and β-amylase (200 kDa) (Sigma Aldrich) were 
eluted using the same buffer conditions as the protein of interest.  Approximately 100 µg of 
each standard was present in the standard mix.  The void volume (V0) and total column 
volume (Vt) were determined using 2 mg blue dextran (2000 kDa) and 0.025% phenol red 
(0.4 kDa) respectively.  The log of the molecular mass of each protein standard was then 
plotted against the retention time, [(Ve-V0)/(Vt-V0)], in the column, generating a standard 
curve that was used to determine the apparent molecular mass of the protein of interest.  
Based on the theoretical and apparent molecular masses, the fractions pertaining to the 
protein of interest can then be combined.  In most cases, the first peak eluting within the void 
volume is consistent with the GroEL/GroES chaperone complex.  If monomeric, the target 
protein will be well separated from the chaperone complex peak.  However, if present in a 
higher oligomeric state (i.e. trimer), the protein will be eluted rather close to the chaperone 
peak.  To ensure complete elimination of potential impurities, the fractions pertaining to the 
chaperone complex and target protein must be analyzed for enzymatic activity. 
Protein Property Analysis using Gel Filtration Chromatography Using HPLC 
 The solubility and oligomeric state of a protein of interest was monitored by gel 
filtration coupled to the HPLC.  The protein of interest was concentrated sequentially to 2x, 
4x, 8x the initial concentration and 100 uL of the protein at each concentration was injected 
onto a G3000SWXL (Tosoh Bioscience) gel filtration column pre-equilibrated with running 
buffer  containing 20 mM MOPS, 400 mM NaCl, pH 7.0.  The column was washed with 
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running buffer with a flow rate of 1 mL/min and the chromatogram was recorded by UV 
absorbance at 280 nm.  The molecular weight of the target protein can be determined through 
comparison to known protein standards.  If the threshold of protein solubility was not 
reached, then there would be one peak area that increased in proportion to the protein 
concentration.  However, if the threshold was reached, then there would be a point at which 
the peak area would not be proportionally increased as the protein concentration increased. 
Site-Directed Mutational Analysis 
Design of Primers and Polymerase Chain Reaction 
 The forward and reverse primers containing the overlapping mutation site were 
designed as described previously (104,230) (Fig 23A).  The PCR reaction was conducted by 
mixing the following components:  10X Pfu buffer, 5µL; 10 mM dNTP mix (New England 
BioLabs), 1 µL; 50-100 ng plasmid DNA; forward and reverse primers (25 µM), 1.5 µL 
each; Pfu Turbo DNA polymerase (Stratagene), 1 µL; water to a final volume of 50µL.  The 
PCR cycle utilized for these reactions is described in Figure 23B.  Once the PCR reaction 
was completed, a 10 µL aliquot was examined by agarose gel electrophoresis using a 1% 
agarose gel.  Once the PCR product was identified on the gel, 10 µL of the PCR product was 
digested with restriction enzyme Dpn I (New England BioLabs) at 37ºC for 1 hour.  A 5 µL 
aliquot of the Dpn I digested product was used to transform 50 µL XL10 gold competent 
cells.   
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Figure 23.  Guidelines for site-directed mutagenesis polymerase chain reaction.  (A)  Strategy for design of 
site directed mutagenesis primers (230).  (B)  Thermocycler program for site-directed mutagenesis PCR. 
 
Small Scale Expression and Purification of Mutant Enzymes 
  The mutant plasmid was chemically transformed into the E. coli protein expression 
cell line (BL21 (DE3), Origami B (DE3), Origami B
chaperone
 (DE3)) followed by plating on 
LB-agar plates with the appropriate antibiotics.  It is important to note that each of these cell 
lines has varying antibiotic resistance as follow:  BL21 (DE3), none; Origami B (DE3), 
tetracycline and kanamycin; Origami B
chaperone
 (DE3), tetracycline, kanamycin, and 
chloramphenicol. Once colonies were formed following overnight incubation at 37°C, a 
single colony was used to inoculate 3 mL LB media with the appropriate antibiotics.  The 
culture was grown overnight at 37°C with constant shaking at 250 rpm.  A 1 mL aliquot of 
the saturated overnight culture was then used to inoculate 100 mL sterile LB media with the 
appropriate antibiotics.  The culture was grown with constant shaking at 250 rpm at 37°C 
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until the O.D.600 reaches 0.6-0.8.  The temperature was then reduced to 22°C followed by the 
addition of 0.2 mM IPTG to induce protein expression.  Take note, 1 mg/mL L-arabinose 
must be added prior to IPTG to induce GroEL/GroES chaperone expression for the Origami 
B
chaperone
 cells.  The cells were then allowed to grow overnight at 22°C with constant shaking 
at 250 rpm followed by harvesting with centrifugation at 6000 rpm for 30 minutes.  The cell 
pellet was resuspended in buffer A corresponding to the column needed for purification (i.e. 
nickel, amylose, heparin, GST, or DEAE).  The resuspended cells were then sonicated 2 x 30 
seconds (output control 4) and the cell lysate was spun at 11,000 rpm for 20 min.  The cell 
lysate was filtered using a 0.45 µm syringe filter and the supernatant was loaded onto a pre-
equilibrated 500 µL column containing the necessary resin.  The column was washed two 
times with 3-4 mL buffer A followed by elution with 1 mL buffer B corresponding to the 
resin used.   
Sulfotransferase Activity Analysis of Mutant Enzymes 
The sulfotransferase activity was determined by incubating approximately 0.3-0.8 µg 
of purified wild type or mutant protein with either 5 µg of completely de-O-sulfated N-
sulfated heparin (from Neoparin) or 1 µg N-sulfo heparosan and 1-5 × 10
5 
cpm of [
35
S]PAPS 
in 100 µL of a buffer containing 50 mM MES, pH 7.0, 10 mM MnCl2, 5 mM MgCl2, and 1% 
Triton X-100.  The reaction was incubated at 37°C for 30 min and quenched by the addition 
of UPAS buffer containing 50 mM NaOAc pH 5.0, 250 mM NaCl, 3 M urea, 1 mM EDTA 
and 0.01% Triton X-100.   The sample was then loaded onto a 200 µL DEAE-Sepharose 
(Sigma-Aldrich) column to purify the [
35
S]heparan sulfate.  The column was washed 4 times 
with UPAS buffer followed by 3 times with a buffer containing 250 mM NaCl and 0.001% 
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Triton X-100.  The purified [
35
S]HS was eluted with 1 M NaCl and 0.001% Triton X-100.  
The quantity of [
35
S]HS was determined by liquid scintillation counting. 
Large Scale Preparation and Purification of K5 Polysaccharide 
 The E.coli strain NCDC Bi 8337-41 (ATCC# 23506) was utilized for production of 
the K5 bacterial polysaccharide.  A 100 mL culture containing sterile LB medium was 
inoculated with a glycerol cell stock of K5P bacterial polysaccharide and grown at 37°C for 
approximately 8 hours.  A 13 mL aliquot from the 100 mL culture was then used to inoculate 
one L cultures for 6 L and grown for 16-18 hours at 37°C.  The cells were then harvested by 
centrifugation at 7000 rpm for 30 min.  The supernatant was filtered through a 1.5 µM filter 
(Whatman) and the pH of the solution was adjusted 5.  Once the pH was adjusted, the 
supernatant was mixed at 1:1 ratio with DEAE column buffer A containing 20 mM sodium 
acetate pH 5.0 and 50 mM NaCl.  The solution was loaded onto a 100 mL DEAE Sepharose 
fast flow (GE Healthcare) column pre-equilibrated with water followed by 1 L filtered buffer 
A at a flow rate of 10 mL/min.  After the material was completely loaded, the column was 
washed with 1L filtered A before switching to elution buffer B containing 1M NaCl.  Buffer 
B was loaded onto the column up to a volume of approximately 200 mL and then the flow 
rate was stopped for 1 hour before eluting the K5P.  The K5P was eluted with approximately 
400 mL buffer B or until eluent was clear.  The collected K5P eluent was ethanol precipitated 
overnight at -20°C by mixing the eluent with an equal volume of 100% reagent ethanol.  The 
precipitate was centrifuged at 7000 rpm for 30 minutes and resuspended in water before 
splitting equally into two 50 mL centrifuge tubes.  A final volume of 50% saturated 
ammonium sulfate was added to the precipitated K5P and incubated on ice for 15 minutes.  
The gel like precipitate was collected by spinning at 6000 rpm for 30 minutes followed by 
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removing the supernatant from the gel like precipitate.  This process was repeated using a 
final volume of 60% saturated ammonium sulfate.  The gel precipitate was resuspended in 10 
mL water and dialyzed overnight in water with MWCO 12-14,000 membrane (Spectrapor), 
leaving 2 times the amount of headspace for expansion.  The dialyzed sample was recovered 
and loaded onto a 20 mL DEAE Sepharose fast flow (GE Healthcare) column connected to 
the FPLC pre-equilibrated with buffer containing 20 mM sodium acetate, 50 mM NaCl pH 
5.0 at a flow rate of 2 mL/min.  The method was first calibrated by mixing a small volume of 
K5P (~5-10 mL) with a trace of 150 µL [
3
H]K5P to monitor elution of the K5.  Every other 
fraction eluted from the DEAE column was counted for radioactivity to check for [
3
H]K5P.  
The radioactive K5 eluted just before the protein peak appearing on the FPLC chromatogram.  
The polysaccharide was eluted in 35 mL fractions using buffer B containing 1M NaCl with a 
gradient length of 10 CV.  The eluted K5P was (1:1) phenol/chloroform extracted by adding 
1-2 mL phenol/chloroform and rotating overnight at 4°C.  The sample was centrifuged at 
6000 rpm for 30 minutes and the supernatant collected followed by ethanol precipitation 
overnight at -20°C.  The sample was pelleted at 6000 rpm for 30 minutes and resuspended in 
DEAE column buffer A before loading onto the pre-equilibrated DEAE column.  The same 
method was repeated eluting with buffer B containing 20 mM sodium acetate pH 5 and 1 M 
NaCl and collecting 4 mL fractions over a gradient length of 10 CV.  The K5P again eluted 
in a total volume of 35 mL.  The pooled K5P was dialyzed overnight against water in 
MWCO 12-14,000 membrane.  The sample was dried down and the tubes were weighed to 
determine the approximate amount of K5P.   
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Modification of Heparan Sulfate Polysaccharides Using PAPS Regeneration System 
 The PAPS regeneration system can be utilized to overcome product inhibition by 
PAP when attempting to sulfate polysaccharides.  This system relies on aryl sulfotransferase 
IV (Ast-IV) and a high concentration of p-nitrophenyl sulfate (PNPS) to maintain a 
continuous supply of PAPS.  To enzymatically sulfate heparan sulfate polysaccharides, the 
K5 (~ 10 mg) was mixed with purified 5 mL Ast-IV (1 mg/mL), 40 µM PAP, 1 mL of 100 
mM PNPS, and 50 mM MES pH 7.0, 0.5% Triton X-100 to a final volume of 40 mL.  The 
yellow-colored reaction mixture was incubated for 15 min at RT with constant nutation to 
initiate PAPS production followed by the addition of 5 mL (~5 mg) heparan sulfate 
sulfotransferase.  The reaction was incubated overnight at RT with constant nutation.  When 
working with multimilligram quantities of K5P, multiple reactions must be prepared 
assuming 10 mg K5P per reaction mixture.  Following incubation, each reaction mixture was 
centrifuged at 6000 rpm for 20 minutes to pellet any precipitated enzyme.  The material was 
loaded onto a 3 mL DEAE Sepharose fast flow column pre-equilibrated with 5 CV water 
followed by 10 CV buffer A containing 20 mM Tris pH 7.4, 250 mM NaCl.  The DEAE 
column was washed with 5 CV buffer A followed by elution with 1 CV buffer B containing 1 
M NaCl.  The eluted material was dialyzed against 5 mM ammonium bicarbonate using 
MWCO 3500 membrane (Spectrapor) overnight at 4°C, dried down to completion and 
resuspended in distilled water.   
Disaccharide Analysis of Heparan Sulfate Polysaccharides 
Enzymatic Degradation Using Heparin Lyases 
 Cleavage with heparin lyases results in the generation of a Δ4,5-unsaturated uronic 
acid at the non-reducing end, which is easily detectable at a UV absorbance of 232 nm.  With 
  
67 
that said, the polysaccharides were digested to disaccharides using a mixture of the heparin 
lyases.  Approximately 10-20 µg modified (or unmodified) K5 polysaccharide was incubated 
with 200 µL 50 mM Na2HPO4 pH 7.0 and 10 µL of each heparin lyase (I, II, and III) at 37°C 
overnight.  The reaction was boiled for 2 min at 100°C to terminate the reaction followed by 
centrifugation at 13,000 rpm for 2 minutes.  A 100 µL aliquot of the sample was then mixed 
with 130 mM tetrabutylammonium dihydrogenphosphate (TBA) and 100 µL reverse phase 
ion pairing (RPIP) buffer A containing 38 mM NH4H2PO4, 2 mM H3PO4, 1 mM TBA.  The 
mixture was then loaded onto a RPIP C18 column (Vydac 218TP, 5 µm, Cat#218TP 54) 
connected to the HPLC at a flow rate of 0.5 mL/min with UV detection at 232 nm.  This 
column was pre-equilibrated with 14% buffer B containing 38 mM NH4H2PO4, 2 mM 
H3PO4, 1 mM TBA, and 50% CH3CN. The disaccharides were eluted from the column by 
increasing the percentage of buffer B from 14% to 30% at 45 min, 39% at 60 min, and then 
100% at 85 min.  The composition of the disaccharides from the injected sample was then 
determined by comparison to the elution times of a set of disaccharide standards (Seikagaku 
Corporation 400576 Unsaturated Heparan/Heparin disaccharide mixture H mix).  For the 
standard mix, 20 µL of 0.1 mM standard mix solution was mixed with 130 mM TBA and 180 
µL RPIP buffer A and analyzed using RPIP-HPLC analysis using the same buffer conditions.  
Please note, if analyzing radiolabeled material, at least 10,000 cpm of [
35
S] or [
3
H] HS must 
be loaded onto the RPIP column to generate sufficient results.   
Chemical Degradation Using Low pH 1.5 Nitrous Acid 
 Low pH nitrous degradation at pH 1.5 is utilized to cleave heparan sulfate 
polysaccharides after the N-sulfo glucosamine residue.  This cleavage will maintain the 
configuration of the uronic acid.  The dried [
35
S]-radiolabeled HS sample was resuspended in 
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60 µL water, using 1/3 of the material for disaccharide analysis.  Approximately 10 µg of 
cold heparan sulfate must be added to the radiolabeled sample as a cold carrier.  A 40 µL 
aliquot of 1:1 ratio of 0.5 M H2SO4:0.5 M Ba(NO2)2 was added to the HS material.  The 
H2SO4:Ba(NO2)2 mixture must first be centrifuged at 13,000 rpm for 1 min and the 
supernatant added to the HS.  The reaction is incubated on ice for 30 min followed by the 
addition of 20 µL 7:3 (1M Na2CO3:1M NaHCO3) pH 9.5 to terminate the reaction.  A 20 µL 
aliquot of 0.5 M sodium borohydride in 0.1 M NaOH was added to the sample and incubated 
for 30 min at 50°C.  The reaction is then cooled to room temp before the addition of 20 µL of 
10 M acetic acid to stop the reduction and release the hydrogen gas.  The sample must be 
vortexed once the acetic acid is added.  Phenol red (1 µL of 5% phenol red) was then added 
as an indicator.  If the color of the solution was yellow, then stepwise addition of 10 M 
NaOH was completed until the color turns light red.  The sample was then loaded onto a pre-
equilibrated P-2 (BioRad) column using 0.1 M ammonium bicarbonate for elution.  The 
material was collected in 1 mL fractions using a fraction collector.  The [
35
S]-labeled 
disaccharide products were monitored by radioactive counting of each P-2 fraction, 
collecting and pooling the eluted material.  The disaccharide product was dried down using 
the Speedvac followed by resuspension in ddH2O.  A 50 µL aliquot (~10-20,000 cpm) of the 
sample was then mixed with 120 mM tetrabutylammonium dihydrogenphosphate (TBA) and 
100 µL ddH2O to a final volume of 250 µL. The mixture was then loaded onto a RPIP C18 
column (Vydac 218TP, 5 µm, Cat#218TP 54) connected to the HPLC at a flow rate of 0.5 
mL/min with UV lamp setting at 232 nm.  Buffer A consisted of 9.5 mM NH4H2PO4, 0.5 
mM H3PO4, 1 mM TBA.  The column was pre-equilibrated with 14% buffer B containing 9.5 
mM NH4H2PO4, 0.5 mM H3PO4, 1 mM TBA, and 30% CH3CN. The disaccharide products 
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were eluted from the column by increasing the percentage of buffer B from 14% to 30% at 
45 min, 39% at 60 min, and then 100% at 85 min.  The composition of the disaccharides 
from the injected sample was then determined by coelution with appropriate disaccharide 
standards (145). 
Isolation of Chicken 2OST DNA 
 The truncated chicken 2OST cDNA consisting of E52-N356 was cloned by fusing 
two expressed sequence tags cDNA clones ChEST584h10 and ChEST850d20, which were 
purchased from ARK-Genomics (Roslin Institute, Midlothian, UK).  The N-terminal 
fragment of 2OST (E52-F198) was amplified from the EST clone ChEST584h10 by PCR 
using two primers: ATAGAACAACGTCATACAGCAGATGGCC (O785) and 
CAAAGGTCTTCTTATCCCCCTG (O791).  An NcoI site was then introduced to the N-
terminal fragment by PCR using primer 
ATTAATTACCATGGAGAGATAGAACAACGTCATA (O781, where the NcoI site is 
underlined) and primer O791.  The N-terminal fragment was digested with NcoI prior to the 
ligation with the C-terminus as described below.  The C-terminal fragment of 2OST (D199-
N356) was amplified from the EST clone ChEST850d20 by PCR using two primers:  
pATGAATGTGTGGCAGCTGGA (O790, containing 5’-phosphate) and 
ATTAAATAAAGCTTTTCTTAGTTTGATTTGGGGT (O781, where the Hind III site is 
underlined).  The C-terminal fragment was then digested with Hind III.  Both N-terminal and 
C-terminal fragments were ligated by a rapid ligation kit (Roche).  The truncated chicken 
2OST cDNA (E52-N356) was then amplified from ligated N- and C-terminal fragments by 
PCR using primers O780 and O781 and cloned into the PET-32b vector (Novagen) using 
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NcoI and Hind III sites.  The truncated chicken 2OST cDNA was confirmed by sequencing 
analysis (University of North Carolina at Chapel Hill Genome Analysis Facility). 
Cloning, Expression and Purification of Chicken 2OST 
The maltose binding protein (MBP)-2OST fusion protein was prepared using a 
modified pMAL-c2x vector (New England Biolabs).  The amino acid sequence of MBP was 
truncated at Asn-367 and contained the mutation E359A (59).  The linker region encodes 
three alanine residues (A368-A370) and contained a NotI site for cloning.  The catalytic 
domain of chicken 2OST (D69-N356) was cloned into the vector by using the NotI and 
BamHI sites.  The MBP-2OST protein was expressed in Origami B (DE3) cells (Novagen).  
Cells were grown in a shaker at 37°C in sterile LB medium and induced with 0.5 mM 
isopropyl-β-D-thiogalactopyranoside once the temperature of the cell culture was drop to 
18°C.  Cells were pelleted at 6000 rpm for 10 min, resuspended in 25 mM Tris pH 7.5, 500 
mM NaCl, and 1 mM DTT, and then lysed by sonication 3 x 1 min (output 7, duty cycle 50).  
MBP-2OST was bound to amylose resin (New England Biolabs), eluted with 40 mM 
maltose, and then loaded onto a HR16/60 Superdex 200 (Amersham) column pre-
equilibrated in buffer containing 25 mM Tris pH 7.5, 500 mM NaCl, 1 mM DTT, 40 mM 
maltose.  The purified protein was then dialyzed overnight against 25 mM Tris pH 7.5, 75 
mM NaCl, 5 mM maltose, and 1 mM DTT.  PAP was added to 1 mM concentration.  The 
sample was concentrated to 19 mg/mL, followed by the addition of more PAP for a final 
concentration of 4 mM.   
Crystallization of Chicken 2OST 
  Crystals of MBP-2OST were formed by using the sitting drop vapor diffusion 
technique at 4°C.  The sitting drop contained 1 µL of protein solution, mixed with 1 µL of 
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reservoir solution consisting of 100 mM BisTris-propane pH 6.0, 1.7 M ammonium citrate, 
and 10 mM phenol.  For data collection, crystals were transferred to 100 mM BisTris pH 6.0, 
1.8 M ammonium citrate, 1 mM phenol, 25 mM Tris pH 7.5, 75 mM NaCl, 5 mM maltose, 1 
mM PAP and 12% ethylene glycol for 45 seconds and then were flash frozen in liquid 
nitrogen.  Diffraction data were collected on a Rigaku 007HF generated equipped with 
VariMaxHF mirrors and a Saturn92 CCD detector.  For the first crystal, data were collected 
and processed to 2.85Å resolution by using HKL2000.  The program MOLREP was used to 
solve the phase problem using molecular replacement with residues 1-370 of MBP from the 
MBP-RACK1 crystal structure as the starting model.  The search found 1 MBP molecule in 
the asymmetric unit.  To determine the position of 2OST, a search model was created from 
the crystal structure of mouse EST (Protein Data Bank ID code 1AQU) consisting of residues 
from conserved features found in both EST and NST or 3OSTs (D39-Y62, R78-E83, I104-
I146, L189-F210, and P269-K285).  The rest of the 2OST model was built through iterative 
cycles of model building in O, refinement in CNS, and density modification by using solvent 
flipping that greatly improved the quality of the electron density maps.  A second crystal 
structure was used to collect a dataset at 2.65 Å.  This dataset was used for the final rounds of 
refinement and model building, maintaining the same set of reflections for the free R 
calculations as the first out to 2.85 Å.  The final model consists of all residues in MBP 1-370 
and residues D69-K354 in 2OST with 95.6% of residues in the 98% favored region and 
99.7% in the 99.8% allowed region, as determined by MOLPROBITY. 
Preparation of Chicken 2OST Mutant Plasmids 
 The 2OST mutants were prepared using 2OST-pMAL-c2x plasmid as the template 
and a modified method from the Stratagene QuickChange mutagenesis protocol (230).  The 
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mutagenesis primers were synthesized by Invitrogen.  The resultant constructs were 
sequenced to confirm the expected mutation (University of North Carolina at Chapel Hill 
Genome Sequencing Facility). 
Expression and Purification of 2OST Mutant Proteins 
 Origami B (DE3) cells were transformed with the 2OST mutant protein expression 
vector using the method listed above.  A single colony was inoculated into 3 mL LB medium 
supplemented with 50 µg/mL carbenicillin, 12.5 µg/mL tetracycline, and 15 µg/mL 
kanamycin and grown overnight at 37°C with constant shaking.  A 1 mL aliquot of the 
saturated overnight culture was added to 100 mL LB supplemented with the same antibiotics.  
The culture was grown at 37°C for 3-4 hours until the O.D.600 reached 0.6-0.8.  The 
temperature of the shaker was then dropped to 18°C to cool down the culture.  The protein 
expression was induced with 0.5 mM isopropyl-β-D-galactopyranoside with constant shaking 
for 18-20 hours at 18°C.  The cells were harvested by centrifugation at 6000 rpm for 10 min 
in a 50 mL centrifuge tube.  The cell pellet was resuspended in 8 mL buffer A containing 25 
mM Tris pH 7.5, 500 mM NaCl, 1 mM DTT.  The cells were lysed by sonication in a small 
sonication bottle on ice 2 x 45 seconds (output 4, duty cycle 50) followed by centrifugation at 
11,000 rpm for 20 min.  The cell lysate was filtered through a 0.45 µm syringe filter 
(Millipore).  The filtered lysate was loaded onto a disposable poly-prep column (Bio-Rad) 
containing 500 µL amylose-agarose (New England Biolabs) resin which has been pre-
equilibrated with buffer A.  The protein was loaded onto the amylose resin, washed with 2 
CV buffer A, and then eluted with 1 M buffer B containing 40 mM maltose.  A small aliquot 
of the 2OST mutant proteins were utilized to analyze for sulfotransferase activity as 
described under the section entitled Sulfotransferase Activity Analysis of Mutant Enzymes. 
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Gel Filtration Chromatography of 2OST Wild Type and 2OST V332STP 
 To determine the oligomeric state of 2OST WT and 2OST V332STP, approximately 
7 mg of amylose-agarose purified 2OST WT or 2OST V332STP was fractionated by gel 
filtration chromatography on a Superdex 200 HiLoad 16/60 column that was equilibrated 
with a buffer containing 20 mM MOPS pH 7.0, 400 mM NaCl, and 40 mM maltose at a flow 
rate of 1 mL/min.  Fractions of 2 mL each were collected.  The eluate was monitored by UV 
absorbance at 280 nm.  The apparent molecular mass of 2OST WT or V332STP was 
determined by comparison with the elution positions of molecular mass standards, including 
cytochrome c (12.4 kDa), carbonic anhydrase (29 kDa), BSA (66 kDa), and β-amylase (200 
kDa) (Sigma Aldrich).  The standard mix contained approximately 100 µg of each standard 
listed.  The void volume (V0) and total column volume (Vt) were determined by using 2 mg 
blue dextran (2,000 kDa) and 0.025% phenol red (0.4 kDa) respectively.  The protein 
standards were eluted using the same buffer conditions as for the 2OST protein. 
Determination of the Substrate Specificity of 2OST R189A 
 Since N-sulfo heparosan contains no IdoUA unit, it was incubated with recombinant 
C5-epi to synthesize the IdoUA unit followed by 2OST modification.  For a 100 µL reaction, 
N-sulfo heparosan (9 µg) was incubated with C5-epi (7 µg) in a buffer containing 50 mM 
MES (pH 7.0), 1% Triton X-100, and 2 mM CaCl2 for 1 hour at 37°C.  To this reaction, 10 
µg of 2OST R189A or 2OST WT and 1.5x10
6 
cpm of [
35
S]PAPS were added and incubated 
at 37° for 1 hour.  The 2-O-[
35
S]sulfo group in the polysaccharide was purified by a DEAE 
column.  The position of the 2-O-[
35
S]sulfo group in the polysaccharide was determined by 
disaccharide analysis.  Briefly, the resultant 
35
S-labeled polysaccharide was degraded to 
disaccharides with nitrous acid at pH 1.5 followed by reduction with sodium borohydride.  
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The disaccharide products were then analyzed by reverse phase ion-pairing HPLC.  The 
identities of the resultant 
35
S-labeled disaccharides were determined by coelution with 
appropriate disaccharide standards (145). 
Preparation of Recombinant C5-Epimerase 
 Human C5-epi was expressed in Origami-B DE3 cells (Novagen), which contain 
pGro7 (Takara, Japan) plasmid expressing chaperonin proteins GroEL and GroES of E. coli. 
Different N-terminal truncated forms of C5-epi were cloned into pMalc2x vector (New 
England BioLab) to form maltose-binding protein (MBP)/Epi fusion proteins. Several N-
truncation points were prepared at Asp-34, Glu-53, Gln-72, Asn-92, Trp-203 and Phe-257. 
The transformed cells were grown in LB medium supplemented with 12.5 μg/mL 
tetracycline, 15 μg/mL kanamycin, 40 μg/mL chloramphenicol and 50 μg/mL carbenicillin at 
37 
o
C. The temperature was decreased to 22 
o
C when the A600 reached 0.4-0.8 followed by 
addition of L-arabinose (1 mg/mL) and isopropylthiogalactopyranoside (0.5 mM) to induce 
the expression of chaperone and C5-epi proteins, respectively. After shaking overnight, the 
cells were pelleted and lysed by sonication. The expressed proteins were then purified using 
an amylose-agarose (New England BioLabs) column following the protocol provided by the 
manufacturer. The protein product was analyzed by 10% SDS-PAGE stained with coomassie 
blue.  
Coupling 2OST and C5-epi to Determine the Activity of C5-epi 
 For a 100 µL total reaction, wild type C5-epi (1.5 μg) was incubated with 2 μg N-
sulfo heparosan in the buffer containing 50 mM MES (pH 7.0), Triton X-100 and 1 mM 
CaCl2 at 37 
o
C for 30 minutes. The mixture was heated at 100
o
C for 5 min and then cooled 
down to room temperature. After centrifugation to discard the insoluble matters, 0.6 μg 
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2OST Y94I, 0.01 mg bovine serum albumin and [
35
S]PAPS (5-7 × 10
5
 cpm) were added to 
the reaction followed by incubation at 37
o
C for another 5 min. The resultant 
35
S-labeled 
polysaccharide was purified by DEAE chromatography. To determine the linear range of this 
assay, a dose response curve was also generated using wild type C5-epi (0-3.3 g) and 2OST 
Y94I mutant (0.6 g). The activities of various C5-epi mutants (1.5 g) were also tested 
using this protocol. 
Disaccharide Analysis of the Polysaccharide Modified by C5-epi and 2OST WT 
 The 
35
S-labeled polysaccharides were prepared as described above except that 2OST 
WT was used. Here we scaled up the reaction volume to 3 ml. Briefly, After a 30-min 
incubation of N-sulfoheparosan with C5-epi or its mutants, the reaction was terminated by 
heating at 100 °C for 5 min. Then 2OST WT, bovine serum albumin, and [
35
S]PAPS were 
added to the supernatant after the reaction mixture was spun down and incubated at 37 °C for 
an additional 5 min. After DEAE column purification, dialysis against deionized water, and 
drying by speed vacuum, the polysaccharide products were subjected to nitrous acid 
degradation at pH 1.5 (29). The disaccharides were separated by a BioGel P-2 column, which 
was equilibrated with 0.1 M ammonium bicarbonate (27, 30). The resultant disaccharides 
were resolved on a C18 column (0.46 × 24 cm; Vydac) under the reverse-phase ion-pairing 
(RPIP)-HPLC conditions. Here, the column was eluted with a stepwise gradient of 
acetonitrile containing 0.5 mM H3PO4, 9.5 mM NH4H2PO4, and 1 mM tetrabutylammonium 
phosphate monobasic (Sigma). The column was washed with 5.2% acetonitrile for 30 min 
first, followed by 15 min of 9% acetonitrile elution and then 60 min of 11.7% acetonitrile 
elution.  The identities of the disaccharides were determined by coeluting with authentic 
disaccharide standards (176). 
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Preparation of 6OST-3 Mutant Plasmids 
 The 6OST-3 mutants were prepared using 6OST-3-pET21b plasmid as the template 
and a modified method from the Stratagene QuickChange mutagenesis protocol (230).  The 
mutagenesis primers were synthesized by Invitrogen.  The resultant constructs were 
sequenced to confirm the expected mutation (University of North Carolina at Chapel Hill 
Genome Sequencing Facility). 
Small Scale Expression and Purification of 6OST-3 Mutant Proteins 
 Origami-B
chaperone
 cells were transformed with the mutant 6OST-3-pET21b plasmid.  
A single colony was inoculated into 3 mL Luria-Bertani (LB) media supplemented with 12.5 
µg/mL tetracycline, 20 µg/mL chloramphenicol, 15 µg/mL kanamycin, and 50 µg/mL 
carbenicillin and allowed to grow overnight at 37°C.  One mL of the overnight culture was 
used to inoculate 100 mL LB supplemented with the aforementioned antibiotics at their 
corresponding concentrations.  The culture was shaken at 250 rpm at 37°C until the OD600 
reached between 0.4 and 0.6.  Once the appropriate OD600 value was reached, the shaker 
temperature was reduced to 22° C to allow the culture to cool down.  After cooling, 1 mg/mL 
arabinose was added to induce chaperone expression followed by the addition of 0.2 mM 
IPTG to induce protein expression.  The culture was allowed to shake 18 to 20 hours at 22°C.  
The cells were harvested by centrifugation for 10 min at 6000 rpm.  The cell pellet was 
resuspended in 8 mL Ni-FF buffer A (30 mM Imidazole, 500 mM NaCl, 25 mM Tris pH 
7.5).  The resuspended cells were then lysed by sonication for 3 x 45 seconds (output control 
7, constant duty cycle) and centrifuged at 14000 rpm for 20 min.  Once the spin was 
completed, the supernatant was filtered through a 0.45 µM syringe filter and loaded onto a 
200 µL Ni-FF gravity column pre-equilibrated with 3 mL of Ni-FF buffer A.  After the 
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unbound protein passed through the column, the column was washed with 3 mL buffer A 
followed by eluting the protein of interest with 1 mL Ni-FF buffer B (300 mM Imidazole, 
500 mM NaCl, 25 mM Tris at pH 7.5). 
Sulfotransferase Activity Analysis of 6OST-3 Mutants 
 To test the sulfotransferase activity of the 6OST-3 mutant proteins, a 50 µL reaction 
was prepared containing 10% Triton X-100, 2.5 µL; 1 M MES pH 7, 2.5 µL; 1 M MgCl2, 
0.25 µL; 2 M MnCl2, 0.25 µL, 10 mg/mL BSA, 0.6 µL; 5 µL mutant enzyme, 5 µg N-
sulfated completely de-O-sulfated heparin, 1 µL; 1x10
7
 cpm powder [
35
S]PAPS; ddH2O, 37.9 
µL.  A negative control without enzyme and a positive control with wild-type 6OST-3 were 
also included for analysis.  The enzymatic reaction was incubated at 37°C for 40 min and 
loaded onto a DEAE (diethyl aminoethyl) column.  The column was washed 2 times with 1 
mL UPAS buffer (50 mM NaOAc pH 5.5, 150 mM NaCl, 6 M urea, 1 mM EDTA, 0.1% 
Triton X-100) and then 3 times with 1 mL 250 mM NaCl solution (50 mM NaOAc, pH 5.5, 
250 mM NaCl, 0.01% Triton X-100).  The sample was eluted from the column with 1 mL of 
1 M NaCl solution (50 mM NaOAc pH 5.5, 1 M NaCl, 0.01% Triton X-100) and 100 µL of 
eluent was mixed with 2 mL scintillation fluid to determine [
35
S] radioactivity.  The activity 
level for the mutant protein was then determined using the following calculation:  (mutant 
cpm – negative control cpm)/wild-type cpm.  An activity level of less than 10% signified that 
an amino acid of interest was indeed necessary for activity.   
Expression and Purification of Trx-6OST-1 
 The thioredoxin (Trx)-chicken 6OST-1 fusion protein constructs were created using a 
pET32(TEV) vector which contains a TEV protease cleavage site for removal of the 
thioredoxin tag.  The 6OST-1-pET32(TEV) plasmid was transformed into Origami B (DE3) 
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cells.  A 100 mL culture of LB supplemented with 12.5 µg/mL tetracycline, 15 µg/mL 
kanamycin, and 50 µg/mL carbenicillin was inoculated with a glycerol cell stock of 6OST-1-
pET32(TEV) and grown overnight at 37ºC with constant shaking at 250 rpm.  A 15 mL 
aliquot of the overnight culture was added to each of the 12L cultures supplemented with the 
same three antibiotics at the appropriate concentrations.  The cultures were grown at 37°C 
until the O.D.600 reached 0.6-0.8 following by reduction of the incubator temperature to 
22°C.  Next, the addition of 0.1 mM IPTG was completed to induce protein expression.  The 
cultures were allowed to shake overnight at 22°C.  The cells were pelleted at 6000 rpm for 10 
min followed by resuspension in 75 mL Nickel buffer A containing 25 mM Tris pH 7.5, 30 
mM imidazole.  A 1:100 ratio of phenylmethylsulfonyl fluoride (PMSF) was added to inhibit 
serine protease digestion.  At this point, the purification by nickel column was completed as 
described in Nickel Sepharose Fast Flow Affinity Chromatography for His6-Tagged Proteins.  
Once the eluted protein fractions were pooled, PAP was added to a final concentration of 1 
mM to keep the protein in solution.  The fusion protein was then treated with TEV protease 
(1:25 digestion) and shaken gently overnight at 4°C.  The TEV cleaved 6OST-1 was diluted 
3x with heparin buffer A containing 25 mM Tris pH 7.0 and 150 mM NaCl and loaded 5 
times onto a 10 mL heparin column coupled to the FPLC at 4 mL/min with a gradient length 
of 10 CV and delay of 75 mL.  The protein was eluted in 4 mL fractions with buffer B 
containing 25 mM Tris pH 7.0 and 1 M NaCl.  The eluted protein from each round of heparin 
purification was pooled and concentrated to 10 mL final volume.  The heparin purified 
6OST-1 was loaded twice (5 mL per injection) onto a pre-equilibrated Superdex 75 column 
at a flow rate of 1 mL/min and eluted in 1 mL fractions with a buffer containing 20 mM 
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MOPS pH 7.0 and 400 mM NaCl.  The eluted 6OST-1 protein fractions from each GPC run 
were pooled and stored at -80°C.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter III 
 
Structurally Guided Mutational Analysis of Heparan Sulfate  
2-O-Sulfotransferase 
 
 
 
 Heparan sulfate 2-O-sulfation is a critical modification within the HS biosynthetic 
pathway.  This critical modification is carried out by heparan sulfate 2-O-sulfotransferase 
(2OST).  The product is involved in mediating signal transduction pathways for fine structure 
formation in different species.  It has been found to be important for kidney development in 
mice as well as limb bud formation in chicken (100,102,103).  Understanding the substrate 
recognition mechanism of this enzyme is essential for determining the role of 2OST in 
embryonic development as well as for the enzymatic approach to obtaining biologically 
relevant HS structures.  Preliminary substrate specificity and mutagenesis studies have 
gained some insight into the molecular mechanism of 2OST (65,99,104). 
In this chapter, we present the homotrimeric crystal structure for 2OST in complex 
with 3’-phosphoadenosine 5’-phosphate (PAP).  Structural based mutational analysis along 
the 2OST active site identified several amino acid residues that are responsible for the 
substrate binding, catalysis, and trimer formation.  Interestingly, we identified three amino 
acid residues that were responsible for redirecting the substrate specificity of 2OST.  The 
mutant 2OST R189A only transferred sulfates to GlcUA moieties within the HS 
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polysaccharide whereas the mutants Y94A and H106A preferentially transferred sulfates to 
the IdoUA units (59).   
Crystallization of 2OST 
 Over the last few years, several attempts to crystallize 2OST were made but proved 
unsuccessful.  Initially, a construct of Chinese hamster 2OST with an N-terminal histidine6 
tag (
N’-His
2OST) was prepared for purification however this protein had very poor solubility.  
It was established that the C-terminal His6 tag enhanced solubility 10 fold compared to an N-
terminal His6 tag (126).  Although the 
C’-His
2OST protein had increased expression and 
solubility, the protein was present in more than one oligomeric state making crystallization 
virtually impossible (126).  Ideally, a protein must be present in one single homogeneous 
population for any hopes of crystallization as it helps to improve crystal formation.  Next, a 
construct expressing 2OST derived from chicken with an N-terminal thioredoxin (Trx) tag 
was prepared, as a Trx tag is known to enhance solubility of a target protein (232).  Although 
the thioredoxin 2OST construct had a much higher level of expression compared to the 
C’-
His
2OST, solubility become a major issue especially when attempting to cleave the Trx tag.  
The final and most promising construct we tested was a chimera of maltose binding protein 
(MBP) fused to the catalytic domain of 2OST derived from chicken.  Chicken was selected 
because it has a higher body temperature at 42°C, in theory making it more stable and 
amenable to crystallization (233).  This fusion protein was highly expressed, very soluble and 
existed in a single homogeneous population thus making crystallization a possibility.   
  For preparing the expression construct, the catalytic domain of chicken 2OST (D69-
N356) was cloned into a modified pMAL-c2x vector possessing three alanine residues 
(A368-A370) in the linker region to reduce flex in the fusion protein to allow for 
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crystallization.  The MBP-2OST fusion protein was expressed in Origami B (DE3) cells and 
purified by affinity chromatography using an amylose column.  From the SDS-PAGE 
analysis in Figure 24, several bands were present on the gel along with the MBP-2OST 
protein (70 kDa) including chaperonin proteins (55 kDa) and MBP (42 kDa) that must be 
eliminated in order to attempt crystallization.  The protein utilized for crystallization trials 
must possess high purity (>90%) therefore any impurities, such as the chaperonin proteins 
and MBP, that may interfere with crystallization must be removed.  A second round of 
purification was then employed using a Superdex 200 gel filtration column to separate the 
fusion protein from impurities including aggregated protein and free MBP.  Based on the 
two-step purification, we were able to obtain a highly active MBP-2OST fusion protein with 
greater than 95% purity.     
 
Figure 24.  SDS-PAGE analysis of purified wild type MBP-2OST.  A small aliquot (5 µg) of MBP-2OST 
purified by amylose resin (lane 1) and 2OST purified by gel filtration chromatography (lane 2) were analyzed 
by SDS-PAGE using a 10% Tris-HCl gel stained with Coomassie Blue.  The purity of the MBP-2OST is greater 
than 95% following GPC purification.   
  
 
  
83 
 Gel filtration chromatography analysis revealed that the fusion protein appeared to 
behave as a trimer in solution ( 
Figure 25).  The molecular mass of monomeric MBP-2OST is approximately 70 kDa.  A 
standard curve was generated using the elution volume and molecular mass of known protein 
standards including β-amylase (200 kDa), bovine serum albumin (66 kDa), carbonic 
anhydrase (29 kDa), and cytochrome c (12.4 kDa).  The void volume (Vo) and total column 
volume (Vt) were determined by resolving blue dextran (2,000 kDa) and phenol red (0.4 
kDa) respectively.  A linear plot of log molecular weight against average retention time 
(Kaverage) in the column gave a slope of -3.87±0.25, y-intercept of 2.93±0.09, and r
2
 value of 
0.99, providing a calculated molecular mass of 210 kDa for the MBP-2OST protein (Fig 23).  
The calculated molecular mass was consistent with that of a trimer. 
A low-resolution crystallographic data set collected from crystals of the catalytic 
domain of hamster 2OST, lacking a fused MBP molecule, revealed similar trimer formation.  
The hamster 2OST was generated by cloning the catalytic domain of hamster 2OST (R63-
N356) into the pET-21b vector (Novagen) by using NdeI and HindIII sites to form a C-
terminal (His)6-tagged 2OST expression construct.  This dataset provided support that the 
MBP molecule did not contribute to formation of the trimeric 2OST complex since the 
hamster 2OST protein did not possess a MBP tag.   
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Structural Analysis of 2OST 
Comparison to Other Known HS Sulfotransferases 
 Through a collaborative effort with Dr. Lars Pedersen from NIEHS, the crystal 
structure of the fusion protein containing MBP and the catalytic domain of chicken 2OST 
was successfully solved.  The crystal structure of MBP-2OST was obtained to 2.65Å in a 
 
Figure 25.  Determination of the apparent molecular weight of 2OST.  The molecular weight of the 
purified 2OST protein was measured by gel filtration chromatography using a Superdex 200 HiLoad 
16/60 column.  The UV absorbance at 280 nm was plotted against elution volume, revealing a single peak 
representing the MBP fusion protein (labeled 2OST), as displayed in the inset.  The molecular weight 
standards used were cytochrome c (12.4 kDa), carbonic anhydrase (29 kDa), bovine serum albumin (66 
kDa), β-amylase (200 kDa).  The void volume (Vo) and total column volume (Vt) were determined by 
resolving blue dextran (2,000 kDa) and phenol red (0.4 kDa) respectively.  The log of the molecular 
weight for each protein standard was plotted against the average retention time (Kaverage) in the column 
giving a slope of -3.87±0.25, y-intercept of 2.93±0.09, and r
2
 value of 0.99.  The MBP fusion protein is 
indicated by an arrow labeled 2OST. 
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binary complex with the inactive sulfo donor, 3’-phosphoadenosine 5’-phosphate (PAP), as 
seen in Figure 26. 
 
Figure 26.  Crystal structure of 2OST. (A) Ribbon diagram of the chimeric construct of MBP (pink) fused to 
the N-terminus of the catalytic domain (Asp69-Lys354) of 2OST (green).  A maltose molecule (yellow) is 
bound to the MBP domain while a PAP molecule (cyan) is bound to the 2OST catalytic domain.  N- and C-
terminal ends of the 2OST domain are labeled.  (B)  Ribbon diagram of the 2OST catalytic domain (green) with 
PAP bound (cyan).  The PSB-loop containing Lys83 is colored pink.  The two conformations of catalytic base 
His142 are also shown.  Residues Ile309-Lys354 of an adjacent molecule in the trimer are shown in orange and 
the disulfide bonds are shown in purple.  Red arrows indicate the substrate binding cleft. All protein structure 
figures were created using MOLSCRIPT and Raster 3D (162,234). 
 
 
The crystal structure revealed that the catalytic domain of 2OST was composed of an 
α/β motif with a central parallel β-sheet flanked by α-helices on both faces of the sheet 
(Figure 26A).  As seen in Figure 26B, a large open cleft for acceptor carbohydrate substrate 
binding was found running across one side of the enzyme exposing the active site, similar to 
the other HS sulfotransferases including the N-sulfotransferase domain of N-deacetylase/N-
sulfotransferase (NST), and the 3OST isoforms 1, 3, and 5 for which crystal structures exist 
(63,79,150,151).  Despite their global similarities, the crystal structure for 2OST possessed 
distinct differences from the other HS sulfotransferases.  Sequence alignments of 2OST to 
NST and 3OST isoforms only demonstrated approximately 12% sequence identity compared 
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to 28% between NST and the 3OST isoforms.  Comparison of 2OST to NST and the 3OSTs 
revealed the lack of an exterior 3-stranded antiparallel β-sheet containing a disulfide bond 
and a small loop off the last strand of the central parallel β-sheet where the proposed catalytic 
base glutamic acid (Glu-184 in 3OST-3) resided.  The crystal structure of 2OST exhibited a 
unique enlongated C-terminal helix followed by a 20 amino acid tail extending away from 
the catalytic domain (Figure 26B and Figure 27).   
The crystal structure of 2OST was indeed strikingly different from the other HS 
sulfotransferases due to the presence of this extended C-terminal tail which formed an 
antiparallel strand arrangement (N345-Y352) with the 5
th
 strand (V104-T110) of the central 
β-sheet of an adjacent monomer (Figure 29A and B and Figure 26B).  This arrangement 
situated C-terminal residues Lys-350 and Glu-349 of one molecule near the substrate binding 
site of a second molecule to potentially stabilize the active site and participate in substrate 
binding (Figure 28B).   
 
 
Figure 27.  Stereo diagram of the superposition of 2OST and 3OST-3.  Superposition of 2OST (green with 
PAP and His-142 in cyan) and 3OST-3 (yellow with catalytic Glu-184 in red) with bound heparan sulfate 
tetrasaccharide (coral) reveals global similarities and specific differences between the two enzymes.  Most 
notable is the extended C-terminus of 2OST involved in trimer formation.   
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Comparison to Cytosolic Sulfotransferases 
HS sulfotransferases, like 2OST, are type II transmembrane Golgi-associated 
enzymes however cytosolic sulfotransferases, such as estrogen sulfotransferase (EST), have a 
buried hydrophobic binding pocket for the acceptor substrate such as a hydrophobic steroid 
(235).  Sequence alignments of 2OST with the cytosolic sulfotransferase EST revealed a 
slightly higher sequence identity of ~16.5% (80).  Interestingly, 7 of the 45 sequence 
conserved residues came from the long α-helix (V182-L188) equivalent to helix 6 in EST, 
that runs across the top of both the donor and acceptor substrate binding pockets (Figure 
28A).  Structural comparison of 2OST to EST revealed the absence of a catalytic glutamate, 
which was noticeably present in NST1 and the 3OSTs.  Instead, 2OST and EST utilized a 
histidine at the end of the 4
th
 strand of their central β-sheet (80).  Like His-108 in EST, a 
structurally equivalent histidine (His-142) was present in 2OST (Fig 28A and B), which had 
been identified by Xu et al. (104) based on comparisons with cytosolic enzymes using 
sophisticated sequence alignments and mutational analysis.  The His-142 residue for 2OST 
existed in two apparent conformations where one conformation positioned the side chain 
away from the substrate binding cleft (conformation A) while the other conformation 
(conformation B) superimposed very well with His-108 of EST.  Conformation B positioned 
the histidine side chain in the active site cleft for a possible role in catalysis (Fig 28A). 
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Figure 28.  Active site residues of 2OST.  (A) Superposition of the active site of 2OST (green) with PAP 
(cyan) and the cytosolic EST enzyme (gray) with PAP and acceptor substrate 17β-estradiol (E2).  The figure 
displays the position of the acceptor OH of E2 with respect to the proposed catalytic base His-108 in EST.  The 
structurally equivalent His-142 of 2OST is shown in the 2 apparent conformations displayed in the crystal 
structure.  In contrast, the position of the proposed catalytic base in 3OST-3 (yellow), Glu-184, is shown 
originating from a different location in the structure, yet the acceptor (data not shown) location is similar to that 
of the OH of E2 in EST (marked by *).  (B) Stereo diagram of the proposed acceptor binding cleft of a 2OST 
molecular (green) and the adjacent C-terminal tail of another 2OST molecule in the trimer (orange).  PAPS 
(purple) is based on superposition of PAPS from the EST structure with bound PAPS (Protein Data Base ID 
code 1HY3) onto the PAP molecule in 2OST.  Residues shown lining the cleft were mutated in this work (Table 
1). 
 
Trimeric Complex of 2OST 
The most distinct structural difference between 2OST and the other HS 
sulfotransferases was that 2OST appeared to function as a trimer.  In the crystal structure of 
MBP-2OST, a 3-fold crystallographic axis ran through the middle of the trimer (Fig 29A and 
B).  Supporting this quaternary structure was the previous study in Figure 25, demonstrating 
that the fusion protein behaved as a trimer in solution as determined by gel filtration 
chromatography.  The results were consistent with a study by Kobayashi et al., 
demonstrating that 2OST isolated from Chinese hamster ovary cells migrated as an oligomer 
by gel filtration chromatography (99). 
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Figure 29.  Trimeric complex of the catalytic domain of 2OST. (A) View of the 2OST trimer looking down 
the 3-fold crystallographic axis (monomers are colored green, blue, and orange).  The active sites containing 
PAP (khaki) are located on the outer surface of the trimer.  (B)  Side view of the trimer based on a ~90º rotation 
of A, along an axis in the plane of the paper.  The hypothetical positions of the transmembrane N-terminal 
helices and the Golgi membrane with respect to the trimer have been sketched into the figure.    
 
 
 
 The orientation of the 2OST monomers within the trimeric complex positioned the N 
termini of all three molecules on one side of the trimer in close proximity to one another (Fig 
29B).  This orientation was consistent with a type 2 membrane-bound protein where all three 
molecules would be anchored to the membrane via their N-terminal transmembrane domains 
(L12-L27) although this region was not present in the crystal structure.  Positioning of the 
monomers within the trimer separated the active sites from one another, suggesting that the 
individual active sites may function independently (Fig 29A).   
 Previous reports indicated that C5-epi formed a complex with 2OST in vivo (96) 
however it is unlikely that C5-epi could occupy one of the monomeric sites of the 2OST 
trimer.  In fact, the 2OST originally purified from Chinese hamster ovary cells, although 
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trimeric, did not contain C5-epi (99).  The proposed in vivo complex could involve a 
supramolecular structure between the trimeric 2OST and C5-epi.   
Structurally Guided Mutagenesis Study of 2OST 
Site-directed mutagenesis studies were performed to identify the roles of specific 
amino acid residues in the catalytic function and substrate specificity of 2OST (Table 1).  
Amino acid residues that are involved in binding to PAP/PAPS were not the focus of this 
study because they were reported in a previous publication (104).  Instead, amino acid 
residues lining the proposed substrate binding cleft were chosen for mutational analysis.  
Mutant enzymes were exposed to two polysaccharide substrates differing in the structure of 
the disaccharide repeating unit.  Completely de-O-sulfated N-sulfated (CDSNS) heparin 
predominantly has the repeating disaccharide of -IdoUA-GlcNS-, while N-sulfo heparosan 
consists of a repeating structure of -GlcUA-GlcNS- (Fig 30).  Testing the activity of the 
2OST mutants with these two different substrates permitted us to identify residues that 
differentiate between IdoUA and GlcUA acceptor substrates in the polysaccharide chain. 
 
 
Figure 30.  Reactions catalyzed by 2OST.  2OST sulfates either the GlcUA unit present in N-sulfo heparosan 
or the IdoUA unit present in CDSNS-heparin.  If the polysaccharide contains both GlcUA and IdoUA units, 
2OST prefers IdoUA. 
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Table 1.  Activity of 2OST WT and mutants toward polysaccharide substrates 
*The 2OST mutants were prepared using a modified site-directed mutagenesis protocol from Stratagene.  The 
protein expression level of the mutant proteins is comparable with the wild type protein as determined by the 
intensity of the Coomassie blue-stained protein band that migrated at 70 kDa on SDS-PAGE. 
†The activity of 2OST was assayed by incubating the purified mutant proteins with either completely de-O-
sulfated N-sulfated heparin (CDSNS-heparin) [(-IdoUA-GlcNS-)n] or N-sulfo heparosan [(-GlcUA-GlcNS-)n] 
and [
35
S]PAPS and the resultant 
35
S-substrate was quantified by DEAE chromatography where 100% activity 
represents the transfer of 155 pmol of sulfate per µg of protein for CDSNS-heparin and 65 pmol of sulfate per 
µg of protein for N-sulfo heparosan under the standard assay conditions.  
  
 
 
Residues Involved in Enzyme Catalysis 
Based on the crystal structure, four residues (Arg-80, His-140, His-142, Arg-288) 
were located near the point of sulfo transfer and thus may be involved in catalysis and/or 
acceptor substrate binding.  Consistent with previous alanine scanning mutagenesis 
experiments, our results demonstrated that these residues were important for activity (104).  
In the crystal structure, Arg-80 and Arg-288 were located near the proposed position of the 
sulfo moiety on the PAPS molecule and therefore could be involved in stabilization of the 
transition state and/or substrate binding (Fig 28B).  The R80A and R288A mutants displayed 
 Sulfotransferase Activity to 
Polysaccharide Substrates 
 Sulfotransferase Activity to 
Polysaccharide Substrates 
2OST 
Mutants
 
CDSNS-Heparin 
(-IdoUA-GlcNS-)n
 
N-Sulfo Heparosan 
(-GlcUA-GlcNS-)n 
2OST 
Mutants
 
CDSNS-Heparin 
(-IdoUA-GlcNS-)n
 
N-Sulfo Heparosan 
(-GlcUA-GlcNS-)n 
 % %  % % 
WT 100 100 WT 100 100 
R80A 1 2 R188A 100 100 
N91A 51 42 R189A 0.3 100 
Y94A 90 7 R190A 100 74 
D95A 80 32 D208A 76 42 
H106A 51 0.4 K213A 100 56 
K111A 100 62 K283A 100 100 
N112A 97 54 K284A 68 42 
H140A 7 < 0.1 R288A 5 10 
H140N 52 14 H330A 100 100 
H142A < 0.1 < 0.1 E349A 31 77 
H142N 20 3 K350A 22 7 
R169A 1 0.3 Y352A 69 43 
Y173A 80 50 V332STP 2 0.5 
D181A 20 11 L342STP 11 3 
Y183A 8 2    
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10% or less activity toward both polysaccharide substrates (Table 1).  Preliminary 
mutagenesis studies using CDSNS-heparin demonstrated similar reduction in sulfotransferase 
activity while maintaining binding affinity to PAP, suggesting a potential role for these 
residues in substrate binding or catalysis (104). 
  Previously, it was demonstrated that the mutations H140A and H142A greatly 
reduced the activity of 2OST and that the double mutant H140A/H142A resulted in complete 
loss of activity (104).  The crystal structure revealed that His-142 is in position to potentially 
serve as a catalytic base facilitating the deprotonation of the acceptor substrate, whereas His-
140 was located more distal to the point of sulfo transfer and was in position to form a 
hydrogen bond with Arg-80.  The H142A mutant of chicken 2OST had no detectable activity 
with the two substrates, supporting its essential role as a catalytic base, while 2OST H140A 
retained about 7% of wild type activity against the IdoUA containing substrate (CDSNS-
heparin).  To further probe the functions of His-140 and His-142, mutants H140N and 
H142N were prepared.  The H140N mutant maintained 52% activity against the IdoUA 
containing substrate and 14% against the GlcUA containing substrate (N-sulfo heparosan).  
Based on the crystal structure, it appeared that the asparagine substitution could still form a 
hydrogen bond with Arg-80.  Thus, the major role of His-140 may be to properly position 
Arg-80.  Surprisingly, the H142N mutant maintains 20% and 3% of wild type activity against 
IdoUA and GlcUA containing substrates, respectively.  In contrast, the equivalent mutation 
of His-107 of human EST to asparagine completely abolished the sulfotransferase activity 
(80).  One possible explanation for the residual activity of the H142N mutant versus H142A 
could be that a water molecule occupies the location of the N2 atom of the histidine side 
chain, stabilized by interactions with Asn-142, and substituted as a weak proton acceptor in 
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the absence of the histidine side chain.  An additional possibility was that the reaction for 
2OST is more dissociative in nature, compared to EST, with greater emphasis on bond 
breaking and stabilization of the leaving group rather than deprotonation of the nucleophile, 
decreasing the need for a strong base.  
Residues Involved in Trimer Formation 
Several residues along the C-terminal tail were subjected to mutational analysis 
including His-330, Glu-349, Lys-350, and Tyr-352 (Fig 28B).  These residues were selected 
as they from hydrogen bonding interactions with the β-strand of the adjacent monomer.  The 
only residue showing a loss of activity greater than 70% was the Lys-350 mutant (Table 1).  
The side chain of this residue was extended into the active site of the adjacent molecule, 
suggesting it could play a minor role in substrate binding.   
Although no single point mutation along the C-terminal tail caused a severe decrease 
in activity, introduction of a premature stop codon after either Val-332 or Leu-342 resulted in 
a drastic loss in activity toward both substrates.  These data suggested that deletion of 
residues along the C-terminus eliminated the intermolecular interactions between the protein 
backbone atoms, disrupting the adjacent active site and potentially caused destabilization of 
the protein and/or the protein trimeric complex.  To determine if the truncation mutant 
disrupted the trimeric complex, the V332STP mutant protein was analyzed by gel filtration 
chromatography.  The chromatogram for the wild type MBP-2OST revealed three distinct 
peaks (Fig 31A) representing aggregated MBP-2OST (peak 1: fractions 3-9) in the void-
volume, trimeric MBP-2OST (peak 2: fractions 12-16) (sample used for crystallization 
trials), and MBP (peak 3: fractions 23-28) respectively.  Of these peaks, the only containing 
sulfotransferase activity was that consistent with the trimer.  
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The mutant (2OST V332STP) revealed a starkly different elution profile from the 
wild type MBP-2OST construct.  The aggregated protein eluted with similar amount and 
position as the normal wild type MBP-2OST, however there was a substantial decrease in the 
intensity of the trimeric 2OST peak and the appearance of an additional peak before MBP 
between fractions 19 and 23 (Fig 31B).  This peak corresponded to a molecular weight of 
approximately 70 kDa and represented monomeric MBP-2OST (Fig 31C).  Sulfotransferase 
activity was detected predominately within the trimeric peak as well as the monomeric 2OST 
peak, but at a lower level.  The activity for the mutant trimer was substantially lower than for 
the wild type protein, suggesting the extended C-terminal tail influenced trimer formation 
and was crucial for the activity.  
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Figure 31.  Comparison of the oligomeric state of 2OST WT to V332STP.  Approximately 7 mg amylose-
agarose column purified wild type or premature stop codon mutant (V332STP) 2OST were analyzed by gel 
permeation chromatography.  The sulfotransferase activity was also determined using CDSNS Heparin as a 
substrate.  Both the UV absorbance and sulfotransferase activity are plotted against fraction number for wild-
type (A) and mutant (B) 2OST.  The molecular weight standards resolved under the same experimental 
conditions are indicated by arrows.  One unit is equivalent to one picomole of sulfate transferred to substrate 
under standard reaction conditions.  Panel C shows specific fractions that were analyzed by SDS-PAGE using a 
10% Tris-HCl gel stained with Coomassie Blue for both the 2OST WT and V332STP.  The fractions analyzed 
are labeled with a number above each lane of the SDS gel.  SDS-PAGE analysis of these fractions from gel 
permeation chromatography confirmed the presence of 2OST within all fractions from 5 to 23.     
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Residues Involved in Substrate Binding and Specificity 
Residues Tyr-183, Arg-169, Asp-181, and Arg-189 were located in the 2OST 
substrate binding cleft but distal to the catalytic core implicating them in acceptor substrate 
binding (Fig 28B and Fig 32).  Mutations of these residues showed a noticeable effect on 
enzymatic activity (Table 1).  Of these mutations, Y183A and R169A resulted in a 
substantial loss of activity toward both CDSNS heparin and N-sulfo heparosan.  Tyr-183 was 
located toward the predicted non-reducing end of the binding pocket based on comparisons 
to the crystal structure of 3-OST-3 (63).  The side chain of Tyr-183 extended into the solvent, 
suggesting it does not play a structural role but rather may play a significant role in substrate 
binding.  The side chain of Arg-169 was located on the reducing end of the binding pocket.  
Most of this side chain was buried with the guanidinium moiety on the surface of the binding 
pocket.  Arg-169 is conserved in NST-1 and the 3-OST isoforms as well.  In the 3-OST-3 
structure with a tetrasaccharide bound, this residue (Arg-248) did not directly interact with 
the substrate (63).  The main role of Arg-169 may be to stabilize the PSB-loop as the 
guanidinium moiety is within hydrogen bonding distance to the backbone carbonyl oxygen of 
Pro-82 in this loop.  Also lining the pocket, but largely buried, is the side chain of Asp-181.  
This residue is in position to form hydrogen bonds with Arg-189 (2.8 Å) and/or Arg-288 (2.9 
Å).  Such interactions suggested that Asp-181 may help position Arg-288 and Arg-189 for 
substrate binding and/or catalysis.  As with Arg-288, replacing Asp-181 with alanine resulted 
in a substantial loss of the sulfotransferase activity toward both CDSNS heparin and N-sulfo 
heparosan (Table 1).  
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Figure 32.  Amino acid residues involved in substrate binding/catalysis.  A closer view of the active site of 
2OST is shown with the secondary structure of 2OST (gray) bound to PAP (magenta) bound.  The residues 
involved in substrate binding/catalysis including Tyr-183, Arg-288, His-140, Arg-80, His-142, and Arg-169 are 
colored green.  
 
Residues Involved in Redirecting Substrate Specificity 
Although wild type 2OST sulfates both GlcUA and IdoUA in HS substrates, the 
mutants Y94A, H106A and R189A showed substantial preference for one substrate over the 
other.  Both Y94A and H106A mutants sulfated CDSNS heparin, the IdoUA containing 
substrate, but lost activity with N-sulfo heparosan, the GlcUA containing substrate, 
displaying 10 fold and 100 fold differences in percent activity, respectively.  These results 
suggest that Tyr-94 and His-106 allow recognition of the GlcUA containing substrate.  Thus, 
replacing either residue with alanine resulted in a substantial preference for the 
polysaccharide substrate containing IdoUA. 
Most impressive was the selective preference of R189A for the GlcUA containing 
substrate over IdoUA.   The mutant R189A retained full activity with the GlcUA containing 
substrate but showed virtually no activity with the IdoUA containing substrate.  This 
observation suggested that residue Arg-189 is likely important for recognition of IdoUA 
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containing substrate and replacing the arginine residue with an alanine does not allow the 
enzyme to exhibit substrate flexibility. 
To further examine the role of Arg-189 in substrate recognition, we reconstituted the 
biosynthesis of IdoUA2S in vitro.  An unepimerized polysaccharide substrate sulfated only 
on the N-position of the glucosamine unit (similar to N-sulfo heparosan (18)), was incubated 
with wild type 2OST and 2OST R189A in the presence or absence of C5-epi, where C5-epi 
converted part of the GlcUA to IdoUA (as illustrated in Fig 33C).  The resultant 
polysaccharides were then characterized by disaccharide analysis of the products (Fig 33A, 
33B).  As expected, the product modified by wild type 2OST predominantly contained 
GlcUA2S in the absence of C5-epi (Fig 33A, red line) or IdoUA2S in the presence of C5-epi 
(Fig 33A, blue line) (98,236).  In contrast, the products modified by 2OST R189A contained 
only GlcUA2S regardless of the absence or presence of C5-epi (Fig 33B), suggesting that the 
mutant protein did not recognize IdoUA as an acceptor unit in the polysaccharide substrate.   
 
 
 
 
 
 
 
  
99 
 
Figure 33.  RPIP-HPLC chromatograms of the disaccharide analysis of 2OST wild type and 2OST 
R189A-modified polysaccharides.  (A) Chromatogram of nitrous acid degraded 2-O-[
35
S]sulfated N-sulfo 
heparosan using 2OST WT enzyme in the presence (blue line) or absence (red line) of C5-epi modification.  (B) 
Chromatogram of nitrous acid degraded 2-O-[
35
S]sulfated N-sulfo heparosan using 2OST R189A enzyme with 
(blue line) or without (red line) C5-epi modification.  (C) Reactions involved in preparing 2OST-modified 
polysaccharide with or without C5-epi and degradation by nitrous acid.  AnMan represents 2,5-
anhydromannitol.     
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The roles of Tyr-94, His-106, and Arg-189 in directing the substrate specificity are 
currently unknown since a crystal structure of a ternary complex containing an appropriate 
oligosaccharide is currently unavailable.  All three mutants of Y94A, H106A, and R189A 
were analyzed by gel filtration chromatography alongside the wild-type to identify any key 
differences in the overall conformation of the protein.  The 2OST wild type and mutant 
proteins presented elution profiles consistent with the MBP-2OST protein used during 
crystallization (Fig 34).  Several fractions were analyzed for sulfotransferase activity, 
revealing activity solely within the trimeric 2OST peak for wild-type as well as all mutant 
2OSTs.  This additional information suggested that the mutant enzymes did not cause 
changes in the overall conformation of the enzyme since all mutants including the wild-type 
2OST maintained the highly active trimeric structure.   
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Figure 34.  Comparison of the oligomeric state of 2OST WT with 2OST Y94A, H106A, and R189A.  
Approximately 20 mg of amylose-agarose column purified WT or mutant (Y94A, H106A, and R189A) 2OST 
was analyzed by gel permeation chromatography.  The sulfotransferase activity was determined by using 
CDSNS heparin as a substrate, and 2OST R189A was analyzed using N-sulfo heparosan as a substrate.  The UV 
absorbance (solid line) and sulfotransferase activity from selected fractions (bar graph) are plotted against 
fraction numbers for 2OST WT and mutants.  One unit is equivalent to 1 pmol of sulfate transferred to the 
substrate under standard reaction conditions.  Some fractions possessed sulfotransferase activity <100 units/mL 
and thus cannot be seen in the bar graph because of axis scaling.  (Insets) Fractions analyzed for 
sulfotransferase activity were also analyzed by SDS-PAGE, with a number above each lane of the picture of the 
SDS gel representing fractions from the gel filtration column.   
 
 
Conclusions 
 The biosynthesis of HS involves a series of specialized enzymes, including glycosyl 
transferases, an epimerase, and various sulfotransferases.  Modification by 2-O-
sulfotransferase, which transfers a sulfo group to both GlcUA and IdoUA units with a strong 
preference for IdoUA, has been implicated in a variety of biological functions (65).  The 
functions of 2-O-sulfated iduronic acid (IdoUA2S) in HS have been demonstrated by in vitro 
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and in vivo studies.  Unlike IdoUA2S, GlcUA2S is much less abundant in the HS isolated 
from natural sources and thus the function of GlcUA2S is currently unknown.  The IdoUA2S 
unit is necessary for binding to numerous growth factors and is crucial for triggering 
fibroblast growth factor-mediated signal transduction pathways (105).  The sequence of 
2OST is highly conserved across most vertebrate genomes including human and chicken, 
suggesting a central physiological role in these organisms.  Several animal knockout studies 
have demonstrated an essential role for this enzyme in animal development (101,103,124).  
With that said, it is necessary to gain a more detailed understanding of the structure-function 
relationship of 2OST in order gain more insight into its role in animal development.   
Here, the crystal structure of 2OST was reported as a MBP fusion protein in complex 
with PAP.  Unlike previously characterized HS sulfotransferases, 2OST is present in a 
trimeric form that appears to be essential for enzymatic activity.  Using the crystal structure 
as a guide, several amino acid residues along the active site that may play a potential role in 
substrate recognition were mutated.  These mutants were analyzed for sulfotransferase 
activity against two polysaccharide substrates differing in repeating disaccharide units and 
compared to the wild type 2OST enzyme.  Several residues were identified that may be 
essential for substrate binding/catalysis including Arg-80, His-140, His-142, Arg-169, Tyr-
184, and Arg-288 with mutation resulting in 10% or less activity towards both substrates 
compared to the wild type.    
 One unique feature of 2OST compared to the other HS sulfotransferases is the 
presence of an extended C-terminal tail that forms an anti-parallel strand arrangement with 
the 5
th
 strand of the central β-sheet of an adjacent monomer.  Mutation of several residues 
including His-330, Glu-349, Lys-350, and Tyr-352 did not demonstrate a significant loss in 
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activity compared to the wild type 2OST.  However, introduction of a premature stop codon 
after either Val-332 or Leu-342, eliminating the C-terminal tail residues, resulted in a 
dramatic loss in sulfotransferase activity.  This result suggests that removal of the C-terminal 
tail disrupts the adjacent active site and potentially destabilizes the trimeric complex of 
2OST.  To further explore this theory, the 2OST V332STP mutant was analyzed by gel 
filtration chromatography and compared to the wild type enzyme.  The V332STP mutant 
revealed a significant reduction in the MBP-2OST trimer and the appearance of a monomeric 
MBP-2OST peak, suggesting a disruption in the trimeric complex.  Analysis of 
sulfotransferase activity of these two peaks detected activity predominately within the 
trimeric peak.  The activity for the trimer within the V332STP mutant was significantly 
lower compared to the wild type (8000 U/mL versus 160,000 U/mL), suggesting that the C-
terminal tail is essential for the formation of the trimer and sulfotransferase activity. 
 Through our mutational analysis, three mutants of Y94A, H106A, and R189A were 
identified that demonstrated a selective preference for one substrate over another.  Both 
Y94A and H106A selectively sulfated the IdoUA-containing substrate (CDSNS-heparin) 
whereas R189A selectively sulfated the GlcUA-containing substrate.  To ensure that these 
three mutants were not causing global changes of the 2OST protein, all three mutants 
alongside the wild type were analyzed by gel filtration chromatography, determining that all 
the mutants migrated as a trimer which possessed all sulfotransferase activity.  These results 
suggest that the mutations do not lead to large scale structural changes that disrupt the active 
trimer, supporting a local change within the active site that causes the differences in substrate 
specificity.   
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 Demonstrating over 300 fold difference in percent activity, the role of R189A mutant 
was further explored by reconstitution of the biosynthesis of IdoUA2S in vitro through 
modification of N-sulfo heparosan with 2OST R189A in the absence or presence of C5-epi 
followed by disaccharide analysis using nitrous acid degradation at pH 1.5.  This process was 
repeated using wild type 2OST for comparison.  Products modified by the wild type 2OST 
predominately contained GlcUA2S-AnMan disaccharides in the absence of C5-epi but solely 
IdoUA2S-AnMan disaccharide products in the presence of C5-epi.  The products modified by 
the R189A mutant, on the other hand, contained only GlcUA2S-AnMan disaccharide 
products regardless of the presence or absence of C5-epi, confirming the mutagenesis results.  
These results suggest that 2OST R189A solely recognizes GlcUA units in the presence of 
IdoUA, which is less likely with wild type 2OST.  One potential application of this mutant 
would be to synthesize therapeutic heparin with reduced side effects.  Heparin-induced 
thrombocytopenia is a major side effect of heparin, caused in part by the binding to platelet 
factor 4.  It is known that the IdoUA2S unit, the product of wild type 2OST modification, is 
involved in heparin binding to platelet factor 4 (237).  Using the 2OST R189A mutant to 
synthesize heparin, the IdoUA2S unit could be replaced with GlcUA2S, hopefully reducing 
the side effect.  Another potential application of the engineered mutant would be to produce 
HS and heparin with highly enriched GlcUA2S units for probing the biological function in 
glycomics studies (238). 
In conclusion, our results have provided structural and biochemical information for 
delineating the mechanism of action of 2OST and evidence for altering the substrate 
specificity of 2OST for the synthesis of HS with unique biological functions. 
 
  
Chapter IV 
 
Determining the Activity of Heparan Sulfate  
C5-Epimerase Using Engineered 2OST 
 
 
Heparan sulfate consists of glucuronic acid (or iduronic acid) linked to glucosamine 
carrying various sulfo groups.  The HS C5-epimerase (C5-epi) is responsible for conversion 
of glucuronic acid to iduronic acid.  The method for determining the C5-epi activity has been 
cumbersome due to the use of a site-specifically 
3
H-labeled polysaccharide substrate.  Here, a 
two-enzyme coupling assay was reported to determine the activity of C5-epi.  Using the 
engineered 2OST mutants identified in Chapter III, an effective assay was designed to 
monitor the activity of heparan sulfate C5-epi (239).  Unlike wild-type 2OST which 
recognizes both glucuronic acid and iduronic acid, the 2OST Y94I mutant transfers sulfate to 
the iduronic acid residue but not glucuronic acid.  The substrate selectivity allowed 
determination of the amount of epimerase activity by simply monitoring the incorporation of 
2-O-sulfo groups onto the IdoUA units by 2OST Y94I.  Our approach will significantly 
reduce the complexity for assaying the activity of C5-epi and facilitate the structural and 
functional analysis of C5-epi. 
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Redirecting the Substrate Specificity of 2OST 
Upon the discovery of the engineered 2OST mutants, there was an opportunity to take 
advantage of their selective properties for the development of an effective assay for C5-epi 
activity.  The current method for determining the activity for C5-epi is less straightforward 
due to the use of a site-specifically tritium labeled polysaccharide substrate.  Campbell et al. 
reported a method to measure the epimerase activity by determining the released tritium that 
was introduced at the C5 position of the GlcUA/IdoUA unit of CDSNS-heparin (93).  The C5-
epi de[
3
H]protonates at the C5-position of a GlcUA or IdoUA unit, dissociating the [
3
H]-label 
from the polysaccharide.  Although this method was sufficient to guide the purification of 
C5-epi from bovine liver (240), a large amount of [
3
H]H2O must be used to prepare the 
tritium labeled polysaccharide which cannot be readily completed in a standard academic 
laboratory.  Another issue with the current assay is that the reversibility of the enzyme causes 
continuous release and addition of the 
3
H-label therefore the measurement could be incorrect.  
The need for a 
3
H-labeled polysaccharide substrate was bypassed to assay the C5-epi activity 
by using a 2OST mutant with altered substrate specificity (Fig 35C).  The substrate used in 
this method was N-sulfo heparosan, a polysaccharide containing solely GlcUA units.  The 
2OST Y94A mutant was engineered to specifically sulfate IdoUA therefore the 2OST mutant 
will not sulfate N-sulfo heparosan unless the GlcUA units have been converted to IdoUA by 
C5-epi.    
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Figure 35.  Chemical reactions catalyzed by C5-epi and 2OST. (A) HS C5-epi catalyzed reaction. HS C5-epi 
catalyzes the conversion of GlcUA unit in HS to IdoUA and the reverse reaction, namely from the IdoUA to 
GlcUA. (B) 2OST WT catalyzed reaction. 2OST WT catalyzes the 2-O-sulfation of both GlcUA and IdoUA 
units in the polysaccharide. (C) Strategy for determining C5-epi activity by coupling C5-epi and 2OST mutant. 
By coupling these two enzymes together, the IdoUA produced by epimerase catalyzed reaction is converted to 
IdoUA2S, which can be detected by the level of [
35
S]sulfate incorporation to the polysaccharide. 
 
 
 
 
The heparan sulfate C5-epi converts GlcUA to IdoUA by abstracting the proton of the 
C5-hydrogen of GlcUA followed by reinsertion of the proton (241), however the reversibility 
of the reaction results in the polysaccharide containing both GlcUA and IdoUA (Fig 35A).  
The resultant polysaccharide could be modified by wild type 2OST to generate IdoUA2S and 
GlcUA2S units within the chain (Fig 35B).  Previously, introducing a single point mutation 
to the active site of 2OST altered the substrate specificity of the enzyme (59).  The 2OST 
mutants, Y94A and H106A, selectively sulfate the IdoUA unit whereas R189A selectively 
sulfates the GlcUA unit.  To further confirm this finding, the susceptibility of 2OST WT and 
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2OST Y94A was compared to N-sulfo heparosan, the GlcUA-containing polysaccharide 
across a range of 2OST concentrations.  Indeed, 2OST Y94A displayed merely basal level of 
sulfation whereas 2OST WT demonstrated excellent activity toward N-sulfo heparosan (Fig 
35A).   
In a separate experiment using CDSNS heparin as a substrate, a polysaccharide 
predominately containing the IdoUA unit, both wild type and mutant 2OST exhibited similar 
susceptibility especially at higher concentrations (Fig 36B).  Taken together, our data suggest 
that the 2OST mutant could be used to detect the presence of IdoUA in the polysaccharide, 
leading to the possibility of assaying the activity of C5-epi as depicted in Figure 36C.  The 
coupling of C5-epi and 2OST is an effective approach to monitor the level of epimerization 
since previous studies reported that 2-O-sulfation prevented “back epimerization” (94,241).  
In other words, the addition of 2-O-sulfo groups will lock the configuration of the iduronic 
acid into place so one can effectively detect the level of conversion.  
 
Figure 36.  The sulfotransferase activity of 2OST WT and Y94A mutant toward different 
polysaccharides. Different amounts of 2OST proteins (0-1.0 μg) were incubated with either 2.0 μg N-sulfo 
heparosan (A) or 2.0 μg CDSNS heparin (B) and 9.9 × 105 cpm of [35S]PAPS for 5 minutes at 37 oC. The 
sulfated polysaccharide was purified by DEAE resin and was determined by scintillation counting. The results 
for 2OST WT were shown in filled circles (-●-) and 2OST Y94A in empty circles (-o-). 
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Optimization of the 2OST Tyr-94 Mutant 
A series of single point mutations were prepared to further optimize the selective of 
the 2OST Tyr-94 mutant.  The Tyr-94 was replaced with the acidic residue such as glutamic 
acid and a basic residue such as arginine.  The size of the side chain was varied by replacing 
with either phenylalanine or glycine.  In addition, a double mutant Y94A/H106A was 
prepared since 2OST H106A demonstrated sulfation of IdoUA units only.  All of the single 
point mutants were expressed on a small scale in Origami B (DE3) cells as MBP fusion 
proteins and purified by an amylose column as described in the Mutational Analysis section.  
With the exception of 2OST Y94R, the purified 2OST Tyr-94 mutants were successfully 
expressed as determined by SDS-PAGE analysis revealing a band at 74 kDa (Fig 37A).  The 
2OST mutants were analyzed for sulfotransferase activity against the two polysaccharide 
substrates of N-sulfo heparosan and CDSNS-heparin and compared to the wild type enzyme 
(Fig 37B).   
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Figure 37.  The expression and the sulfotransferase activity of 2OST mutants. The 2OST mutants were 
overexpressed in Origami-B cells using pMalc2x vector. The purified proteins were analyzed by 10% SDS-
PAGE with 2OST WT (A). The sulfotransferase activities of these mutants were tested using either N-sulfo 
heparosan or CDSNS heparin as a substrate and shown in percentage relative to wild type enzyme (B). 
 
 
 
Among the mutants analyzed, 2OST Y94A retained most of the sulfotransferase 
activity to CDSNS-heparin (80%) while retaining only 5% activity to N-sulfo heparosan.  
This result was consistent with the previous study seen in Table 1 in Chapter III.  Similar 
results were found for the Y94I mutant, retaining activity of 5% and 87% to N-sulfo 
heparosan and CDSNS heparin, respectively.  Substitution of tyrosine to phenylalanine 
(2OST Y94F) or glycine (2OST Y94G) also resulted in a significant loss in activity towards 
N-sulfo heparosan while maintaining substantial activity towards CDSNS-heparin, 
suggesting that the size of the side chain of the Tyr residue is not essential for the substrate 
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selectivity.  Mutation to a negatively charged glutamate residue resulted in significant loss in 
activity toward both substrates, although its sulfotransferase activity to CDSNS-heparin 
decreased even further (19% of wild type 2OST).  The effect of the basic residue arginine on 
substrate selectivity was not determined due to an insufficient quantity of enzyme for use in 
the activity assay (Fig 37A).  The double mutant, 2OST Y94A/H106A, lost nearly all activity 
towards both substrates, which was highly unexpected since the single point mutants 
presented a preference for the IdoUA-containing substrate previously (Table 1).  Since 
substitution of 2OST Tyr-94 with either alanine or isoleucine demonstrated similar 
selectivity to IdoUA units, the 2OST Y94I was utilized in the subsequent study for assaying 
the activity of C5-epi.   
Utilizing 2OST Y94I to Assay C5-Epi Activity 
The 2OST Y94I mutant selectively sulfates IdoUA units therefore the use of this 
mutant protein was employed to detect the level of IdoUA units, resulting from the action of 
C5-epi (Figure 35C).  The GlcUA containing substrate, N-sulfo heparosan, was incubated 
with increasing amounts of C5-epi ranging from 0-66 µg/mL followed by the addition of 
either 2OST WT or 2OST Y94I in the presence of [
35
S]PAPS.  The susceptibility to 2OST 
Y94I modification was elevated with increasing amounts of epimerase as indicated by the 
amount of [
35
S]sulfo groups incorporated into the polysaccharide substrate (Fig 38).  A clear 
linear relationship between the amount of C5-epi and the susceptibility to 2OST Y94I 
modification was observed, suggesting the validity of this method for measuring the activity 
of C5-epi.   
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Figure 38.  Dose response of C5-epi to the [
35
S]sulfation by 2OST Y94I and 2OST WT. Different amounts 
of C5-epi (0-66 μg/mL) were incubated with 2.0 μg N-sulfo heparosan for 30 minutes at 37 
o
C. Then 
epimerization reactions were stopped by boiling for 5 minutes. After centrifugation, the supernatants were 
mixed with either 2OST WT or 2OST Y94I and [
35
S]PAPS (4.4×10
5
 cpm), followed by incubation for 5 
minutes at 37 
o
C. The sulfated polysaccharide was purified by DEAE resin and determined by scintillation 
counting. The results obtained using 2OST WT were shown in filled circles (-●-). And 2OST Y94I in empty 
circles (-o-). 
 
 
A control experiment using 2OST wild type demonstrated a high level of [
35
S]sulfo 
group incorporation into N-sulfo heparosan even in the absence of C5-epi, which was 
expected since wild type 2OST can effectively sulfate GlcUA unit (Fig 38).  The wild type 
protein revealed a very narrow linear range of [
35
S]sulfated product in response to epimerase, 
making it unsuitable for determining the activity of C5-epi with this two enzyme-coupled 
method.  In addition, the ability of the wild type protein to sulfate GlcUA units would make 
it very difficult to monitor the level of IdoUA resulting from C5-epi using this assay since the 
[
35
S]sulfo groups would be incorporated onto both GlcUA and IdoUA units.   
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Applying the Two Enzyme-Coupled Assay to N-Terminally Truncated C5-Epi Mutants 
Once the assay was established, the method was then applied to C5-epi constructs 
differing in truncation sites from the N-terminus.  As previously determined, the human C5-
epi is a 617-amino acid protein consisting of three domains, cytoplasmic (M1-K11), 
transmembrane (N29-N617), and catalytic domain (N29-N617) (242).  The catalytic domain 
of C5-epi was further probed by preparing six different N-terminally truncated C5-epi 
constructs as MBP fusion proteins.  Based on a 3D structural prediction using the 
PredictProtein server, each truncation site was meticulously selected from a flexible loop to 
avoid overall global structural changes in the protein (243).  The truncated C5-epi mutant 
proteins were successfully expressed as MBP fusion proteins and analyzed by SDS PAGE, 
revealing an expected gradual decrease in the size of the truncation mutants (Fig 39A).  The 
C5-epi activity with each truncation mutant was measured by the established method.  The 
truncation mutant C5-epi (N92-N617) demonstrated similar epimerase activity to C5-epi 
(D34-N617), C5-epi (E53-N617), and C5-epi (Q72-N617).  The further truncation mutants, 
C5-epi (W203-N617) and C5-epi (F257-N617), exhibited no epimerase activity as compared 
to the negative control without epimerase (Fig 39B).  Taken together, these data suggested 
that the region of N92-W203 was important for the function of C5-epi.   
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Figure 39.  Activities of different truncations of C5-epi. The different truncations of human heparan sulfate 
C5-epimerase were overexpressed in Origami-B (DE3) cells using the pMalc2x vector. The picture of the 
purified proteins analyzed by SDS-PAGE is shown in Panel A. The values for the activity measured by the 
developed assay are shown in Panel B. 
 
Understanding the Catalytic Mechanism of C5-Epi 
The proposed mechanism of C5-epi has been compared to heparin lyases due to a 
similar transition state intermediate (Fig 40), a carbon anion at the C5 position of the 
GlcUA/IdoUA unit, among the two enzymes (244).  A tyrosine residue (Tyr-257) had been 
implicated in playing an essential role in the catalytic function of heparin lyases therefore it 
was speculated that some of the tyrosine residues could be important for C5-epi (244). 
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Figure 40.  Proposed catalytic mechanisms of C5-epi and heparin lyase II (244). Both C5-epi (left) and 
heparin lyase II (right) catalyzed reactions go through the same carbanion intermediate by abstracting the C5 
proton. This carbanion intermediate can be reprotonated (left) to produce epimerized product, or proceed to an 
elimination reaction by breaking up the glycosidic bond (right). Left, the C5 proton is shown in a circle, which 
can be 
3
H-labeled. 
 
 
 Several selected tyrosine residues of C5-epi were mutated to alanine including Tyr-
146, Tyr-162, Tyr-168, Tyr-208, Tyr-210, and Tyr-222 followed by analyzing their 
epimerase activity in comparison to wild type C5-epi using developed assay.  With the 
exception of Y208A, all of the C5-epi mutants were successfully expressed in Origami B 
(DE3) cells as analyzed by SDS-PAGE with comparable level to the wild type enzyme (Fig 
41A).  The mutants exhibited various levels of C5-epi activity with both Y168A and Y222A 
completely losing epimerase activity (Fig 41B).  The other tyrosine mutants, Y146A, Y162A, 
and Y210A, demonstrated a significant level of activity suggesting a less critical role in 
activity for epimerase.   
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Figure 41.  Analysis of tyrosine mutants of C5-epi. The tyrosine mutants were prepared by site directed 
mutagenesis using the plasmid containing truncated form of human C5-epi (Glu
53
-Asn
617
) as template. The 
purified proteins were analyzed by SDS-PAGE, shown in Panel A. The activities were shown in Panel B. 
  
 
 The results for the C5-epi Tyr mutants were confirmed by disaccharide analysis of the 
2-O-sulfated polysaccharide products using an established method (240).  The biosynthesis 
of the IdoUA2S-containing polysaccharide was reconstituted in vitro through incubation of 
N-sulfo heparosan with various C5-epi tyrosine mutants followed by sulfation with wild type 
2OST.  Wild type 2OST was used to allow for sulfation of both GlcUA and IdoUA units, 
which cannot be achieved with the 2OST Y94I selective mutant.  The resultant 
polysaccharides were then subjected to nitrous acid degradation at pH 1.5 to yield 2-O-
sulfated disaccharide products followed by resolving by reverse phase ion pairing-HPLC to 
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distinguish between IdoUA2S-AnMan and GlcUA2S-AnMan as illustrated in Figure 42E.  
The presence of the IdoUA2S-AnMan disaccharide product was indicative of the active form 
of C5-epi.  The use of wild type C5-epi resulted in the IdoUA2S-AnMan as the major product 
as expected (Fig 42A).  In the absence of C5-epi, GlcUA2S-AnMan was the only detected 
disaccharide product (Fig 42D).  As the epimerase activity decreased (Y146A), the ratio of 
IdoUA2S to GlcUA2S diminished (Fig 42B) compared to the wild type.  For the Y168A 
mutant exhibiting no epimerase activity, there was no IdoUA2S-AnMan present (Fig 42C), 
similar to the disaccharide analysis in the absence of C5-epi (Fig 42D).   
 
 
 
 
 
 
 
 
 
 
 
  
118 
 
Figure 42.  RPIP-HPLC chromatograms of the disaccharide analysis of the polysaccharides modified by 
various C5-epi mutants and 2OST WT. The polysaccharides were prepared by incubating with C5-epi and C5-
epi point mutants followed by the [
35
S]sulfation using 2OST WT. The preparation of the disaccharides is 
illustrated in Panel E. The resultant disaccharides were resolved using RPIP-HPLC as described under 
“Experimental Procedures”. Panel A-D showed the chromatograms of the polysaccharide treated with (A) C5-
epi WT, (B) C5-epi Y146A, (C) C5-epi Y168A and (D) no C5-epi, respectively. 
 
 
 Additional data for the disaccharide analysis of the C5-epi tyrosine mutants was 
provided in Table 2.  Comparison of the ratio of the two disaccharides and the relative C5-epi 
revealed a general trend.  As the C5-epi activity decreased, the ratio of the two disaccharides 
decreased.  These results suggested that the specific tyrosine residues of Tyr-168 and Tyr-
222 were essential to the activity of C5-epi.  A crystal structure of C5-epi would provide a 
more detailed understanding of the role these two tyrosine residues play in the function of the 
  
119 
enzyme.  It is worth noting that the disaccharide analysis was consistent with the results from 
the newly developed assay, further validating the method. 
 
Table 2.  Summary of disaccharide analysis for C5-epi and 2OST modified HS.  
C5-epi 
mutants 
IdoUA2S-AnMan/GlcUA2S-AnMan 
Relative C5-epi 
activity
a
 
 
No C5-epi 
 
≤0.1 
% 
-- 
C5-epi WT 5.3 100 
C5-epi Y146A 2.2 40 
C5-epi Y162A 2.2 23 
C5-epi Y168A ≤0.1 Inactive 
C5-epi Y210A 6.2 71 
C5-epi Y222A ≤0.1 Inactive 
 aThe relative activities were calculated from the data shown in Figure 42. 
 
Conclusions 
With the help of our engineered 2OST enzyme identified in Chapter III, a 
sulfotransferase based assay was developed for measuring the activity of C5-epi.  One of our 
research goals was to understand the mechanism of C5-epi however a simple and rapid assay 
for measuring the activity of this enzyme was currently available.  In this study, we 
developed a sulfotransferase based assay for measuring the C5-epi activity using the 2OST 
mutant (Y94A) that specifically sulfates the IdoUA unit.  We ensured that the Y94A mutant 
was capable of detecting the presence of IdoUA in the polysaccharide by analyzing the 
amount of sulfo groups transferred to either N-sulfo heparosan (GlcUA-containing 
polysaccharide) and CDSNS-heparin (IdoUA-containing polysaccharide) over a range of 
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2OST concentrations.  The Y94A mutant enzyme was incapable of sulfating N-sulfo 
heparosan however it showed excellent activity towards CDSNS-heparin, suggesting that the 
Y94A mutant could be used to detect and modify solely IdoUA within the polysaccharide. 
 We first attempted to expand the substrate selectivity of the 2OST Tyr-94 mutant 
toward IdoUA units by substituting the Tyr-94 with different types of amino acid residues 
including Y94E, Y94F, Y94G, and Y94I.  By comparing the susceptibility of the Tyr-94 
mutants to N-sulfo heparosan and CDSNS-heparin, we found that 2OST Y94A and 2OST 
Y94I have comparable substrate selectivity.  Compared to the other mutants, Y94A and Y94I 
have the best substrate selectivity for IdoUA units thus far.  The mechanistic role of the 
isoleucine (or alanine) could be revealed with the co-crystal structure of 2OST and an 
appropriate oligosaccharide substrate.   
 The similarity in catalytic transition state between heparin lyases and C5-epi has been 
noted since both enzymes involve deprotonation at the C5 position to yield a carbanion 
intermediate.  This similarity may be due in part to structural homology (245).  A recent 
study on dermatan sulfate epimerase, an enzyme catalyzing conversion of GlcUA to IdoUA 
of chondroitin sulfate/dermatan sulfate, provided some evidence for this idea (246).  Based 
on the crystal structure, three residues, His-202, Tyr-257, and His-406, are found in the 
active site of heparin lyase II from Pedobacter heparinus and possibly play a role in catalysis 
(244).  Corresponding histidine (His-205 and His-450) and tyrosine (Tyr-261) residues were 
identified in the dermatan sulfate epimerase by structural modeling and mutation of these 
residues resulted in complete loss of epimerase activity.  Furthermore, the predicted three-
dimensional structure of dermatan sulfate epimerase is very similar to the crystal structure of 
the heparin lyase II (317).  Although no obvious amino acid sequence homology between C5-
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epi and heparin lyases was observed, we speculate that the tyrosine residue may also play an 
important catalytic role for C5-epi due to the fact that both heparin lyase II and C5-epi utilize 
a similar substrate and yield a carbanion intermediate.  We selected tyrosine residues to 
investigate their roles in catalysis.  A total of 31 tyrosine residues are present in human C5-
epi.  Our attention was focused on the tyrosine residues located between Asn-92 and Val-235 
based on the N-terminal truncation mutational analysis and amino acid conservation among 
different species.  We postulated that some of the tyrosine residues between Asn-92 and Val-
235 might contribute to the enzymatic activity as C5-epi N92-N617 is active, whereas C5-epi 
W203-N617 is inactive.  In addition, we found that Glu-105 toVal-235 is the most conserved 
region in the protein (73% identity) among different species including zebrafish, platypus, 
mice and humans.  Indeed, mutation Tyr-168 and Tyr-222 of C5-epi completely abolished 
activity, suggesting their possible roles in the catalytic function of C5-epi.  Due to the 
inability to assess the overall structure of the mutants, we could not rule out the possibility of 
the indirect effect of the tyrosine residues on the catalytic function of C5-epi.  Further 
experimental and structural studies are necessary to determine the precise roles of these 
residues.   
 In conclusion, we were able to develop an effective assay for C5-epi activity by 
coupling C5-epi with the engineered 2OST.  Previously, a similar method was employed 
using wild type 2OST, however wild type 2OST sulfates both GlcUA and IdoUA therefore 
disaccharide analysis was required to identify the presence of the IdoUA2S-AnMan 
disaccharide product (240).  The former method is timely and less quantitative due to the 
involvement of disaccharide analysis.  Our method takes advantage of the engineered 2OST 
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that only sulfates IdoUA units, eliminating the need for disaccharide analysis.  This simple 
and efficient assay will enhance studying the structural and functional relationship of C5-epi.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter V 
 
  
Towards Crystallization of Heparan Sulfate 6-O-Sulfotransferase 
 
 
Heparan sulfate 6-O-sulfation is an essential modification for the synthesis of 
biologically relevant HS structures, particularly for blood coagulation and fibroblast growth 
factor-fibroblast growth factor receptor mediated signaling (123).  The 6OST enzyme plays a 
key role in developmental processes among different organisms.  For Drosophila and C. 
elegans, 6-O-sulfation is necessary for tracheal development and neural development 
respectively (109).  Studies have also been completed for different vertebrates including 
zebrafish and mice.  Zebrafish deficient in 6OST exhibited poor vasculogenesis as this 
enzyme appears to control Wnt-mediated signaling pathways (120).  Disruption of 6OST 
within mice resulted in embryonic lethality and abnormal placentation (117).  The results of 
these knockout studies clearly demonstrate an important biological and physiological role for 
6-O-sulfation within invertebrates and vertebrates.   
Previous studies have identified the necessity of 6OST, especially 6OST-1, for the 
synthesis of anticoagulant heparan sulfate however the mechanism of this enzyme is poorly 
understood (106).  Our ultimate goal is to co-crystallize one or more of the 6OST isoforms 
with PAP and/or a heparin-like oligosaccharide.  This will help gain new insight into the 
substrate recognition mechanism by the 6OSTs and provide a more elaborate understanding 
of the HS sulfotransferase mechanism.  Our laboratory has successfully prepared several 
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heparan sulfate enzymes for crystallization including 3-O-sulfotransferase isoforms 1, 3, and 
5 as well as 2OST, which makes our chances for crystallizing 6OST very feasible 
(59,63,150,151).  Obtaining a robust protein with high solubility and purity is critical for 
crystallization, which often takes a considerable amount of time and effort when attempting 
to identify the best expression vector system.  As we aimed towards crystallization of 6OST, 
we utilized a homology model of 6OST based on sequence homology with structurally 
known sulfotransferases such as 3OST-3.  This homology model provided some insight into 
the role certain amino acid residues may play in catalysis as well as substrate specificity of 
6OST.  Preliminary mutational analysis of these residues helped provide some insight into 
the contribution of specific amino acid residues towards substrate specificity, PAPS binding, 
and catalysis. 
Expression and Purification of 6OST Isoforms 
To identify the most promising 6OST protein for crystallization, various expression 
constructs of 6OST-1 and 6OST-3 possessing different fusion tags were prepared as 
summarized in Table 3.  The results of each expression construct will be discussed in the 
sections to follow. 
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Table 3.  Summary of analyzed 6OST protein expression constructs 
6OST 
Isoform 
Species Fusion Tag Sequence Notes 
6OST-3 Mouse His6 P120-P449 (1) Low expression @ 5 mg/L 
(2) Poor solubility 
6OST-3 Mouse MBP P120-P449 (1) 2-fold higher expression compared                                                   
to His-6OST-3 
(2) Heterogeneous population 
6OST-1 Chicken MBP Y30-W408 (1) Highest activity among 6OST-1 cuts 
(2) Protein aggregation 
(3) Heterogeneous population 
(4) Precipitation with tag removal 
6OST-1 Chicken MBP H60-W408 (1) Protein aggregation 
(2) Heterogeneous population 
(3) Precipitation with tag removal 
6OST-1 Chicken MBP P68-W408 (1) Protein aggregation 
(2) Heterogeneous population 
(3) Precipitation with tag removal 
6OST-1 Chicken MBP V85-W408 (1) Lowest activity among 6OST-1 cuts 
(2) Protein aggregation 
(3) Heterogeneous population 
(4) Precipitation with tag removal 
6OST-1 Chicken Trx Y30-W408 (1) Single monomeric population 
(2) Decreased protein aggregation 
6OST-1 Chicken Trx Y30-E382 (1) Single monomeric population 
(2) Decreased protein aggregation 
(3) 2.5-fold higher expression compared to 
6OST-1 (Y30-W408) 
 
 
 
 
Heparan Sulfate 6OST-3 
Based on previous success with crystallization of His6 tagged 3OST-1 derived from 
mouse (150), we initially attempted crystallization of a His6 fusion protein containing the 
catalytic domain (P120- P449) of mouse 6OST-3.  However, we discovered it was extremely 
difficult to upscale the protein expression for His6-6OST-3 for further biochemical 
characterization.  The maximum amount of protein obtained for His6-6OST-3 was 5 mg/L 
total protein, which was not enough for completing isothermal titration calorimetry studies.  
Therefore, we transitioned to a maltose binding protein (MBP) fusion protein to help improve 
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the expression and solubility based on previously reported success (232), resulting in 10 
mg/L total protein with greater than 80% purity.  The fusion protein was prepared by cloning 
the mouse catalytic domain (P120-P449) into the pMALc2x/TEV vector using XbaI and 
HindIII restriction enzyme sites followed by transformation into Origami B cells.  The 
protein was isolated from the Origami B cells and purified by an amylose column, then 
loaded to a gel permeation chromatography (GPC) column for protein property analysis.  
GPC analysis revealed that most of the protein eluted as aggregated protein (peak 1) in the 
void volume at 45 mL (peak 1), suggesting that the protein was not properly folded (Fig 43).  
Based on the standard curve generated in Figure 25 in Chapter III, the calculated molecular 
weight of MBP-6OST-3 was determined to be 205 kDa.  The theoretical molecular weight of 
MBP-6OST-3 is approximately 70 kDa. Comparison to the calculated molecular weight 
suggests that the fusion protein exists as a trimer in solution.  Peak 3 is consistent with free 
MBP with a molecular weight of approximately 42 kDa, which was also confirmed by SDS-
PAGE analysis.   
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Figure 43.  FPLC chromatogram of the purification of MBP-6OST-3 by gel permeation chromatography.  
Approximately 25 mg of amylose purified MBP-6OST-3 was analyzed by gel permeation chromatography 
using a Superdex 200 HiLoad 16/60 column.  The UV absorbance at 280 nm was plotted against elution 
volume.  Each peak is labeled with a number and identified as follows: 1, aggregated MBP-6OST-3; 2, MBP-
6OST-3; 3, MBP.   
 
As seen with 2OST previously discussed in Chapter III, the MBP-2OST protein used 
for crystallization existed as a trimer in solution which was consistent with the previous 
results by Kobayashi et al., demonstrating that MBP-2OST isolated from CHO cells migrated 
as a trimer by GPC (99).  Interestingly, the 6OST originally isolated from CHO cells by 
Habuchi et al. migrated as a monomer when analyzed by gel permeation chromatography 
(108).  Based on the CHO cell results, the MBP-6OST-3 protein is not representative of the 
protein under physiological conditions, suggesting there could be some intermolecular 
interactions occurring between more than one monomer of MBP-6OST-3.  The 6OST protein 
is known to possess ten cysteine residues, which could potentially allow for disulfide bond 
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formation among the 6OST monomers.  These interactions must be interrupted to heighten 
the chances of protein crystallization.   
Although 6OST-3 is more promiscuous in substrate specificity, the 6OST-1 enzyme 
is known to be relevant for production of anticoagulant HS (106).  Therefore, we decided to 
attempt crystallization with 6OST-1 to gain understanding of its substrate specificity on the 
oligosaccharide level as determined by the sulfation patterns surrounding the modification 
site, specifically for synthesis of the AT-binding pentasaccharide.  Previous studies in our 
laboratory had demonstrated a high level of expression for 6OST-1, offering some promise 
for crystallization.   
Heparan Sulfate 6OST-1 
Maltose Binding Protein (MBP) Fusion Protein Expression System 
In an attempt to crystallize 6OST-1, the MBP molecule was fused to the N-terminus 
of the catalytic domain of chicken 6OST-1.  The 6OST-1 catalytic domain was inserted into 
pMalc2x vector possessing a TEV protease cleavage site using the restriction enzyme sites of 
HindIII and BamHI.  The TEV protease cleavage site is for removal of the MBP molecule to 
produce untagged 6OST-1.  The higher body temperature for chicken offers a more stable 
environment for crystallization as was successfully seen with 2OST (59).  Several constructs 
were prepared with different truncations at the N-terminus of chicken 6OST-1 as seen in 
Figure 44A.  These N-terminal truncations serve to remove the transmembrane region of 
6OST-1 with the likelihood of increasing protein solubility.  
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Figure 44.  Representation of the N-terminal truncations of chicken 6OST-1 and analysis of the 
oligomeric state using different expression cell lines.  (A)  Amino acid sequence of chick 6OST-1.  The 
truncation positions of various 6OST-1 constructs are shown on the sequence of chick 6OST-1. (B)  Protein 
property analysis of the different MBP-6OST-1 fusion proteins containing various N-terminal truncations using 
Origami B cells with or without the co-expression of chaperonin proteins.  Each of the MBP-6OST-1 constructs 
was purified by amylose column and loaded onto a pre-equilibrated Superdex 200 16/60 HiLoad GPC column 
for protein property analysis.   
 
 
 
The MBP-6OST-1 fusion proteins were expressed in two different Origami B (DE3) 
cell lines, one of which expresses E. coli chaperonin proteins, GroEL and GroES, to assist 
with protein folding known as Origami B
chap
.  The other Origami B (DE3) cell line does not 
express the chaperonin proteins.  The MBP-6OST-1 fusion proteins were purified by affinity 
chromatography using an amylose resin followed by purification by a GPC column to 
determine the oligomeric state.   
Figure 45 reflects amylose affinity chromatography (Fig 45A) followed by GPC 
purification (Fig 45B) of the 3
rd
 N-terminal truncation protein containing residues P58-W408 
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of the 6OST-1 catalytic domain.  The GPC chromatograms revealed four distinct peaks (Fig 
45B).  The size of MBP-6OST-1 is approximately 70 kDa.  Based on the standard curve 
generated in Figure 25 of Chapter III, peaks 2 and 3 were consistent with trimeric and 
monomeric MBP-6OST-1 respectively.  The peaks represent aggregated MBP-6OST-1 (peak 
1) in the void volume, trimeric MBP-6OST-1 (peak 2), monomeric MBP-6OST-1 (peak 3), 
and MBP (peak 4).  As with the MBP-6OST-3 protein, most of the protein existed in the 
aggregated form in the void volume, suggesting improper folding.  We clearly demonstrated 
that the chaperone-assisted MBP-6OST-1 protein expression level was much higher.  Several 
fractions from each peak were analyzed for sulfotransferase activity among the chaperone 
assisted 3
rd
 cut MBP-6OST-1 protein.  Of these peaks, the only ones containing 
sulfotransferase activity were those consistent with the trimeric (peak 2) and monomeric 
(peak 3) 6OST-1.  The presence of two populations of the 3
rd
 cut 6OST-1 with similar 
enzymatic activity will decrease the likelihood of obtaining crystals since the protein has the 
ability to shift between the monomeric and trimeric states in solution.  Interestingly, 
repeating transformation and protein expression of the 6OST-1 3
rd
 cut plasmid into Origami 
B
chap
 cells resulted in solely a trimeric peak with high sulfotransferase activity when analyzed 
by gel permeation chromatography.  This suggests that the protein has the ability to shift 
between the monomeric and trimeric states, making it very difficult to isolate the 
physiologically relevant monomer of 6OST for crystallization.   
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Figure 45.  Comparison of differentially expressed chicken MBP-6OST-1 3
rd
 cut fusion protein.  The 
MBP-6OST-1 3
rd
 cut protein (P68-W408) was expressed in two different Origami B (DE3) cell lines, one co-
expressing chaperonin proteins to assist with protein folding.  The expressed fusion proteins were purified by 
amylose resin (A), revealing similar expression profiles with (blue line) or without (red line) the assistance of 
chaperone.  Approximately 25 mg amylose purified MBP-6OST-1with (blue line) or without (red line) 
chaperone respectively was analyzed by gel filtration chromatography (B).  Each peak is labeled with a number 
and identified as follows: 1, aggregated MBP-6OST-1; 2, trimeric MBP-6OST-1, monomeric MBP-6OST-1; 4, 
MBP. 
 
 
 
The same experimental procedures were applied to the other N-terminally truncated 
MBP-6OST-1 fusion proteins however GPC analysis revealed conflicting results.  Based on 
the results of the 3
rd
 cut 6OST-1 fusion protein, it would appear that the Origami B
chap
 cells 
  
132 
are the best for improving protein expression, however expression in either cell line resulted 
in various oligomeric states among all the 6OST-1 different cuts.  When expressed in the 
chaperone assisted Origami B cells, the MBP-6OST-1 proteins existed as trimers with 
activity solely within the trimer peak.  However, expression in the Origami B cells without 
chaperone assistance resulted in a mixture of both oligomeric states with similar 
sulfotransferase activity present in both populations.   
Based on comparison of the protein property analysis, it appears that the Origami B 
cell line without chaperone is the best expression cell line for producing the active 
monomeric 6OST-1 however the major issue is the insubstantial amount of monomer 
produced during expression.  The predominant aggregated 6OST-1 peak (peak 1 in Fig 45B) 
suggested that that protein is not being properly folded, which could explain the poor 
expression of the monomer.  Protein aggregation was also a major issue for the MBP-6OST-
3 protein (Fig 43), which could suggest that the MBP fusion protein is not the best expression 
system for 6OST.  It should be noted that the MBP molecule can be cleaved from 6OST-1 by 
the use of TEV protease, but cleavage resulted in extensive precipitation.  The high level of 
precipitation implies that the protein possesses poor solubility without the presence of the 
MBP tag.  Therefore, it will be difficult to crystallize 6OST using the MBP expression 
system due to the major issues of folding, solubility, and oligomerization.   
Thioredoxin Fusion Protein Expression System 
Studies have indicated that a thioredoxin tag can significantly enhance the solubility 
of insoluble proteins.  Therefore, we turned our attention towards preparation of a 
thioredoxin-6OST-1 fusion protein (232).  The Trx-6OST-1 fusion protein was prepared by 
performing N- and C-terminal truncations of chicken 6OST-1 as seen in Figure 47A.  To 
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prepare the C-terminally truncated protein, a premature stop codon was introduced at Glu-
382 to generate 6OST-1 E382STP, which was previously shown to enhance protein solubility 
of 3OST-3 (63).  The transmembrane (TM) region has been removed from the N-terminus of 
6OST-1 consistent with the 1
st
 cut presented in Figure 44, since previous studies in our 
laboratory indicated that this region was not essential for the enzymatic activity.  In addition, 
truncation of the TM domain has been shown to increase protein expression and solubility 
(247).  The C-terminal truncation was selected based on a secondary structure prediction 
using mGenTHREADER that predicted a randomly coiled region at the C-terminus of 6OST-
1.   
The 6OST-1 1
st
 cut DNA was cloned into the pET32b(TEV) vector using the 
restriction sites BamHI and HindIII, followed by site-directed mutagenesis PCR to generate 
the premature stop codon at Glu-382.  The 6OST-1-pET32b(TEV) plasmid was transformed 
and expressed in Origami B (DE3) cells, followed by purification by a nickel column 
coupled to the FPLC.  We also prepared a Trx fusion protein containing the 6OST-1 1
st
 cut 
(Y30-W408) sequence for comparison, which will be referred to as 6OST-1 wild-type (WT).  
We found that removal of the randomly coiled region at the C-terminus of 6OST-1 gave 2-3 
fold higher expression while maintaining a full level of sulfotransferase activity.   
For a rapid assessment of the oligomeric state for the 6OST-1 WT and E382STP 
fusion proteins, we utilized gel permeation chromatography coupled to the HPLC.  Small 
scale expression and purification by a benchtop nickel column was completed for both 
6OST-1 proteins.  A small aliquot of each of the Trx-6OST-1 fusion proteins were then 
loaded onto a pre-equilibrated G4000SWXL (Tosoh Bioscience) GPC column at a flow rate of 
0.5 mL/min using buffer containing 20 mM MOPS pH 7.0 and 400 mM NaCl (Fig 46).  
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Analysis of the GPC chromatograms revealed that both 6OST-1 WT and E382STP fusion 
proteins exist as monomers with molecular weights of 58 kDa and 55 kDa respectively.  
Several fractions from the GPC column were analyzed for sulfotransferase activity and the 
results revealed that the activity was present solely within the monomeric peak.  The 
sulfotransferase activity was comparable within each sample suggesting that the C-terminus 
is most likely not essential for the 6OST-1 activity.   
The thioredoxin tag was cleaved from the fusion proteins to produce untagged 6OST-
1 using TEV protease.  The cleaved 6OST-1 samples were also analyzed by GPC-HPLC, 
revealing a similar profile with similar sulfotransferase activity.  Unlike the MBP-6OST-1 
fusion proteins, the Trx fusion protein can be cleaved to produce a soluble and active 
monomeric 6OST-1 protein, indicating a potential for crystallization of 6OST-1.  Although 
both 6OST-1 WT and E382STP demonstrated good expression and solubility on a small 
scale, this may not be indicative of the situation on a large scale.  With that said, we must 
proceed with scaling up the expression of these two enzymes to hopefully determine if one or 
both may offer promising results for crystallization trials.   
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Figure 46.  Protein property analysis of Trx-6OST-1 WT and E382STP by GPC-HPLC.  All samples were 
loaded onto a G4000SWXL (Tosoh Bioscience) GPC column  equilibrated with 20 mM MOPS pH 7.0 and 400 
mM NaCl at a flow rate of 0.5 mL/min.  For each Trx-6OST-1 fusion protein, a 250 µL of the nickel purified 
protein was loaded onto the GPC and the elution was monitored with UV absorbance at 280 nm.  (A) GPC-
HPLC analysis of standard mix.  A 50 µL aliquot of the standard mix (Sigma) was loaded and the molecular 
weight of the protein standards is labeled above each peak.  (B) GPC-HPLC analysis of Trx-6OST-1 wild type.  
(C)  GPC-HPLC analysis of Trx-6OST-1 E382STP.  The identity of each protein peak is labeled and the elution 
times of the standards are indicated by an arrow.   
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Upon completion of the GPC-HPLC, the Trx-6OST-1 WT and E382STP fusion 
proteins were expressed in Origami B cells and purified on a large scale (3-liter prep) as 
outlined in Figure 47C.  The cell extract was first loaded onto a nickel-agarose column.  
Once eluted from the nickel column, the thioredoxin tag was cleaved from the 6OST-1 
protein using Tobacco etch virus (TEV) protease followed by two additional purification 
steps, the first of which included binding heparin-sepharose resin (New England Biolabs) 
followed by gel permeation chromatography (GPC) using a HR 16/60 Superdex 75 
(Amersham) column.  Approximately 0.13 mg and 0.32 mg of total protein of WT and 
E382STP 6OST-1 respectively remained after several rounds of purification, suggesting the 
expression level is very low.  SDS-PAGE analysis of 6OST-1 E382STP following each 
round of purification revealed a significant increase in purity (Fig 47B).  It may appear that 
only 50% of the protein was recovered after GPC purification seen in Lane 3, however, the 
heparin-purified sample loaded on the gel had been concentrated for other experimental 
studies.  There was greater than 90% of enzymatic activity recovered after each round of 
purification.  The SDS-PAGE analysis following each round of purification is not shown for 
the WT 6OST-1 protein however the results were similar with a substantial amount of 
sulfotransferase activity present solely within the monomeric peak.   
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Figure 47.  Purification of chicken 6OST-1 E382STP. (A) Domain structure of chicken 6OST-1.  The N-
terminal and C-terminal truncations are located at Tyr30 and E382 respectively.  TM represents transmembrane 
region; RC represents random coiled region.  (B) Flow chart outlining the steps towards purification of 6OST-1 
E382STP.  (C) SDS-PAGE analysis of 6OST-1 E382STP following each round of purification.  Lane 1, Nickel-
purified Trx-6OST-1 prior to TEV digestion; Lane 2, Heparin-purified 6OST-1 following TEV digestion; Lane 
3, GPC-purified 6OST-1 following heparin purification.   
 
The solubility of the cleaved 6OST-1 WT and E382STP proteins was then examined 
following GPC purification.  The two proteins were dialyzed against a buffer containing 25 
mM Tris pH 7.5 and 150 mM NaCl to reduce the salt concentration.  Ideally, the protein must 
exist in a low salt environment up to a maximum of 200 mM NaCl to allow hydrogen bond 
formation between protein molecules.  However, lowering the salt concentration can often 
result in protein precipitation.  Therefore, we wanted to drive the limits of the WT and 
E382STP 6OST-1 proteins to ensure protein stability.  The protein concentration was 
monitored by UV280nm following dialysis for the WT and E382STP, giving concentrations of 
0.014 mg/mL (0.13 mg total) and 0.03 mg/mL (0.32 mg) respectively.  Based on comparison 
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of the GPC profiles and amount of total 6OST-1 protein obtained, the expression of 
E382STP appears to be 2.5 fold higher than that of the wild type protein.  Thus, we decided 
to pursue crystallization studies using 6OST-1 E382STP.  
In order to obtain a substantial amount of untagged 6OST-1 E382STP, the level of 
expression of the Trx fusion protein must be considerably increased.  We decided to increase 
the level of bacterial expression from 3-liter to 10-liter.  The untagged 6OST-1 E382STP was 
prepared as presented in Figure 47C.  As was previously demonstrated by the rapid GPC-
HPLC analysis, analysis by gel permeation chromatography coupled to FPLC  revealed a 
monomeric 6OST-1 E382STP protein (43 kDa) eluted at 60 mL with little aggregated protein 
at 45 mL (Fig 48A).  We then wanted to test the purity and solubility of the GPC-purified 
6OST-1 E382STP protein.  The protein was concentrated up to 16-fold at a concentration of 
approximately 1 mg/mL with constant monitoring by SDS-PAGE after each concentration 
step as seen in Figure 48B.  There appears to be no loss in protein during each concentration 
step, suggesting that the protein is highly soluble and there is no protein precipitation. Taken 
together, our data suggest that we should be able to obtain a soluble 6OST-1 protein with 
exceptionally high purity and enzymatic activity.  The limiting factor is the amount of 
material recovered after the purification steps.  After 16x concentration, the 6OST-1 
E382STP protein was only at 0.6 mg/mL with a total amount of approximately 600 µg from a 
10-liter preparation.  Despite the low yield, we continued our pursuit to crystallizing 6OST-1 
E382STP due to the presence of a highly pure, soluble, and active monomeric 6OST-1 
protein that are all essential protein qualities for crystallization.   
 The expression was scaled up to a 36-liter prep to enhance amount of protein, 
obtaining 37.5 mg (1.5 mg/mL) of Trx-6OST-1 E382STP protein from the nickel column.  
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Following TEV protease cleavage and the heparin and GPC column purification steps, 
approximately 3.4 mg pure cleaved 6OST-1 E382STP was isolated.  There was clearly a 
significant loss of material during the steps towards purification, which could easily be lost 
during the TEV cleavage step if the material began to precipitate as only the supernatant is 
applied to the heparin column.   
 
Figure 48.  Determination of the oligomeric state of 6OST-1 E382STP. (A)  Approximately 8 mg of 
heparin-Sepharose column purified 6OST-1 E382STP was analyzed by gel permeation chromatography using a 
Hi-Load Superdex 75 column at a flow rate of 1 mL/min.  The UV absorbance at 280 nm is plotted against 
elution volume.  The molecular mass standards resolved under the same experimental conditions are indicated 
by arrows. (B) SDS-PAGE analysis of GPC-purified 6OST-1 E382STP at different concentrations. The sample 
was concentrated 16-fold by Centricon (MWCO 10,000) to approximately 1 mg/mL. 
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The GPC purified 6OST-1 E382STP was concentrated 16X to a final concentration of 
approximately 2 mg/mL and a small 200 µL aliquot was analyzed for solubility within 
different salt environments.  The 200 µL of protein was split into 100 µL each, currently 
present in 20 mM MOPS pH 7.0 and 400 mM NaCl, and then diluted to a final concentration 
of either 100 mM or 200 mM NaCl in 20 mM Tris pH 7.0.  Following dilution, each pilot 
protein sample was concentrated using a Microcon Ultracel YM-10 concentrator and 
monitored by SDS-PAGE (Fig 49).  The pilot sample in 200 mM NaCl could not be 
concentrated up to 16X due to an issue with the microcon concentrators.  However, it is clear 
that the intensity of the protein band does not increase proportionally within the 200 mM 
NaCl environment.  For the 100 mM NaCl pilot sample, the protein was successfully 
concentrated to 8X the original concentration however there appears to be a loss in material 
at the 16X concentration step (Fig 49).  Interestingly, there was no obvious protein 
precipitation during the concentration steps for the 100 mM pilot sample, but there is 
definitely potential for damaging the resin when applying and removing such low protein 
volumes to the microcon tubes.  At this point, one can assume that 6OST-1 E382STP can 
exist in extremely low salt environments and still be sufficiently stable.  The remaining 16X 
concentrated GPC purified 6OST-1 E382STP was diluted to a final salt concentration of 100 
mM and concentrated to approximately 4 mg/mL in 750 µL.  The protein was distributed to 
our collaborative crystallographer at NIEHS, Dr. Lars Pedersen, to perform crystallization 
trials but unfortunately there was not a substantial amount of protein for extensive 
crystallization studies to be successfully employed. 
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Figure 49.  SDS-PAGE analysis of pilot samples of 6OST-1 E382STP within different salt environments.  
Two pilot samples, 100 µL each, of untagged GPC pure 6OST-1 E382STP were diluted in buffers containing 20 
mM Tris pH 7.0 to reduce the salt concentration to 100 mM NaCl or 200 mM NaCl.  PAP was added to a final 
concentration of 1 mM to keep the protein in solution.  The pilot samples were concentrated with Microcon 
Ultracel concentrators as indicated above.  The band at 42 kDa represents 6OST-1 E382STP as indicated by the 
arrow.      
 
 Based on the results from the different expression systems utilized for 6OST-1, it 
appears that the use of the thioredoxin protein expression system offers the most potential for 
isolation of the physiologically relevant monomeric 6OST-1 protein with considerable 
sulfotransferase activity.  The expression of the premature stop codon E382STP is 
significantly higher than the WT 6OST-1 however it still poses the major drawback of a low 
yield for completion of crystallization studies.   In the near future, we aim to clone the 6OST-
1 E382STP into a fixed arm pET32bX vector, which possesses similar function to the 
pMALX vector used for crystallization of 2OST.  As with the pMALX vector, the linker 
region of pET32bX vector encodes several alanine residues to reduce the flex in the fusion 
protein (59).  This will allow the 6OST-1 protein to tightly fold next to the thioredoxin 
protein to allow for crystallization.  No TEV cleavage site is present within the pET32bX 
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vector and therefore the Trx-6OST-1 protein will be crystallized as a fusion protein.  The 
combined use of the thioredoxin protein expression system and Origami B cells for bacterial 
expression should serve to enhance the solubility and folding of 6OST-1 in the cytoplasm 
thus enhancing the likelihood of a crystal structure for 6OST.  
 Mutational Analysis of 6OST-3 
A structural neighbor prediction using GenThreader identified both 3OST-3 and 
NST-1 as the closest in fold recognition to that of 6OST.  We generated a homology model 
for mouse 6OST-3 based on the crystal structure of 3OST-3 (Fig 50).  From the amino acid 
sequence alignment of 6OST-3 and 3OST-3, we identified several amino acid residues that 
could play a potential role in PAPS binding, substrate recognition and catalytic function.  
These amino acid residues were systematically mutated to alanine and analyzed for 
sulfotransferase activity using CDSNS-heparin as seen in Table 4.  Several of the residues 
are evolutionarily conserved across species, suggesting their central role in the function of 
6OST.   
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Table 4.  Preliminary mutational analysis of heparan sulfate 6OST-3 
 
 
 
 
 
 
 
 
 
 
 
 
The potential defect correlates with the role a certain amino acid residue may play in 6OST function based on 
structural homology with 3OST-3.  The defects are labeled as follows:  
a 
Binding to polysaccharide substrate; 
b
 
Binding to PAPS; 
c 
Catalytic base for ST reaction.  The conservation of the amino acid residue across various 
species is indicated by Y (yes) or N (no). 
 
 
As were determined with the other structurally known cytosol and Golgi resident 
sulfotransferases, the highly conserved 5’-phosphosulfate (PKT/SGTTW/AL) and 
3’-phosphate (IT/YV/I/LLRNPA/KDR/VL/AVSYYY/Q) binding sequence motifs were also 
identified in 6OST-3 (Fig 50B and 51) (235).  Mutation of a potential 5’-phosphate binding 
residue, Lys-154, of 6OST-3 nearly abolished sulfotransferase activity compared to the wild-
type 6OST-3.  The corresponding lysine within 3OST-1 (Lys-68), 3OST-3 (Lys-162), EST 
(Lys-48), and NST-1 (Lys-614) have previously been established as playing a pivotal role in 
HS 6OST-3 
Mutants 
Sulfotransferase 
Activity 
(%) 
Potential 
Defect 
Evolutionary 
Conservation 
WT 100   
H151A 56 S
a 
Y 
H151Y <1 S Y 
Q153A 22 S Y 
H151A/Q153A 2 S Y 
K154A <1 P
b 
Y 
K181A 100 S Y 
K182A 100 S N 
K190A 83 S N 
K191A 10 S N 
E192A 7 C
c 
N 
D210A 52 C Y 
E213A 88 C Y 
R244A <1 P Y 
S252A 8 P Y 
E253A 47 S Y 
H256A 14 C Y 
R259A 100 S Y 
T381A 74 S Y 
R382A 90 S N 
S384A 76 S N 
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the sulfo transfer by forming a hydrogen bonding network with the 5’-phosphosulfate group 
of PAPS (63,150,247,248) (63,80,150).  Using the binary complex of 3OST-3 and PAP as a 
model, the corresponding Lys-154 residue is predicted to be within 2.8 Å of the 5’-phosphate 
of PAP (Fig 51).  
 
Figure 50.  Homology model of 6OST-3.  (A) Crystal structure of 3OST-3.  The substrate binding sites are 
highlighted: The PAPS-binding loop is shown in magenta (where Gln
153
 of 6OST-3); the region after helix -5 is 
shown in yellow (where Arg
259
 of 6OST-3); and the long coil region before a-helix 11 in blue (where Asn
299
, 
Thr
381
, Arg
382
, and Ser
384
 of 6OST-3).  (B) Amino acid sequence alignment of 3OST-3 and 6OST-3.  The amino 
acid residues involved in binding to HS are labeled in blue.  The amino acid residues involved in binding to 
PAPS are in red.  H256 (in green) is likely to serve as a catalytic base for 6OST.  The residues involved in both 
substrate and PAPS binding are labeled purple.   
 
 
 The potential 3’-phosphate binding residues of Arg-244 and Ser-252 within 6OST-3, 
which are conserved among all the structurally known sulfotransferases, resulted in 0.6% and 
8% sulfotransferase activity respectively when mutated.  The serine residue, known to 
stabilize PAPS in EST, is conserved in NST-1 (Ser-712) and the 3OSTs (Ser-159 in 3OST-1 
and Ser-251 in 3OST-3) (249).  Based on the binary complex of 3OST-3 with PAP, the 
corresponding Ser-252 in 6OST-3 can be predicted to be positioned as a part of the 
conserved α-helix (α5) that is in close proximity to the PAP binding site (Fig 51).  With the 
exception of NST-1, a highly conserved arginine residue exists within the structurally known 
A. B. 
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HS sulfotransferases and EST that corresponds to Arg-244 in 6OST-3.  The preliminary 
mutational analysis revealed that Lys-154, Arg-244, and Ser-252 of 6OST-3 are most likely 
involved in binding to the sulfo donor, PAPS, to assist with the sulfuryl transfer reaction.  
For further verification, these mutants must be analyzed by isothermal titration calorimetry 
(ITC) for PAP binding as has been established with 3OST-1 and 2OST (104,150).  The 
active donor PAPS is chemically unstable and cannot be utilized during ITC however studies 
have indicated that PAP binding affinity is indeed representative of PAPS (104).  If the 
mutant proteins do not bind PAP when analyzed by ITC, the loss of sulfotransferase activity 
can be explained by the decreased PAPS binding.  These biochemical characterization 
studies cannot be completed until the issue of low 6OST expression is resolved. 
 
Figure 51.  Representation of the PAPS binding residues of 6OST-3 based on the structure of 3OST-3 
with PAP bound.  With PyMol, the 6OST-3 model was prepared using the structure of the binary complex of 
3OST-3 and PAP.  The highlighted residues are conserved in both 3OST-3 and 6OST-3 and identified as 
potentiating PAPS binding.  The corresponding 6OST-3 residues are labeled.  The Lys-54 of 6OST-3 is 
predicted to be 2.8 Å away from the 5’-phosphate of PAP.  The Ser-252 and Arg-244 residues of 6OST-3 are 
predicted to be approximately and 2.7 Å and 3.22 Å respectively away from the 3’-phosphate of PAP.   
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Based on the sequence alignment with 3OST-3, the next subset of 6OST-3 amino acid 
residues analyzed were those with the potential for HS substrate recognition (Table 4).  
Several residues were subjected to mutational analysis including His-151, Gln-153, Lys-181, 
Lys-182, Lys-190, Lys-191, Glu-253, Arg-259, Thr-381, Arg-382, and Ser-284.  The only 
residue showing a noteworthy reduction in sulfotransferase activity was that of Q153A with 
22% activity compared to WT.  The mutant H151A only saw a reduction in activity to 56% 
compared to the WT however generation of a double mutation H151A/Q153A saw a strong 
reduction in activity to 2%.  Removal of both residues had a more drastic effect on activity 
than when only one residue was mutated, suggesting that Gln-153 and His-151 may 
potentially interact to stabilize the transition state and/or substrate binding.  A previous 
publication identified a single point mutation of H151Y within the 6OST coding domain of 
the kal-1 gene of C. elegans, a gene whose mutation induces a neurological disorder known 
as Kallman disease (125).  Interestingly, generation of the H151Y mutation within 6OST-3 
essentially abolished sulfotransferase activity.  This result is very difficult to explain as the 
tyrosine residue would still be in position to form a hydrogen bond with the 5’-sulfate of 
PAPS as well as interact with the Gln-153, whereas an alanine residue (H151A) loses all 
these stabilizing interactions.  A more extensive mutational analysis must be completed in 
order to determine the potential influence of these amino acid residues in substrate binding.   
Following mutational analysis of potential PAPS and substrate binding residues, the 
focus turned towards the identification of a catalytic base for 6OST.  Based on sequence 
homology with 3OST-3, several residues were identified as potential catalytic bases, 
including Glu-192, Asp-210, Glu-213, and His-256.  Among these mutant enzymes, only 
E192A and H256A showed a significant reduction in activity to 7 and 14% activity 
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respectively (Table 4).  The histidine residue is conserved in all 6OSTs among different 
species, suggesting its importance for the function of 6OST.  The glutamic acid residue, on 
the other hand, is not conserved across species and therefore may not contribute to the 
catalytic function.  The identification of a potential catalytic base for 6OST is inconclusive 
based on the homology model with 3OST-3 and preliminary mutational analysis.  The 
presence of a crystal structure will serve to identify the contribution of Glu-192 and His-256 
to the activity of 6OST.   
Conclusions 
In order to crystallize 6OST, we had to first identify the best expression system to 
increase our likelihood of obtaining a highly expressed and soluble protein in a homogeneous 
population.  After several attempts to improve the expression of 6OST-3 using His6 or MBP 
tags, we turned our attention to 6OST-1 since it was previously found to possess high 
expression in our hands.  The level of expression and purity of 6OST-1 was greatly enhanced 
using a MBP fusion tag however the protein exists as a heterogeneous population.  Although 
we can isolate the monomeric form of MBP-6OST-1 by gel permeation chromatography, we 
are concerned that the monomer can convert to the trimer during crystallization, making 
crystallization virtually impossible.  Ideally, we want 6OST-1 to be present in a single stable 
population with a high level of sulfotransferase activity.  Another issue with the MBP-6OST-
1 protein is the presence of aggregated protein in the void volume, indicating a problem with 
folding.  The MBP tag was also incapable of being removed from 6OST-1 without excessive 
protein precipitation.  The drawbacks of a heterogeneous population, improper folding, and 
protein precipitation upon cleavage suggest that the use of the MBP tag is most likely not the 
best option for expressing 6OST-1.   
  
148 
Once we exhausted all possibilities with the use of the MBP fusion protein expression 
system, we focused our attention on the thioredoxin (Trx) fusion protein expression system 
which is known to improve the solubility and stability of proteins.  We worked with two Trx-
6OST-1 constructs, WT and the premature stop codon E382STP, identifying both as 
promoting formation of a highly active monomer when analyzed by GPC-HPLC however the 
6OST-1 WT protein had poor expression compared to the premature stop codon.  GPC 
analysis revealed a monomeric 6OST-1 protein with a slight presence of aggregated protein, 
but it is much lower than that for MBP-6OST-1.  At this point, it appears that we have been 
able to overcome all the issues that were seen with the MBP-6OST-1 fusion protein however 
the Trx expression system is not without flaws.  Although higher compared to 6OST-1 WT, 
the expression level of the Trx-6OST-1 E382STP protein is still very low.  To overcome the 
issue with low expression, we plan to continue pursuing the Trx expression system but with 
the use of a fixed arm vector, which will maintain the Trx-6OST-1 as a fusion protein.  This 
fusion protein will have a fixed linker region to reduce flex and allow the 6OST-1 E382STP 
protein to tuck next to the Trx protein, hopefully promoting crystallization.  This fixed arm 
vector system proved successful with crystallization of the MBP-2OST fusion protein (59).   
As we worked towards crystallization of 6OST, we completed preliminary mutational 
analysis of 6OST-3 based on a sequence homology model with the structurally known 3OST-
3 and EST.  Several residues were identified that could potentially be involved in PAPS 
binding and substrate binding.  Using the ternary complex of 3OST-3 with PAP and HS 
tetrasaccharide as a model, Lys-154 was proposed to be located within 3 Å of the 5’-
phosphate of PAP while Arg-244 and Ser-252 are potentially within hydrogen bonding 
distance to the 3’-phosphate of PAP.  Based on the combined activity results and homology 
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model, we can confidently identify these three residues as PAPS binding residues for 6OST-
3.  The potential substrate binding residues, His-151 and Gln-153, did not reveal a drastic 
loss in sulfotransferase activity when mutated but a double mutation of both residues resulted 
in a 50-fold reduction in activity compared to the wild type 6OST-3.  These two residues, 
His-151 and Gln-153, may possibly interact with each other to stabilize the transition state 
and/or substrate binding to 6OST-1 however this cannot be confirmed without the presence 
of a ternary complex of 6OST with PAP and an appropriate HS substrate.  
Throughout this study, we were capable of identifying a promising expression 
construct for preparing 6OST-1, leading us one step closer towards crystallization.  We also 
identified several amino acid residues that are important to the function of 6OST.  Once the 
crystal structure of 6OST is solved, we will be able to identify the substrate recognition 
mechanism and catalytic mechanism of this poorly understood enzyme.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter VI 
 
Conclusions 
 
 Heparan sulfate is a highly sulfated linear polysaccharide ubiquitously present on the 
cell surface and within the extracellular matrix. HS participates in a wide range of 
physiological and pathophysiological functions, including embryonic development, 
inflammatory response, blood coagulation, and assisting viral/bacterial infections (250).  
Heparin, a special form of HS, is a commonly used anticoagulant drug. The sulfation pattern 
of the HS polysaccharide governs its functional selectivity (251).  Understanding the 
structure–function relationship of HS may allow us to manipulate HS biosynthesis to design 
HS/heparin with improved anticoagulant efficacy and exploit heparin or heparin-like 
molecules for the development of anticancer and antiviral drugs (234).  However, obtaining 
HS oligosaccharides or polysaccharides with defined structures remains a challenge.  Despite 
many examples of success with chemical synthesis of short-HS fragments, the synthesis of 
molecules larger than hexasaccharides is extremely difficult. Using HS biosynthetic enzymes 
to prepare biologically active polysaccharides and oligosaccharides has offered a promising 
alternative approach (162,176,240,252).   
The HS sulfotransferases contribute to the structural diversity of HS, however the 
mechanism by which these enzymes recognize the HS substrate and catalyze the transfer of a 
sulfo group from PAPS to the modification site is poorly understood.  Extensive studies for 
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3OST-3 including the elucidation of a ternary complex of 3OST-3 with PAPS and a HS 
tetrasaccharide have provided some insight into the general catalytic mechanism of the HS 
sulfotransferases (63).  However, more elaborate work is necessary to understand the 
substrate recognition mechanism for each sulfotransferase since each is known to possess 
stringent substrate requirements at and surrounding the modification site.  The combination 
of a structural biology approach with site-directed mutagenesis could prove very effective for 
elucidating the mechanism of action of the structurally unknown sulfotransferases, 2OST and 
6OST.   
The initial focus of this dissertation resided within crystallization of 2OST.  Over the 
past few years, several attempts in our laboratory to solve the crystal structure of 2OST had 
proven unsuccessful due to problems with solubility, heterogeneity, and low expression.  
However, utilizing a MBP fusion protein eliminated all of these issues at hand and helped us 
obtain the crystal structure of MBP-2OST in a binary complex with PAP (59).  Unlike the 
other structurally known HS sulfotransferases, 2OST was determined to exist as a trimer that 
is essential for enzymatic activity.  This result is consistent with the 2OST originally isolated 
from CHO cells, representing the physiologically relevant form of 2OST (99).  Interestingly, 
2OST possesses an extended C-terminal tail that was identified as playing a crucial role in 
trimer formation as deletion of these C-terminal residues disrupted the interactions among the 
monomers within the trimer. 
 Using the crystal structure as a guide, several residues along the active site of 2OST 
were identified that could be involved in substrate binding.  The His-142 residue was 
identified as the proposed catalytic base for 2OST, which contrasts with the NST-1 and the 
3OSTs that rely on a glutamic acid as the catalytic base (63,79,81,150,253).  This proposed 
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catalytic residue overlays very well with the catalytic base, His-108, of the cytosolic estrogen 
sulfotransferase, and alignment of EST with 2OST suggested a higher sequence identity 
between these two enzymes than with the HS 3OSTs and NST-1.  Mutation of His-142 
resulted in abolition of sulfotransferase activity, supporting its catalytic role for the function 
of 2OST.  Based on the EST-PAPS structure and preliminary mutational analysis of 2OST, 
the catalytic residues that coordinate with PAPS were identified and provided better insight 
into the molecular mechanism of 2OST (80,104).   The catalytic mechanism of 2OST is 
proposed as follows:  In the absence of substrate, a hydrogen bonding interaction between 
2OST Ser-172 and the 3’-phosphate of PAPS serves to control the dissociation of the 5’-sulfo 
group of PAPS by Lys-83.  The Lys-83 residue coordinates with the side chain oxygen of 
Ser-172.  When the substrate binds in the active site and the His-142 initiates catalysis, the 
Lys-83 undergoes a conformational change to dissociate from the Ser-172 residue.  The Lys-
83 then forms a hydrogen bond with the bridging oxygen between the 5’-sulfo and 5’-
phosphate groups of PAPS, promoting dissociation of the PAP leaving group.  This change in 
Lys-83 conformation could be caused by the buildup of partial negative charge on the 
bridging oxygen as the catalytic histidine deprotonates the 2-OH acceptor position of the 
substrate and then nucleophilically attacks the sulfur atom of PAPS (80).  This proposed 
mechanism could be validated by the presence of a ternary complex of 2OST with an 
appropriate oligosaccharide substrate.   
Further examination of the potential substrate binding residues helped to identify 
residues that altered the spectrum of specificity for 2OST.  Specifically, the mutant R189A 
only transferred sulfates to GlcUA moieties within the HS polysaccharide whereas 2OST 
mutants Y94A and H106A preferentially transferred sulfates to IdoUA units.  These results 
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suggest that Arg-189, His-106, and Tyr-94 are important for directing the specificity of 
2OST.  The exact mechanism is currently unknown due to the lack of an available ternary 
complex with an appropriate oligosaccharide.  It is known that the three selective mutants 
migrate as trimers when analyzed by gel permeation chromatography, suggesting that these 
mutations do not support a large scale structural change of 2OST.  The difference in 
specificity is most likely caused by a local effect.   Our results demonstrate the feasibility for 
manipulating the substrate specificity to synthesize selected HS products that cannot be 
achieved by the wild type 2OST. 
Utilizing the substrate selective 2OST mutants, specifically the IdoUA-preferring 
mutant, we were able to design an assay for the determination of HS C5-epi activity (239).  
The current assay for C5-epi activity includes monitoring the release of a [
3
H]-proton at the 
C5-position of uronic acid of a tritium labeled polysaccharide (93).  Although effective, this 
assay requires an abundant amount of [
3
H]-labeled water which is not readily prepared in an 
academic laboratory.  The new assay bypasses the need for a radiolabeled polysaccharide 
through the use of the 2OST mutant.  The concept behind the epimerase assay is that a 
polysaccharide containing solely GlcUA units is incubated with C5-epi to convert GlcUA to 
IdoUA.  Once the epimerization step is completed, the 2OST Tyr-94 mutant enzyme is 
added, which will only recognize IdoUA residues within the polysaccharide chain.  The level 
of 2-O-sulfation can be monitored by the use of [
35
S]-labeled PAPS, and this level is 
proportional to the activity of C5-epi.   
In hopes of increasing the sulfotransferase activity of the Tyr-94 mutant towards the 
IdoUA-containing substrate, the Tyr-94 residue was subjected to several mutations, including 
replacing the tyrosine side chain with an acidic or basic residue such as Glu or Arg.  The size 
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of the side chain was altered with the use of Phe or Gly.  Based on the results, it appears that 
only the Y94A and Y94I mutants produced the highest sulfotransferase activity towards the 
IdoUA-containing substrate.  Since Y94A and Y94I possess similar selectivity, the 2OST 
Y94I mutant was selected for use in the C5-epi activity assay.  The validity of using the 
2OST mutant was confirmed by the linear relationship seen with the number of sulfo groups 
transferred by 2OST Y94I and the C5-epi concentration.  A control experiment using WT 
2OST demonstrated that a high level of sulfo groups was incorporated into the GlcUA-
containing polysaccharide even in the absence of C5-epi as WT 2OST is capable of sulfating 
both GlcUA and IdoUA.  This result implies that 2OST WT cannot be used for analyzing the 
activity of C5-epi.  The C5-epi activity assay was determined to be useful for screening 
several C5-epi mutants differing in truncation size and also helped to identify N92-W203 as 
being important for the function of C5-epi.   
Based on comparable transition state, the catalytic mechanism of C5-epi is proposed 
to be similar to that of the heparin lyases.  The presence of a tyrosine residue (Tyr-257) was 
found to be essential for heparin lyase II catalysis based on the crystal structure of heparin 
lyase II (244).  Although there is no significant sequence homology among heparin lyase II 
and C5-epi, we can speculate that the presence of tyrosine residues may also be important for 
the function of the epimerase as mutation of the tyrosine residue (Tyr-261) in dermatan 
sulfate epimerase corresponding to Tyr-257 in heparin lyase II abolished activity (246).  
Based on the C5-epi truncation data, we located several tyrosine residues for mutational 
analysis.  Confirmed by disaccharide analysis, the tyrosine mutational analysis identified 
Tyr-168 and Tyr-222 as being essential to C5-epi function with mutation resulting in 
complete abolition of activity.  These results provide some preliminary insight into the 
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catalytic mechanism of C5-epi however a combination of the crystal structure of C5-
epimerase and extensive mutational analysis will help provide more detailed information into 
the structural mechanism of this enzyme. 
Another focus of this research project was geared towards the crystallization of 
6OST.  As we attempted to identify the ideal expression system for 6OST, we completed 
preliminary mutational analysis based on a homology model with the structurally known 
3OST-3.  The fold recognition program, GenThreader, identified 3OST-3 as being the closest 
in homology to 6OST-3.  Based on the sequence alignment between 3OST-3 and 6OST-3, 
we identified several amino acid residues that may be important for the function of 6OST.  
Like the other HS sulfotransferases and cytosolic sulfotransferase, EST, 6OST contains the 
highly conserved PAPS binding motif.  Mutation of those residues including Lys-154, Arg-
244, and Ser-252 nearly abolished sulfotransferase activity compared to the wild type, 
suggesting a pivotal role for these residues in recognizing PAPS.   
Based on the ternary complex of 3OST-3 with PAP and a HS tetrasaccharide, several 
residues have been indicated as being essential for binding of the substrate to 3OST-3.  These 
corresponding residues in 6OST-3 identified two residues of Gln-153 and His-151 that may 
be important for substrate recognition.  Single point mutations of these two residues 
demonstrated no significant reduction in activity, although a double mutant of 
H151A/Q153A presented a drop in activity to 2%.  These results suggest that the residues 
may interact with one another and PAPS to assist with substrate recognition and/or transition 
state stabilization.  A combination of a crystal structure and extensive mutational analysis 
should provide a clearer picture of the role of specific amino acids in the function of 6OST. 
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Alongside mutational analysis, vigorous work was completed to identify the best 
expression system towards crystallization of 6OST.  After several attempts using His6 and 
MBP tags which were deemed successful with 3OST-1 and 2OST respectively (59,150), the 
thioredoxin expression system finally showed the most promise.  Two Trx-6OST-1 
constructs, WT (Y30-W408) and E382STP (Y30-E382) were prepared, differing in length at 
the C-terminus of 6OST-1.  The 6OST-1 E382STP protein is simply a premature stop codon 
within a randomly coiled region of 6OST-1 based on a secondary structure prediction. The 
WT and E382STP Trx-6OST-1 fusion proteins were analyzed by GPC-HPLC and 
determined to exist as monomers, which is consistent with a previous study identifying 6OST 
isolated from CHO cells as a monomer (108).  Although monomeric, the WT 6OST-1 did not 
exhibit comparable expression to E382STP therefore E382STP was utilized for potential 
crystallization.  Although 6OST-1 E382STP offers promising results, the expression level is 
still extremely low.  The pressing issue with poor expression must be overcome in order to 
increase the likelihood of obtaining a crystal structure for 6OST-1.   
At this point, the thioredoxin expression system has been identified as the most 
promising system for 6OST-1 expression, and the premature stop codon 6OST-1 E382STP 
shows the most potential for producing a monomeric protein with potent solubility and 
activity.  To improve the expression level of 6OST-1 E382STP, the E382STP could be 
cloned into a fixed arm pET32X vector which will produce a Trx-6OST-1 that cannot be 
cleaved.  The fixed arm vector will place the Trx and 6OST-1 proteins in very close contact 
to reduce protein dynamics and hopefully allow for crystallization.  If successful, a more 
elaborate mutational analysis can be completed to validate the preliminary results and gain 
further insight into the substrate recognition mechanism of 6OST. 
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Appendix I 
 
 
Utilizing Tyrosylprotein Sulfotransferase  
For the Preparation of Sulfated Proteins 
 
 
 
Background & Significance 
Tyrosine O-Sulfation 
 The post-translational modification of the tyrosine residues of several plasma 
membrane and secretory proteins trafficking the trans-Golgi network, mediated by 
tyrosylprotein sulfotransferase (TPST), has been found to play an essential role in promoting 
protein-protein interactions between two secretory proteins, a secretory protein and its 
receptor, and two plasma membrane proteins (254,255).  According to the UniProtKB 
database (http://www.uniprot.org/), there are currently 376 known tyrosine-sulfated proteins, 
37 of which are human proteins (256).  The majority of the human proteins included blood 
coagulation proteins, adhesion molecules, peptide hormones, extracellular matrix proteins, 
and G-protein coupled receptors (Table 5) (256,257).     
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Table 5.  Known human tyrosine sulfated proteins  
Class Protein Functional Role Citations 
Adhesion  Endoglycan L-selectin binding (258) 
Molecules Glycoprotein IBα Thrombin/vWF binding (259,260) 
 PSGL-1 P- & L-selectin binding (261-263) 
Coagulation  Factor V Thrombin cleavage (264,265) 
Factors Factor VIII Thrombin cleavage, vWF binding (266,267) 
 Factor IX Unknown (268-270) 
 Fibrinogen γ’ chain Unknown (271) 
Matrix Proteins Dermatopontin Unknown (272) 
 Procollagen Type III Unknown (273) 
 Fibronectin Unknown (274) 
 Vitronectin Unknown (275) 
Serpins α2-antiplasmin Unknown (276) 
 Heparin cofactor II Thrombin inhibition (277) 
G-Protein  CCR5 CCL3/CCL4/CCL5 binding (278) 
Coupled CCR2B CCL2 binding (279) 
Receptors CXCR4 CXCL12 binding (280) 
 CX3CR1 CX3CL1 binding (281) 
 C5α receptor C5a binding (282) 
 TSH receptor TSH binding (283) 
Gastrin/CCK  Gastrin Prograstrin processing (284) 
Family Cholecystokinin CCK-A receptor binding (285) 
Miscellaneous α-fetoprotein Unknown (286) 
 Amyloid precursor 
protein 
Unknown (287) 
 C4 α chain Cleavage by C1s (277,288) 
 Choriogonadotropin 
α chain 
Unknown (289) 
 FGF-7 Unknown (290) 
 M2B3 antigen Unknown (291) 
 Thyroglobuliln Unknown (292) 
 
 
 
Tyrosylprotein sulfotransferases (TPST) catalyze the transfer of a sulfo group from 
the universal donor PAPS to tyrosine residues of proteins (Fig 52).  The detailed catalytic 
mechanism for the TPST enzymes is currently unknown.  Tyrosine sulfation occurs in the 
trans Golgi, preceding the sorting of secretory proteins (293). 
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Figure 52.  Tyrosylprotein sulfotransferase reaction scheme.  TPST catalyzes the transfer of a sulfo group 
from the universal donor PAPS to the hydroxyl group of a peptidyltyrosine residue to generate sulfotyrosine and 
PAP.  
  
Two isoforms of TPST exist in both human and mouse, sharing 67% sequence 
identity between the isoforms.  With the exception of Drosophila malenogaster, which lacks 
a second TPST gene, many vertebrates and invertebrates have orthologs for TPST-1 and 
TPST-2 (256,294,295).   The sequence identity among each TPST isoform within different 
species is greater than 90%, suggesting evolutionary conservation among these enzymes.  
Both proteins are type II membrane-bound Golgi-resident enzymes possessing a short N-
terminal cytoplasmic tail, a 17-residue transmembrane domain, 40-residue stem region, and 
catalytic domain containing four conserved cysteine residues (296,297) (Fig 53).  Recently, a 
single TPST gene was identified in the plant Arabidopsis, which is strikingly different from 
TPSTs identified in animal species in that it is a type I transmembrane protein with a larger 
catalytic domain (446 residues) and more N-glycosylation sites possessing no significant 
sequence homology with sequences of animal species (294,298).  The only noteworthy 
sequence homology is that of residues 371-447 of Arabidopsis TPST with a C-terminal 
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region of heparan sulfate 6OST-2.    Although the Arabidopsis TPST is also located in the 
Golgi, it lacks any 5’-PSB and 3’-PB motifs that are highly conserved within the cytosolic 
and carbohydrate sulfotransferases (294).  It will be interesting to determine if the catalytic 
mechanism and structures of the plant and animal TPSTs are similar. 
 
Figure 53.  Domain structure for human TPST enzymes.  Human TPST-1 and -2 are type II transmembrane 
proteins of similar size (370-377 amino acid residues) with three domains including a short N-terminal 
cytoplasmic tail (CT), transmembrane (TM) region, stem region, and a Golgi luminal catalytic domain.  The 
two isoforms share 67% sequence identity (299).  Four cysteine residues including the 5’-PSB and 3’-PB motifs 
are conserved within the catalytic domain of TPST from all species. 
 
 
TPST-1 and TPST-2 are optimally active at pH 6.0 and 6.5 respectively and are 
stimulated by the presence of manganese but inhibited by the presence of calcium.  TPST-2 
is also stimulated by the presence of magnesium whereas TPST-1 is not (256,299).  Previous 
activity studies with different peptide substrates including P-selectin glycoprotein-1 and 
several chemokine receptors have identified TPST-1 as having a much lower KM and Vmax 
compared to TPST-2, implying higher enzymatic activity for TPST-1 (299).  These 
enzymatic properties are very important to note for future studies to be presented.  Based on 
sequence comparisons and in vitro studies with various synthetic peptides, a consensus 
sequence has been predicted for tyrosine sulfation that includes an acidic residue (Glu or 
Asp) adjacent to the Tyr and at least three acidic amino acids within five residues of Tyr.  A 
basic residue adjacent to the Tyr residue was found to abolish sulfation (293,300,301).  The 
  
161 
tyrosine residue must be significantly separated from glycosylation sites and cysteine 
residues, both of which have been found to prevent TPST binding (293,302).   
The TPST enzymes are expressed in all human tissues however the level of 
expression was varied in various tissues.  TPST-1 is highly expressed in the reproductive 
organs including testis and uterus, in neuronal tissues including brain cerebellum, fetal brain, 
and spinal cord (256,299).  On the other hand, TPST-2 is highly expressed in the liver, 
bladder, blood, bone marrow, thyroid, placenta, and other various organs (256).  The distinct 
expression levels of these two isoforms suggest that these enzymes possess distinct biological 
functions and different protein target specificities (256).   
The role of tyrosine O-sulfation in animal development was examined through in vivo 
studies using mice.  Mice deficient in TPST-1 exhibited reduced body weight and increased 
postimplantation fetal death (303) whereas deficiency in TPST-2 lead to infertility in males 
(297).   The reduced body weight in TPST-1 deficient mice has been speculated to be due to 
the lack of tyrosine sulfation of two known sulfated gastrointestinal peptide hormones known 
as gastrin and CCK (303).  A double knockout study in mice demonstrated death in the early 
postnatal period due to cardiopulmonary insufficiency.  Those mice that were able to survive 
the postnatal period exhibited primary hypothyroidism shortly thereafter, suggesting that 
certain tyrosine sulfated proteins were required for pulmonary function at birth and normal 
thyroid function postnatally (304).  A compensatory effect has been suggested for TPST 
activity since deletion of a single TPST gene did not affect survival rate as was the case for 
deletion of both TPST genes.  These results suggest a significant role for tyrosine O-sulfation 
in distinct physiological functions.   
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 Tyrosine O-sulfation plays a role in several physiological and pathophysiological 
functions, some of which include inflammation, pathogen invasion, and hemostasis.  One of 
the most well-studied tyrosine sulfated proteins is that of P-selectin glycoprotein ligand-1 
(PSGL-1), a protein involved in leukocyte-mediated inflammation.  One hallmark of 
inflammation is the migration of leukocytes into tissues.  Leukocytes will roll on and adhere 
to endothelial cells lining blood vessel walls at a site of inflammation.  This adhesion step is 
mediated by the interaction between P-selectin on activated endothelial cells with PSGL-1 
present on leukocytes.  Extensive studies have indicated the importance of the N-terminal 20 
amino acid residues of PSGL-1 in P-selectin binding with deletion of these residues resulting 
in complete abolition of P-selectin binding.  There are three potential tyrosine sulfation sites 
within the N-terminal region of PSGL-1 as seen in Figure 54. 
 
Figure 54.  The N-terminal 20 amino acid residues of mature PSGL-1.  The three potential sulfated tyrosine 
residues are highlighted in red.  The acidic amino acid residues are underlined. 
 
 The importance of tyrosine sulfation of the three tyrosine residues within the N-
terminal region of PSGL-1 has been extensive studied.  Synthetic peptides similar to the N-
terminal region of PSGL-1 were found to be successfully sulfated by both TPST-1 and -2 
(256,305).  Wilkins et al. (261) determined that [
35
S]-sulfate can be metabolically 
incorporated into PSGL-1, with base hydrolysis causing release of [
35
S]-sulfotyrosine and a 
significant reduction in P-selectin binding.  These results suggest the feasibility of tyrosine 
sulfation of the amino terminal tyrosine residues of mature PSGL-1.  Simultaneous mutation 
  
163 
of the three tyrosine residues within the 20 amino acid N-terminal region of PSGL-1 
significantly reduced P-selectin binding (262).  In addition, enzymatic desulfation of PSGL-1 
using a bacterial arylsulfatase released sulfate from tyrosine and demonstrated a significant 
reduction in the ability of PSGL-1 to bind P-selectin (261).   
 Tyrosine sulfation has been found to play an important role in chemokine receptor 
binding and function for leukocyte trafficking.  Chemokines are released from several tissues 
in response to inflammation and function through the binding and activation of chemokine 
receptors, G-protein coupled receptors that are expressed on the surface of leukocytes (256).  
The N-terminal region of chemokine receptors, containing tyrosine residues, has been found 
to be important for interaction with cognate chemokines.  For example, the chemokine 
receptor CXCR3, which has two potential tyrosine sulfation sites, was found to bind with its 
cognate chemokines, CXCL10/IP-10 and CXCL11/I-TAC, with high affinity however 
mutation of each tyrosine residue resulted in complete to 5-10 fold reduction of activity 
compared to wild type (306).  Mutation of both tyrosine residues within the CXCR3 receptor 
displayed no binding with CXCL0/IP-10 or CXCL11/I-TAC (306).  Colvin et al. also studied 
the level of [
35
S]-sulfate incorporation into wild type and single tyrosine mutant CXCR3 
receptors.  The single tyrosine receptor mutants demonstrated a reduction in [
35
S]-sulfated 
incorporation while the double tyrosine receptor mutant exhibited no binding (307) 
 Although tyrosine sulfation of chemokine receptors was found to be important for 
leukocyte trafficking during inflammation, studies have also indicated a pathophysiological 
role for tyrosine sulfated chemokine receptors in pathogen invasion, specifically for HIV 
infection.  Two known chemokine receptors, CCR5 and CXCR4, were determined to act as 
co-receptors along with CD4 for HIV viral fusion and entry (308-311).  The role of tyrosine 
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sulfation for CCR5 in binding to HIV has been established.  Studies have indicated that the 
N-terminal region of CCR5 possesses four potential tyrosine sulfate sites, which are crucial 
for the entry of HIV-1 into host cells (312).  Inhibition of tyrosine sulfation of CCR5 resulted 
in a significantly reduced binding affinity of CCR5 for gp120/CD4 complexes where gp120 
corresponds to a HIV envelope protein that initially binds to CD4 present on host cells (278).  
In vitro binding studies between gp120/CD4 complexes and a synthetic peptide representing 
the N-terminal region of CCR5 revealed the importance of tyrosine sulfation for binding 
(313).  There is only one tyrosine residue present in the N-terminal region of CXCR4 
however it does not seem to play a major role in HIV entry compared to CCR5 (280).  
Tyrosine sulfation has also been implicated in stimulating the interaction of a blood antigen 
known as DARC (Duffy Antigen and Receptor for Chemokines) with the erthyrocyte 
receptor for the malarial parasite Plasmodium vivax (314).  The ability of tyrosine sulfated 
receptors to stimulate invading pathogens such as HIV and malaria somewhat discredits the 
importance of post-translational modifications in human diseases, but could prove to be 
potentially successful therapeutic targets for these diseases.   
 Several blood coagulation proteins including factors V, VIII, IX, and fibrinogen are 
tyrosine sulfated post-translationally in mammalian cells.  Factors VIII and V function to 
enhance the rate of activation of factor X and prothrombin respectively.  Both coagulation 
proteins possess six potential tyrosine sulfate sites (264,266,267,315).  For both factors, the 
tyrosine residues must be sulfated for efficient thrombin cleavage and full procoagulant 
activity (267,316).  A deficiency in factor VIII results in hemophilia A, the most common 
type of blood clotting disorder.  Recombinant factor VIII derived from Chinese hamster 
ovary cells has been utilized as a replacement therapy in hemophilia patients (317).  Plasma 
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and recombinant factor VIII possess 100% tyrosine sulfation as well as similar clotting 
activity, recovery and half-life, making recombinant factor VIII an effective therapeutic for 
hemophilia A (317). 
 Factor IX, which serves to activate factor X, undergoes several post-translational 
modifications during synthesis in mammalian cells including the addition of N-and O-linked 
carbohydrates, glutamic acid γ-carboxylation, tyrosine sulfation, serine phosphorylation, and 
aspartic acid β-hydroxylation (264,317-320).  Factor IX is initially synthesized as a 55 kDa 
protein which then undergoes these extensive post-translational modifications during transit 
that are essential for the normal functioning of factor IX (269).  During activation by 
cleavage using factor XIa, factor IX is cleaved at two argininyl peptide bonds results in the 
formation of activation domain (12 kDa) and activated factor IXa (43 kDa)(321).  Regarding 
tyrosine sulfation, there is solely one site for potential tyrosine sulfation at Tyr-155 located 
within the activation domain of factor IX (269,322).  Recombinant factor IX, commonly used 
during replacement therapy since it is free of human infectious agents, has only minor 
differences in post translational modifications from plasma-derived factor IX (317).  
However, the tyrosine residue is less than 15% sulfated in recombinant factor IX, which is 
speculated to be the cause for approximately 30% reduced recovery in hemophilia patients 
(269).  Due to the reduced recovery, patients must receive a much higher dose (1.2 times the 
calculated dose) of recombinant factor IX (269).  If the issues of recovery of rFIX can be 
resolved, rFIX could prove to be a very effective therapeutic for Hemophilia B patients.  The 
use of TPST to increase the level of tyrosine sulfation of rFIX could potentially enhance the 
recovery upon administration. 
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Materials & Methods 
Expression and Purification of MBP-TPST Fusion Constructs 
 The maltose binding protein (MBP)-TPST fusion protein constructs were created 
using the same modified pMAL-c2x vector (New England Biolabs) utilized for the MBP-
2OST protein.  The TPST-pMALX plasmid was transformed into Origami B cells expressing 
the GroEL/GroES chaperonin proteins as aforementioned.  A 1 L stock of LB supplemented 
with 100 µg/mL carbenicillin, 50 µg/mL kanamycin, 35 µg/mL chloramphenicol, and 12.5 
µg/mL tetracycline was inoculated with 50 µL glycerol cell stock of TPST-pMALX and 
grown overnight at 37°C with constant shaking at 275 rpm.  A 60 mL aliquot of overnight 
cell culture was added to each of the 12 L cultures supplemented with all four antibiotics at 
the appropriate concentrations.  The cultures were grown at 37°C until the O.D.600 reached 
0.7-0.8 following by reduction of the incubator temperature to 23°C.  L-arabinose (1 mg/mL) 
was first added to induce chaperone expression followed by the addition of 0.5 mM IPTG to 
induce protein expression.  The cultures were allowed to shake overnight at 23°C.  The cells 
were pelleted at 6000 rpm for 15 min followed by resuspension in 15 mL buffer A containing 
25 mM Tris pH 7.5, 500 mM NaCl, 1 mM DTT.  The cells were sonicated 4 times for 20 
seconds each followed by centrifugation at 18000 rpm for 35 minutes.  The supernatant was 
purified by amylose resin, eluting with buffer containing 25 mM Tris pH 7.5, 500 mM NaCl, 
1 mM DTT, and 40 mM maltose.  The eluate concentrated down to 10 mL using a Centricon-
Plus 70 concentrator with monitoring of the A280 followed by concentration with Amicon 
Ultra-15 concentrator until the volume was approximately 4.5 mL.  The concentrated MBP-
TPST protein was loaded onto a Superdex 200 16/60 and eluted with buffer containing 20 
mM MOPS, 500 mM NaCl, 1 mM DTT, 40 mM maltose pH 7.0.  The purified protein was 
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diluted with heparin buffer A containing 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM DTT, 
and 5 mM maltose to reduce to NaCl concentration to approximately 250 mM.  The diluted 
material was then loaded onto a heparin column and eluted with buffer containing 25 mM 
Tris pH 7.5, 750 mM NaCl, 1 mM DTT, and 5 mM maltose.  The protein is diluted and 
stored in 25 mM Tris pH 7.5, 200 mM NaCl, 1 mM DTT, 5 mM maltose, and 4 mM PAP.  
These constructs were prepared by Dr. Raj Gosavi at the National Institute of Environmental 
Health Sciences. 
Expression and Purification of GST-TPST Fusion Constructs 
 The GST-TPST fusion protein constructs were created using the pGEXT4T3(TEV) 
vector which contains a TEV protease cleavage site for removal of the GST tag.  The TPST-
pGEXT4T3(TEV) plasmid was transformed into Origami B cells expressing the 
GroEL/GroES chaperonin proteins as aforementioned.  A 1 L stock of LB supplemented with 
100 µg/mL carbenicillin, 50 µg/mL kanamycin, 35 µg/mL chloramphenicol, and 12.5 µg/mL 
tetracycline was inoculated with 50 µL glycerol cell stock of TPST- pGEXT4T3(TEV) and 
grown overnight at 37°C with constant shaking at 275 rpm.  A 60 mL aliquot of overnight 
cell culture was added to each of the 12 L cultures supplemented with all four antibiotics at 
the appropriate concentrations.  The cultures were grown at 37°C until the O.D.600 reached 
0.7-0.8 following by reduction of the incubator temperature to 23°C.  L-arabinose (1 mg/mL) 
was first added to induce chaperone expression followed by the addition of 0.5 mM IPTG to 
induce protein expression.  The cultures were allowed to shake overnight at 23°C.  The cells 
were pelleted at 6000 rpm for 15 min followed by resuspension in 15 mL buffer A containing 
25 mM Tris pH 7.5, 500 mM NaCl, 1 mM DTT.  The cells were sonicated 4 times for 20 
seconds each followed by centrifugation at 18000 rpm for 35 minutes.  The supernatant was 
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purified by glutathione sepharose 4B resin, eluting with buffer containing 25 mM Tris pH 
7.5, 500 mM NaCl, 1 mM DTT, and 40 mM glutathione.  The eluate was concentrated down 
to 3.5 mL using an Amicon Ultra-15.  The concentrated GST-TPST protein was split into 2 
tubes followed by the addition of 50 µL TEV protease to each tube and rocked overnight at 
4°C for complete cleavage of the GST tag.  The cleaved material was loaded onto a Superdex 
200 16/60 column and eluted with buffer containing 20 mM MOPS, 500 mM NaCl, 1 mM 
DTT pH 7.0.  The GPC purified TPST protein was diluted with heparin buffer containing 25 
mM Tris pH 7.5, 250 mM NaCl, 1 mM DTT to reduce the final salt concentration for proper 
binding to the heparin column.  The diluted TPST was then loaded onto a heparin column, 
eluting with 25 mM Tris pH 7.5, 750 mM NaCl, 1 mM DTT.  The pooled heparin fractions 
were then diluted to bring the final NaCl concentration to 200 mM and the protein was stored 
in 25 mM Tris pH 7.5, 200 mM NaCl, 1 mM DTT, 4 mM PAP.  These constructs were 
prepared by Dr. Raj Gosavi at the National Institute of Environmental Health Sciences.   
Determination of the Activity of TPST 
 Based on an established method (323), the rate of sulfation of the synthetic PSGL-1 
peptide (QATEYEYLDYDFLPEC) (Global Peptide Services) by tyrosylprotein 
sulfotransferase (TPST) was assayed by using the following 100 µL reaction conditions: 2 
µM (2x10
5
 cpm) PAPS, 4.5 µg peptide substrate, 40 mM MES pH 7.0, 20 mM MnCl2, 50 
mM NaF, 1 mM 5’-AMP, 0.5% Triton X-100, and 100 µg TPST enzyme.  The reaction was 
incubated at 30°C for 20 min followed by termination with 400 µL ice cold 75 mM EDTA 
pH 7.0.  The [
35
S]-sulfated peptide product was separated from [
35
S]PAPS by reverse phase 
chromatography using C18 Sep-Pak cartridges (Waters).  The cartridges were washed with 5 
mL methanol containing 0.05% trifluoroacetic acid followed by 5 mL water with 0.05% 
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trifluroacetic acid.  Once the sample was loaded onto the pre-equilibrated cartridges, the resin 
was washed with 6 mL water/0.05% TFA and eluted with 2 mL methanol/0.05% TFA.  The 
amount of [
35
S]-sulfated peptide was determined by liquid scintillation counting of the total 
methanol eluent.   
SDS-PAGE Analysis of BeneFIX® Coupled to Autoradiography 
 For a 50 µL reaction, the following components are used:  2x10
5 
cpm
 
[
35
S]PAPS, 4.5 
µg BeneFIX, 40 mM MES pH 7.0, 20 mM MnCl2, 50 mM NaF, 1 mM 5’-AMP, 0.5% Triton 
X-100, and 100 µg TPST enzyme.  The reaction was incubated at 30°C for 20 min followed 
by the addition of SDS gel sample buffer (1:1 v/v) (Bio-Rad).  A 20 µL aliquot of the sample 
was loaded onto a 10% Tris-HCl SDS gel and run slowly at 50 volts.  For protein size 
comparison, a 5 µL aliquot of [
14
C]methylated protein ladder (Amersham) subjected to 
electrophoresis alongside the samples. At the end of electrophoresis, the SDS gel was then 
soaked in a fixing solution containing 50% methanol and 10% acetic acid followed by 
application to QuickDraw blotting paper (Sigma) and covered with Saran wrap.  The gel was 
dried for 2 hours at 80°C in a slab gel vacuum dryer  followed by exposure to BioMax 
maximum resolution (MR) X-ray film (Kodak) for several days at -80 °C before processing 
the film.   
Research Introduction 
 Tyrosine O-sulfation, catalyzed by tyrosylprotein sulfotransferase (TPST), is a 
common post-translational modification in multicellular eukaryotic organisms, affecting 
protein characteristics such as enzymatic activity, protein longevity, and interactions with 
other proteins (295,296).  Protein tyrosine sulfation plays a role in several biological 
functions including inflammation, hemostasis, and autoimmunity (264,296,324).  
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 We have turned our attention to the role of tyrosine sulfation in hemostasis, 
particularly of blood coagulation protein factor IX which has a single tyrosine sulfation site 
at Tyr-155 (322).  Factor IX deficiency leads to the onset of the rare bleeding disorder known 
as hemophilia B.  The current treatment option for hemophilia B patients is factor IX 
replacement therapy.  However, the recovery following intravenous infusion is reduced due 
to the decreased level of tyrosine sulfation.  BeneFIX®, a FDA approved recombinant factor 
IX (rFIX) therapeutic, is of particular interest because it does not possess complete sulfation.   
It possesses only 15%, at the Tyr-155 residue, possibly contributing to its low recovery 
following administration (317).  This is strikingly different from plasma-derived FIX which 
has almost 100% sulfation at the site.  Our goal is to successfully sulfate the single tyrosine 
residue (Tyr-155) present within recombinant factor IX using TPST constructs differing in 
isoform and truncation in hopes of improving its stability for clinical use.  In collaboration 
with Dr. Lars Pedersen at NIEHS, we would also like to crystallize the TPST enzyme to gain 
insight into its substrate recognition mechanism.   
Here, we present preliminary data that includes screening for the TPST construct with 
the highest activity towards an extensively used peptide substrate.  Following the peptide 
sulfation assay, we identified two TPST constructs possessing the potential for effective 
tyrosine sulfation of BeneFIX® by way of Western blot analysis.  This initial study 
demonstrates the feasibility of sulfating recombinant factor IX using tyrosylprotein 
sulfotransferase. 
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Experimental Results  
Determining the Sulfotransferase Activity of Various TPST constructs 
Based on previous success with 2OST using MBP fusion protein expression systems, 
we initially expressed several human TPST constructs containing various N- and C- terminal 
truncations as MBP fusion proteins in Origami B
chap
 cells.  The truncations were prepared to 
probe for the catalytic domain of TPST.  We aim to determine the shortest possible TPST 
construct possessing high sulfotransferase activity to increase our likelihood of protein 
crystallization.  Once expressed, these MBP-TPST fusion proteins were purified by amylose 
resin followed by gel permeation chromatography and analyzed for sulfotransferase activity 
using a well-studied synthesized peptide (QATEYEYLDYDFLPEC) (Tables 6 and 7).   This 
peptide represents the N-terminal residues of the mature P-selectin glycoprotein ligand 1 
(PSGL-1), an inflammatory protein known to be sulfated by TPST.  PSGL-1 contains three 
tyrosine sulfate sites that have been shown to be sulfated in mammalian cells (261).  We 
originally tested the MBP-TPST-1 (Table 6) and MBP-TPST-2 (Table 7) constructs at a pH 
of 7.0, but we later identified through a literature search that the average optimal pH for both 
TPSTs was approximately 6.25 (299).  Therefore, all of the prepared constructs were tested 
under both pH conditions.  For both TPST-1 and TPST-2 constructs, the reactivity towards 
the PSGL-1 peptide substrate did indeed increase by at least two-fold or more under the 
lower pH conditions.  These results were consistent with a previous study utilizing a similar 
PSGL-1 peptide substrate (ATEYEYLDYDFL)  in that the activity increases approximately 
two-fold when reducing the pH from 7.0 to 6.25 (299). 
None of the MBP-TPST constructs demonstrated significant activity towards the 
peptide substrate except TPST-1 (S39-Q355), possessing reactivity towards the substrate of 
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28.5 pmol SO4
-2
/4 µg relative activity at pH 6.25.  Based on the activity analysis, there was 
no general trend in terms of truncation size versus sulfotransferase activity however it 
appeared that the activity was higher for the TPST-1 constructs.  The higher activity for 
TPST-1 was consistent with Mishiro et al. which demonstrated that full length TPST-1 had a 
much lower KM  and Vmax compared to TPST-2 (299).   
 
 Table 6.  Analysis of MBP-TPST-1 fusion proteins to PSGL-1 peptide substrate  
TPST-1  
Constructs 
Reactivity 
 @ pH 7.0 
Reactivity  
@ pH 6.25 
 pmol SO4
-2
/4 µg 
peptide 
pmol SO4
-2
/4 µg 
peptide 
G25-E370 1.7   3.6 
S39-Q355 4.9 28.5 
S39-E370 3.4 10.3 
Y65-Q355 0.2   2.4 
Y65-E370 0.1   0.4 
K67-Q355 0.1   0.8 
K67-E370 0.1   0.4 
M69-Q355 0.1   0.8 
M69-E370 0.1   0.2 
  * The specific activity of PAP[
35
S] is 22,000 cpm/pmol. 
 
 
 
 
 The lack of a highly active TPST construct, even for the longer constructs containing 
the majority of the catalytic domain, raised concerns with the use of the MBP fusion protein 
expression system.  The modified pMAL vector utilized for expression of the MBP-TPST 
fusion proteins possessed a mutated linker region encoding three alanine residues (A368-
A370) to reduce flex in the fusion protein to facilitate crystallization.  This would allow the 
TPST protein to nestle against the MBP protein, potentially obstructing access to the active 
site.  This modified vector does not possess a TEV protease cleavage site therefore TPST 
cannot exist as a free protein.   
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Table 7.  Analysis of MBP-TPST-2 fusion proteins to PSGL-1 peptide substrate 
TPST-2  
Constructs 
Reactivity 
 @ pH 7.0 
Reactivity 
@ pH 6.25 
 pmol SO4
-2
/4 µg 
peptide 
pmol SO4
-2
/4 µg 
peptide 
G25-S377 1.4 5.6 
Y64-S377 0.3 9.6 
Y64-K354 0.2 3.5 
K66-K354 0.1 2.5 
K66-S377 0.0 0.3 
M68-K354 0.2 1.0 
M68-S377 0.1 2.5 
 * The specific activity of PAP[
35
S] is 22,000 cpm/pmol. 
 
 
  
 The results with the MBP-TPST proteins caused us to direct our attention to another 
fusion tag of glutathione S-transferase (GST).  The GST fusion protein system has proven 
very successful for crystallization of other known HS sulfotransferases including NST-1 and 
3OST-3 (63,79).  We focused on the more significant N-terminal truncation constructs of 
TPST-1 (M69-Q355) and (M69-E370) and TPST-2 (K66-K354) and (K66-S377) to heighten 
our chances of protein crystallization.  The GST-TPST fusion proteins were expressed in 
Origami B
chaperone
 cells and purified by a GST column.  Once eluted from the GST column, 
the GST-TPST fusion proteins were cleaved by TEV protease to remove the GST tag 
followed by purification by gel permeation chromatography and finally heparin 
chromatography.  The TPST enzymes, free of tag, were analyzed for activity using the 
aforementioned PSGL-1 peptide sulfation assay (Table 8), revealing a significant increase in 
activity for both TPST isoforms compared to the MBP-TPST fusion proteins.  These results 
confirmed the potential inhibitory effects by the presence of the MBP tag.  The TPST-1 
constructs, differing in sequence length, possess similar activity with the PSGL-1 peptide 
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regardless of pH conditions, suggesting potential for crystallization as these two proteins 
exhibited no issues with protein aggregation upon GST cleavage or low expression.  Based 
on the peptide sulfation assay results, the most promising TPST constructs of TPST-1 (M69-
Q355) and TPST-1 (M69-E370) were selected to test the sulfation of recombinant factor IX.   
 
Table 8.  Analysis of untagged TPST constructs to PSGL-1 peptide substrate 
TPST 
Constructs 
TPST 
Isoform 
Reactivity 
@ pH 7.0 
Reactivity 
@ pH 6.25 
  pmol SO4
-2
/4 µg 
peptide 
pmol SO4
-2
/4 µg peptide 
M69-Q355 1 18.1 28.1 
M69-E370 1 17.8 30.9 
K66-K354 2 9.6 19.2 
K66-S377 2 0.9 4.5 
* The specific activity of PAP[
35
S] is 22,000 cpm/pmol. 
 
 
 
Utilizing TPST-1 (M69-Q355) & (M69-E370) For Tyrosine Sulfation of rFIX 
 Upon identification of two highly active TPST-1 constructs, we then wanted to test 
their ability to sulfate the single tyrosine residue (Tyr-155) of recombinant factor IX.  We 
completed sulfation analysis by incubating a known rFIX therapeutic, BeneFIX®, with each 
TPST-1 construct in the presence of [
35
S]-radiolabeled PAPS followed by SDS-PAGE and 
exposure to X-ray film (Fig 55).  The molecular weight of rFIX is approximately 55 kDa, 
which was consistent with the band present on the autoradiograph for each TPST-1 construct 
by comparison to a [
14
C]-radiolabeled protein ladder.   Although the two TPST-1 constructs 
exhibited similar sulfotransferase activity towards the peptide substrate as seen in Table 8, 
they do not show comparable activity towards factor IX.  The band intensity for rFIX 
modified by the shorter TPST-1 construct (M69-Q355) was slightly higher, suggesting a 
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higher level of tyrosine sulfation compared to the longer construct.  We did attempt sulfation 
of rFIX with the two TPST-2 constructs of (K66-K354) and (K66-S377) however the 
autoradiograph revealed no bands corresponding to radiolabeled factor IX, potentially 
implying that factor IX is not a substrate for TPST-2.  Based on this preliminary data, we can 
conclude that factor IX is indeed a substrate for TPST-1. 
 
 
Figure 55.  Autoradiograph of recombinant factor IX (BeneFIX®) modified by TPST-1 constructs of 
various truncation size (M69-E370 and M69-Q355).  Approximately 4 µg of BeneFIX® was incubated with 
100 µg each TPST-1 enzyme in the presence of 1x10
6
 cpm PAPS followed by SDS-PAGE analysis and 
exposure to maximum resolution X-ray film.  The band at 55 kDa represents O- [
35
S]-sulfated factor IX.   
 
   
 
 With the recent success modifying rFIX with TPST-1 (M69-Q355), we wanted to test 
the limit of rFIX saturation by the TPST enzyme.  The TPST-1 (M69-Q355) enzyme was 
incubated with [
35
S]-radiolabeled PAPS and various concentrations of BeneFIX® ranging 
from 0-64 µg followed by SDS-PAGE analysis and autoradiography (Fig 56A).  As the 
concentration of rFIX increased, the level of sulfation increased as indicated by an increase 
in band intensity representing O-[
35
S]-sulfated rFIX at 55 kDa.  The dried SDS gel was 
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exposed to a phosphor screen to quantify the band intensity as the light emitted from the 
phosphor screen will be proportional to the amount of radioactivity in the sample (Fig 56B).  
Based on the quantification, it appears that the sulfation of the rFIX substrate reaches the 
point of saturation at 32 µg.  Although there is a decrease in band intensity at 64 µg, we 
would need to complete further studies to explore the possibility of substrate inhibition.  We 
clearly demonstrated that the level of sulfation by TPST-1 increased as the factor IX 
substrate concentration increased.  
 
 
 
Figure 56.  Autoradiograph representing TPST-1 modified recombinant factor IX over various 
concentrations.  (A) Approximately 100 µg of TPST-1 (M69-Q355) was incubated with various concentrations 
of BeneFIX® (0-64 µg) in the presence of 1x10
6
 cpm PAPS followed by SDS-PAGE analysis and exposure to 
maximum resolution X-ray film.  The band at 55 kDa represents O-[
35
S]-sulfated recombinant factor IX.  (B) 
The SDS gel was exposed to a phosphor screen and the bands were quantified using ImageQuant. 
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 Although it was clearly demonstrated that the shorter TPST-1 construct exhibited a 
higher level of sulfation, we wanted to compare the sulfation efficiency over various rFIX 
concentrations to determine if the sequence length indeed plays a role in the level of sulfation 
(Fig 57).  Using ImageJ to calculate the band intensity, it does appear that the sulfation 
efficiency is better for the shorter construct with a proportional increase (2-fold) in band 
intensity as the concentration of rFIX increased.  The longer construct appears to reach 
saturation more rapidly than the shorter construct, suggesting the binding affinity could be 
different.  Binding studies among the rFIX and TPST-1 constructs using ITC analysis could 
help explain this difference.  Interestingly, the TPST-2 constructs, also differing in sequence 
length, demonstrated a 4-fold difference in activity when analyzed by the peptide sulfation 
assay at pH 6.25 (Table 8).  Taking this into account along with the discrepancy among 
factor IX sulfation with the TPST-1 constructs, it appears that the C-terminal end of the 
catalytic domain of TPST could be playing some inhibitory role.  We would need to prepare 
a series of constructs differing in C-terminal truncation sites to prove this theory.    
 
 
 
Figure 57.  Tyrosine sulfation of recombinant factor IX at various concentrations using two TPST-1 
constructs.  BeneFIX ranging from 0-32 µg was incubated with [
35
S]PAPS and approximately 100 µg TPST-1 
(M69-E370) or (M69-Q355).  Following the ST reaction, the samples were loaded onto a 10% Tris-HCl SDS-
gel along with a 
14
C-labeled protein ladder for size comparison.  Following SDS-PAGE, the gel was exposed to 
an X-ray film and processed after two weeks.  The arrow indicates the O-[
35
S]-sulfated factor IX band at 55 
kDa.   
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Conclusions 
This research project approaches blood coagulation from a different angle than 
standard in our laboratory.  We normally focus on targeting inhibition of factor Xa and 
thrombin through binding of heparin/HS to the serine protease inhibitor antithrombin in order 
to induce anticoagulation.  Instead, we turned our attention to promoting coagulation by 
targeting factor IX within pathway.  Hemophilia B, or Christmas disease, is characterized by 
a deficiency in plasma factor IX.  The most common treatment for hemophilia B patients is 
factor IX replacement therapy using recombinant factor IX derived from bacterial cell 
systems as with the FDA approved drug, BeneFIX® (317).  During the synthesis of Factor 
IX, the protein is subjected to post-translational processing during transit through the Golgi, 
one of which includes tyrosine O-sulfation.  Previous studies have indicated that plasma 
derived factor IX is more than 90% tyrosine sulfated at one position, Tyr-155 (268).  Using 
an effective tyrosine sulfation predictor known as Sulfinator, we confirmed that the Tyr-155 
residue was indeed the site of sulfation for factor IX.  For recombinant factor IX (rFIX), only 
15% of the Tyr-155 residue is sulfated which has been correlated with reduced factor IX 
recovery, approximately 30% reduction, during treatment (317).  Through the use of 
tyrosylprotein sulfotransferase (TPST) that is known to sulfate tyrosine residues, we could 
potentially improve the level of sulfation of rFIX and in turn enhance the recovery upon 
administration.   
With intentions to crystallize one of the two TPST isoforms, several constructs were 
prepared including MBP-TPST and GST-TPST fusion proteins and screened for activity 
using the peptide substrate, PSGL-1.  The construct, such as TPST-1 (M69-Q355), 
containing the smallest portion of the catalytic domain while still maintaining high 
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sulfotransferase activity and solubility offers the most promise for crystallization purposes.  
The screening method was also beneficial for identifying two constructs with potential for 
sulfating factor IX, including TPST-1 (M69-E370) and (M69-Q355) at the single site of 
tyrosine sulfation (Tyr-155). 
 Using SDS-PAGE analysis coupled to autoradiography, we were able to prove that 
the shorter TPST-1 construct, containing residues M69-Q355, was able to sulfate factor IX 
over a range of concentrations up to 32 µg whereas the longer TPST-1 construct (M69-E370) 
appears to demonstrate a significantly lower level of sulfation with saturation at 8 µg factor 
IX.   More studies must be completed to identify any differences in factor IX binding affinity 
among the two constructs as well as potential inhibition by the substrate.  A previously 
developed assay that relies on mass spectrometry could prove beneficial for understanding 
the kinetic parameters of these two TPST-1 constructs (325).   
Based on the preliminary results, we successfully proved that factor IX is indeed a 
substrate for TPST-1, although there are some limitations to our current methodology.  It 
appears that the level of sulfation by the TPST-1 enzyme is somewhat low, implying that 
100% sulfation may not have been achieved at the site of tyrosine sulfation (Tyr-155).  There 
is the possibility that other cofactors may be involved in promoting tyrosine sulfation of 
factor IX however there is no current evidence to support this idea.  Unlike the peptide 
substrate, we cannot employ the use of the C18 cartridges for purifying and analyzing 
tyrosine sulfated FIX as the sulfated protein binds very tightly to the resin and cannot be 
eluted from the cartridge.  Therefore, we must develop an analytical technique for 
determining the sulfation level of our modified product.  We will most likely be able to 
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utilize RPIP-HPLC analysis.  We must select a column resin containing a shorter alkyl chain 
length such as C4 since we are working with a protein instead of a peptide like with PSGL-1.   
Although we are not yet confident that the level of sulfation by the TPST-1 constructs 
is at 100% for the recombinant factor IX, we have undoubtedly shown that the recombinant 
TPST-1 enzyme is capable of sulfating factor IX.  There is no evidence for utilizing TPST to 
sulfate factor IX to date, suggesting the novelty of our work.  If we are able to prove the 
sulfation level achieved by the shorter TPST-1 construct, we could potentially complete in 
vivo studies using mice deficient in factor IX to study the implications of the tyrosine 
sulfated factor IX as an improved replacement therapy.   
This project is certainly in the infant stages of development, although our results do 
offer the possibility of utilizing recombinant enzymes to generate proteins with biological 
relevance and therapeutic implications.    
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